CA2340616A1 - Secreted proteins and polynucleotides encoding them - Google Patents

Secreted proteins and polynucleotides encoding them Download PDF

Info

Publication number
CA2340616A1
CA2340616A1 CA002340616A CA2340616A CA2340616A1 CA 2340616 A1 CA2340616 A1 CA 2340616A1 CA 002340616 A CA002340616 A CA 002340616A CA 2340616 A CA2340616 A CA 2340616A CA 2340616 A1 CA2340616 A1 CA 2340616A1
Authority
CA
Canada
Prior art keywords
seq
nucleotide sequence
nucleotide
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002340616A
Other languages
French (fr)
Inventor
Dario Valenzuela
Olive Yuan
Heidi Hoffman
Jeff Hall
Peter Rapiejko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphagene Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2340616A1 publication Critical patent/CA2340616A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.

Description

DEMANDES OU BREVETS VOI.UMINEUX
LA PRESENTS PARTIE DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS D'UN TOME.
CEC~ EST LF TOME _ ~"DE o~ _ -NOTE. Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets ~ r.
JUMBO APPLlCATIONS/PATENTS
THIS SECTION OF THE APPLfCATIONIPATENT CONTAINS MORE ~'~
THAN ONE VOLUME
. THlS 1S VOLUME ~F
PIOTE:.Eor additional volumes please coniact'the Canadian Patent Ofiffice SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THElvvi This application is a continuation-in-part of the following applications:
(1) provisional application Ser. No. 60/097,638 (GI 6908), filed August 24,1998;
(2) provisional application Ser. No. 60/097,659 (GI 6909), filed August 24,1998;
(3) provisional application Ser. No. 60/099,618 (GI 6910), filed September 9,1998;
{4) provisional application Ser. No. 60/102,092 (GI 6912), filed September 28,1998;
{5) provisional application Ser. No. 60/109,978 (GI 6914), filed November 25,1998;
(6) provisional application Ser. No. 60/113,645 (GI 6916), filed December 23,1998; and (7) provisional application Ser. No. 60/113,646 (GI 6917), filed December 23,1998;
all of which are incorporated by reference herein.
FIELD OF THI~ INVENTION
The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
BACKGROUND OF THE INVENTION
Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader 3 0 sequence motif, as well as various PCR based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the 3 5 polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE TN~1FNTION
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:1 from nucleotide 683 to nucleotide 934;
(c) a polynucieotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vbll 1 deposited with the ATCC under accession number 98846;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vbll 1 deposited with the ATCC under accession number 98846;
(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vbll 1 deposited with the ATCC under accession number 98846;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vbll 1 deposited with the ATCC under accession number 98846;
(g) a polynucleotide encoding a protein comprising the amino acid 2 0 sequence of SEQ ID N0:2;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:2;
(i) a polynucleotide which is an allelic variant of a polynucleotide of 2 5 (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-{h); and 3 0 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:1.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
NO:1 from nucleotide 683 to nucleotide 934; the nucleotide sequence of the full-length protein coding sequence of clone vbll 1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vbll_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vbl l 1 deposited with the ATCC under accession number 98846.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID N0:2.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID NO:1.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group 2 0 consisting of:
(aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID N0:1; and (ab) the nucleotide sequence of the cDNA insert of clone vbll 1 deposited with the ATCC under accession number 98846;
2 5 (ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and 3 0 (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and (bb) the nucleotide sequence of the cDNA insert of clone vbll 1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:1 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the 1 S cDNA sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934, and extending rnntiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934.
2 0 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:2;
(b) a fragment of the amino acid sequence of SEQ ID N0:2, the 2 5 fragment comprising eight contiguous amino acids of SEQ ID N0:2; and (c) the amino acid sequence encoded by the cDNA insert of clone vbll 1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:2. In further preferred 3 0 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:2, or a protein comprising a fragment of the amino acid sequence of SEQ

pCT/US99/19351 ID N0:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID N0:2.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 63 to nucleotide 482;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 201 to nucleotide 482;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vbl2_1 deposited with the ATCC under accession number 98846;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vbl2_1 deposited with the ATCC under accession number 98846;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vbl2_1 deposited with the ATCC under accession number 98846;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vbl2_1 deposited with the ATCC under accession number 98846;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:4;
(i) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:4;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or {i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:3.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:3 from nucleotide 63 to nucleotide 482; the nucleotide sequence of SEQ ID
N0:3 from nucleotide 201 to nucleotide 482; the nucleotide sequence of the full-length protein coding sequence of clone vbl2_1 deposited with the ATCC under accession number 98846;
or the nucleotide sequence of a mature protein coding sequence of clone vbl2_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vbl2_1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4 having biological activity, the fragment preferably comprising eight {more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID N0:4.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:3.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:3, but excluding the poly{A) tail at the 3' end of SEQ ID N0:3; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vbl2_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said probe{s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);

and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize.in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:3, but excluding the poly(A) tail at the 3' end of SEQ ID N0:3; and (bb) the nucleotide sequence of the cDNA insert of clone vbl2_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:3 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the 2 0 cDNA sequence of SEQ ID N0:3 from nucleotide 63 to nucleotide 482, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:3 from nucleotide 63 to nucleotide 482, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:3 from nucleotide 63 to nucleotide 482. Also preferably the polynucleotide isolated according to the above 2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:3 from nucleotide 20I to nucleotide 482, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:3 from nucleotide 201 to nucleotide 482, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:3 from nucleotide 201 to nucleotide 482.
3 0 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:4;

(b) a fragment of the amino acid sequence of SEQ ID N0:4, the fragment comprising eight contiguous amino acids of SEQ ID N0:4; and (c) the amino acid sequence encoded by the cDNA insert of clone vbl2_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:4, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID N0:4.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 1195 to nucleotide 1527;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:5 from nucleotide 1468 to nucleotide 1527;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vbl4_1 deposited with the ATCC under accession number 98846;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vbl4_1 deposited with the ATCC under accession number 98846;
(f) a poiynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vbl4_1 deposited with the ATCC under accession number 98846;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vbl4_l deposited with the ATCC under accession number 98846;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:6;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ TD N0:6;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (ar(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:5.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:5 from nucleotide 1195 to nucleotide 1527; the nucleotide sequence of SEQ
ID N0:5 from nucleotide 1468 to nucleotide 1527; the nucleotide sequence of the full-length protein coding sequence of clone vbl4_1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vbl4_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by 2 0 the cDNA insert of clone vbl4_1 deposited with the ATCC under accession number 98846.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:6, or a 2 5 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment comprising the amino and sequence from amino acid 50 to amino acid 59 of SEQ ID N0:6.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:5.
3 0 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:5, but excluding the poly(A) tail at the 3' end of SEQ ID N0:5; and (ab) the nucleotide sequence of the cDNA insert of clone vbl4_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:5, but excluding the poly(A) tail at the 3' end of SEQ ID N0:5; and (bb) the nucleotide sequence of the cDNA insert of clone 2 0 vbl4_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b}(iii).
2 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:5 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:5. Also preferably the polynucleotide isolated 3 0 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:5 from nucleotide 1195 to nucleotide 1527, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:5 from nucleotide 1195 to nucleotide 1527, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:5 from nucleotide 1195 to nucleotide 1527. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:5 from nucleotide 1468 to nucleotide 1527, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:5 from nucleotide 1468 to nucleotide 1527, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:5 from nucleotide 1468 to nucleotide 1527.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:6;
(b) a fragment of the amino acid sequence of SEQ ID N0:6, the fragment comprising eight contiguous amino acids of SEQ ID N0:6; and (c) the amino acid sequence encoded by the cDNA insert of clone vbl4_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 2 0 of SEQ ID N0:6, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID N0:6.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucieotide comprising the nucleotide sequence of SEQ ID
N0:7;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 82 to nucleotide 294;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:7 from nucleotide 109 to nucleotide 294;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vel I 1 deposited with the ATCC under accession number 98846;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yell 1 deposited with the ATCC under accession number 98846;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vell 1 deposited with the ATCC under accession number 98846;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone yell 1 deposited with the ATCC under accession number 98846;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:8;
(i) a polynudeotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:B having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:8;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and 2 0 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:7.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:7 from nucleotide 82 to nucleotide 294; the nucleotide sequence of SEQ ID
N0:7 from 2 5 nucleotide 109 to nucleotide 294; the nucleotide sequence of the full-length protein coding sequence of clone vell_1 deposited with the ATCC under accession number 98846;
or the nucleotide sequence of a mature protein coding sequence of clone yell 1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 3 0 of clone yell 1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID N0:8.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:7.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:7, but excluding the poly{A) tail at the 3' end of SEQ ID N0:7; and (ab) the nucleotide sequence of the cDNA insert of clone vell_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:7, but excluding the poly{A) tail at the 3' end of SEQ ID N0:7; and (bb) the nucleotide sequence of the cDNA insert of clone vell_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said primers) to human genomic DNA in 3 0 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:7 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:7 from nucleotide 82 to nucleotide 294, and extending rnntiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:7 from nucleotide 82 to nucleotide 294, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:7 from nucleotide 82 to nucleotide 294. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:7 from nucleotide 109 to nucleotide 294, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:7 from nucleotide 109 to nucleotide 294, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:7 from nucleotide 109 to nucleotide 294.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:8;
(b) a fragment of the amino acid sequence of SEQ ID N0:8, the 2 0 fragment comprising eight contiguous amino acids of SEQ ID N0:8; and (c) the amino acid sequence encoded by the cDNA insert of clone vel l 1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:8. In further preferred 2 5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:8, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:8 having biological activity, the fragment comprising the amino acid sequence from 3 0 amino acid 30 to amino acid 39 of SEQ ID N0:8.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9 from nucleotide 22 to nucleotide 468;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9 from nucleotide 118 to nucleotide 468;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
(g) a poiynucleotide encoding a mature protein encoded by the cDNA
insert of clone vf2_1 deposited with the ATCC under accession number 98846;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment 2 0 comprising eight contiguous amino acids of SEQ ID N0:10;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
2 5 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:9.
3 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:9 from nucleotide 22 to nucleotide 468; the nucleotide sequence of SEQ ID
N0:9 from nucleotide 118 to nucleotide 468; the nucleotide sequence of the full-length protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
or the nucleotide sequence of a mature protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vf2_1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 69 to amino acid 78 of SEQ ID NO:10.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:9.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:9, but excluding the poly(A) tail at the 2 0 3' end of SEQ ID N0:9; and (ab) the nucleotide sequence of the cDNA insert of clone vf2_I deposited with the ATCC under accession number 98846;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and 2 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that 3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:9, but excluding the poly(A) tail at the 3' end of SEQ ID N0:9; and (bb) the nucleotide sequence of the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID
N0:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:9 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:9 from nucleotide 22 to nucleotide 468, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:9 from nucleotide 22 to nucleotide 468, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:9 from nucleotide 22 to nucleotide 468. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:9 from nucleotide 118 to nucleotide 468, and extending contiguously from a 2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:9 from nucleotide I18 to nucleotide 468, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:9 from nucleotide 118 to nucleotide 468.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino and sequence selected from the group 2 5 consisting of:
(a) the amino acid sequence of SEQ ID NO:10;
(b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID N0:10; and {c) the amino acid sequence encoded by the cDNA insert of clone vf2_1 3 0 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino ands of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ
ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 69 to amino acid 78 of SEQ ID N0:10.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:11 from nucleotide 124 to nucleotide 1641;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11 from nucleotide 262 to nucleotide 1641;
(d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
(f) a polynucleotide comprising the nucleotide sequence of a mature 2 0 protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vg2_1 deposited with the ATCC under accession number 98846;
(h) a polynucleotide encoding a protein comprising the amino acid 2 5 sequence of SEQ ID N0:12;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ iD N0:12;
(j) a polynucleotide which is an allelic variant of a polynucleotide of 3 0 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:11.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:11 from nucleotide 124 to nucleotide 1641; the nucleotide sequence of SEQ
ID N0:11 from nucleotide 262 to nucleotide 1641; the nucleotide sequence of the full-length protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
or the nucleotide sequence of a mature protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vg2_1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID N0:12.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:11.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vg2_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) ~ isolating the DNA polynucleotides detected with the probe{s);

and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and (bb) the nucleotide sequence of the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 0 corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641. Also preferably the polynucleotide isolated according to the above 2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
NOal from nucleotide 262 to nucleotide 1641, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
NO:11 from nucleotide 262 to nucleotide 1641, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 262 to nucleotide 1641.
3 0 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:12;

(b) a kagment of the amino acid sequence of SEQ ID N0:12, the fragment comprising eight contiguous amino acids of SEQ ID N0:12; and (c) the amino acid sequence encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino ands of SEQ ID N0:12, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:12 having biological activity, the fragment comprising the amino acid sequence kom amino acid 248 to amino acid 257 of SEQ ID N0:12.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected kom the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13 kom nucleotide 380 to nucleotide 892;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:13 from nucleotide 416 to nucleotide 892;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vjl 1 deposited with the ATCC under accession number 98846;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vjl_1 deposited with the ATCC under accession number 98846;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vjl 1 deposited with the ATCC under accession number 98846;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vjl 1 deposited with the ATCC under accession number 98846;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:14;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:I4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:14;
(j) a polynucleotide which is an allelic variant of a polynucleotide of {a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(i) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a~-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (ar(i) and that has a length that is at least 25% of the length of SEQ ID N0:13.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:13 from nucleotide 380 to nucleotide 892; the nucleotide sequence of SEQ ID
NO:13 from nucleotide 416 to nucleotide 892; the nucleotide sequence of the full-length protein coding sequence of clone vjl 1 deposited with the ATCC under accession number 98846;
or the nucleotide sequence of a mature protein coding sequence of clone vj1 1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vj1 1 deposited with the ATCC under accession number 98846. in further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:14, or a polynucleotide 2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 80 to amino acid 89 of SEQ ID N0:14.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:13.
3 0 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
{a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:13; and (ab) the nucleotide sequence of the cDNA insert of clone vjl_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:13; and (bb) the nucleotide sequence of the cDNA insert of clone vjl_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said primers) to human genomic DNA in 2 0 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:13 . Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:13 from nucleotide 380 to nucleotide 892, and extending contiguously from a nucleotide sequence 3 0 corresponding to the 5' end of said sequence of SEQ ID N0:13 from nucleotide 380 to nucleotide 892, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:13 from nucleotide 380 to nucleotide 892. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:13 from nucleotide 416 to nucleotide 892, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:13 from nucleotide 416 to nucleotide 892, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:13 from nucleotide 416 to nucleotide 892.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:14;
(b} a fragment of the amino acid sequence of SEQ ID N0:14, the fragment comprising eight contiguous amino acids of SEQ ID N0:14; and (c) the amino acid sequence encoded by the cDNA insert of clone vj1 1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:14. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:14, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:14 having biological activity, the fragment comprising the amino acid sequence 2 0 from amino acid 80 to amino acid 89 of SEQ ID N0:14.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15;
2 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 62 to nucleotide 1057;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 659 to nucleotide 1057;
(d) a polynucleotide comprising the nucleotide sequence of the full-3 0 length protein coding sequence of clone vll 1 deposited with the ATCC
under accession number 98846;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vl1 1 deposited with the ATCC under accession number 98846;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vll 1 deposited with the ATCC under accession number 98846;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vl1 1 deposited with the ATCC under accession number 98846;
{h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ TD N0:16;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:16;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:15.
2 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:15 from nucleotide 62 to nucleotide 1057; the nucleotide sequence of SEQ ID
N0:15 from nucleotide 659 to nucleotide 1057; the nucleotide sequence of the full-length protein coding sequence of clone v1I 1 deposited with the ATCC under accession number 98846;
or the nucleotide sequence of a mature protein coding sequence of clone vll 1 deposited 2 5 with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vll 1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having 3 0 biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 161 to amino acid 170 of SEQ ID N0:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:15.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:15, but excluding the poly(A) tail at the 3' end of SEQ ID N0:15; and (ab) the nucleotide sequence of the cDNA insert of clone v11 1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that 2 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:15, but excluding the poly(A) tail at the 3' end of SEQ ID N0:15; and (bb) the nucleotide sequence of the cDNA insert of clone 2 5 vll_1 deposited with the ATCC under accession number 98846;
(ii) hybridizing said prixner(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
3 0 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:15 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:15 from nucleotide 62 to nucleotide 1057, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:IS from nucleotide 62 to nucleotide 1057, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:15 from nucleotide 62 to nucleotide 1057. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:15 from nucleotide 659 to nucleotide 1057, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:15 from nucleotide 659 to nucleotide 1057, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:15 from nucleotide 659 to nucleotide 1057.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:16;
(b) a fragment of the amino acid sequence of SEQ ID N0:16, the fragment comprising eight contiguous amino acids of SEQ ID N0:16; and (c) the amino acid sequence encoded by the cDNA insert of clone vlI 1 deposited with the ATCC under accession number 98846;
2 0 the protein being substantially free from other mammalian proteins.
Preferably such protein comprises the amino acid sequence of SEQ ID N0:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 2 5 of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 161 to amino acid 170 of SEQ ID N0:16.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
3 0 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 74 to nucleotide 529;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 140 to nucleotide 529;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 9883$;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vk2_1 deposited with the ATCC under accession number 98838;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:18;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:18;
(j) a polynucleotide which is an allelic variant of a polynucleotide of 2 0 (a}-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and 2 5 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:17.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:17 from nucleotide 74 to nucleotide 529; the nucleotide sequence of SEQ ID
N0:17 3 0 from nucleotide 140 to nucleotide 529; the nucleotide sequence of the full-length protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838;
or the nucleotide sequence of a mature protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vlc2-1 deposited with the ATCC under accession number 98838. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment preferably comprising eight {more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID N0:18.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:17.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:17, but excluding the poly(A) tail at the 3' end of SEQ ID N0:17; and (ab) the nucleotide sequence of the cDNA insert of clone 2 0 vk2_1 deposited with the ATCC under accession number 98838;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe{s);
2 5 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
3 0 (ba) SEQ ID N0:17, but excluding the poly(A) tail at the 3' end of SEQ ID N0:17; and (bb) the nucleotide sequence of the cDNA insert of clone v~ 1 deposited with the ATCC under accession number 98838;

WO 00/11015 PC1'/US99/19351 (ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:17 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:17 from nucleotide 74 to nucleotide 529, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:17 from nucleotide 74 to nucleotide 529, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:17 from nucleotide 74 to nucleotide 529. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:17 from nucleotide 140 to nucleotide 529, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:17 from nucleotide 140 to nucleotide 529, to a nucleotide sequence corresponding to the 3' end of 2 0 said sequence of SEQ ID N0:17 from nucleotide 140 to nucleotide 529.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:18;
2 5 (b) a fragment of the amino acid sequence of SEQ ID N0:18, the fragment comprising eight contiguous amino acids of SEQ ID N0:18; and (c) the amino acid sequence encoded by the cDNA insert of clone vic2_1 deposited with the ATCC under accession number 98838;
the protein being substantially free from other mammalian proteins. Preferably such 3 0 protein comprises the amino acid sequence of SEQ ID N0:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:18, or a protein comprising a fragment of the amino acid sequence of SEQ

WO 00/11015 PC1'/US99/19351 ID N0:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID N0:18.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19 from nucleotide 174 to nucleotide 3170;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19 from nucleotide 1098 to nucleotide 3170;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb21 1 deposited with the ATCC under accession number 98862;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb21 1 deposited with the ATCC under accession number 98862;
2 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vb21_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:20;
(i) a polynudeotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:20;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 3 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a~(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a~(i) and that has a length that is at least 25% of the length of SEQ TD N0:19.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:19 from nucleotide 174 to nucleotide 3170; the nucleotide sequence of SEQ
ID N0:19 from nucleotide 1098 to nucleotide 3170; the nucleotide sequence of the full-length protein coding sequence of clone vb21_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vb21 1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID

having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 494 to amino acid 503 of SEQ ID N0:20.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:19.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:19, but excluding the poly(A) tail at the 3' end of SEQ ID N0:19; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vb21 1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);

and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:19, but excluding the poly{A) tail at the 3' end of SEQ ID N0:19; and (bb} the nucleotide sequence of the cDNA insert of clone vb21_I deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:19 , but excluding the poly{A) tail at the 3' end of SEQ ID N0:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 0 corresponding to the cDNA sequence of SEQ ID N0:19 from nucleotide 174 to nucleotide 3170, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:19 from nucleotide 174 to nucleotide 3170, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:19 from nucleotide 174 to nucleotide 3170. Also preferably the polynucleotide isolated according to the above 2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:19 from nucleotide 1098 to nucleotide 3170, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:19 from nucleotide 1098 to nucleotide 3170, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:19 from nucleotide 1098 to nucleotide 3170.
3 0 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:20;

(b) a fragment of the amino acid sequence of SEQ ID N0:20, the fragment comprising eight contiguous amino acids of SEQ ID N0:20; and {c) the amino acid sequence encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:20. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO~O, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 494 to amino acid 503 of SEQ ID N0:20.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:21 from nucleotide 74 to nucleotide 1453;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:21 from nucleotide 224 to nucleotide 1453;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc35 1 deposited with the ATCC under accession number 98862;
(e) a polynucleotide encoding the full-length protein encoded by the 2 5 cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc35_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:22;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:22 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:22;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a~(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:21.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:21 from nucleotide 74 to nucleotide 1453; the nucleotide sequence of SEQ ID
N0:21 from nucleotide 224 to nucleotide 1453; the nucleotide sequence of the full-length protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 2 0 of clone vc35_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:22, or a polynucleotide 2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 225 to amino acid 234 of SEQ ID N0:22.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:21.
3 0 Further embodiments of the invention provide isolated polynudeotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:

(i) preparing one or more polynudeotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:21, but excluding the poly(A) tail at the 3' end of SEQ ID N0:21; and (ab) the nucleotide sequence of the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynudeotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynudeotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:21, but excluding the poly(A) tail at the 3' end of SEQ ID N0:21; and (hb) the nucleotide sequence of the cDNA insert of done 2 0 vc35_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:21, and extending contiguously from a nucleotide sequence con:esponding to the 5' end of SEQ
ID N0:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:21 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:21. Also preferably the 3 0 polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:21 from nucleotide 74 to nucleotide 1453, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:21 from nucleotide 74 to nucleotide 1453, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:21 from nucleotide 74 to nucleotide 1453. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:21 from nucleotide 224 to nucleotide 1453, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:21 from nucleotide 224 to nucleotide 1453, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:21 from nucleotide 224 to nucleotide 1453.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino and sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:22;
(b) a fragment of the amino acid sequence of SEQ ID N0:22, the fragment comprising eight contiguous amino acids of SEQ ID N0:22; and (c) the amino acid sequence encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:22. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty} contiguous amino acids 2 0 of SEQ ID N0:22, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 225 to amino acid 234 of SEQ ID N0:22.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
2 5 (a} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:23 from nucleotide 135 to nucleotide 368;
(c} a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:23 from nucleotide 243 to nucleotide 368;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc36_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:24;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:24 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:24;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and 2 0 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (ar(i) and that has a length that is at least 25% of the length of SEQ ID N0:23.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:23 from nucleotide 135 to nucleotide 368; the nucleotide sequence of SEQ ID
N0:23 2 5 from nucleotide 243 to nucleotide 368; the nucleotide sequence of the full-length protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of clone .vc36_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 3 0 of clone vc36_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID N0:24.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:23.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:23, but excluding the poly(A) tail at the 3' end of SEQ ID N0:23; and (ab) the nucleotide sequence of the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:23, but excluding the poly(A) tail at the 3' end of SEQ ID N0:23; and (bb) the nucleotide sequence of the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in 3 0 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b){iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:23, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:23 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:23 from nucleotide 135 to nucleotide 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:23 from nucleotide 135 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:23 from nucleotide 135 to nucleotide 368. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:23 from nucleotide 243 to nucleotide 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:23 from nucleotide 243 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:23 from nucleotide 243 to nucleotide 368.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:24;
(b) a fragment of the amino acid sequence of SEQ ID N0:24, the 2 0 fragment comprising eight contiguous amino acids of SEQ ID N0:24; and (c) the amino acid sequence encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:24. In further preferred 2 5 embodiments, the present invention provides a protein comprising a fragment of the amino and sequence of SEQ ID N0:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:24, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:24 having biological activity, the fragment comprising the amino acid sequence 3 0 from amino acid 34 to amino acid 43 of SEQ ID N0:24.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:25 from nucleotide 370 to nucleotide 1662;
(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;
(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc38_1 deposited with the ATCC under accession number 98862;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:26;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:26 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:26;
(i) a polynucleotide which is an allelic variant of a polynucleotide of 2 0 (a)-(f) above;
(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in {a~(h); and 2 5 (1) a polynudeotide that hybridizes under stringent conditions to any one of the polynucleotides specified in {ar(h) and that has a length that is at least 25% of the length of SEQ ID N0:25.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:25 from nucleotide 370 to nucleotide 1662; the nucleotide sequence of the full-length 3 0 protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:26, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 210 to amino acid 219 of SEQ ID N0:26.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:25.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:25, but excluding the poly(A) tail at the 3' end of SEQ ID N0:25; and (ab) the nucleotide sequence of the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;
2 0 (ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and {iii) isolating the DNA polynucleotides detected with the probe(s);
and 2 5 (b) a process comprising the steps of:
{i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:25, but excluding the poly{A) tail at the 3 0 3' end of SEQ ID N0:25; and (bb) the nucleotide sequence of the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:25, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:25 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:25. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:25 from nucleotide 370 to nucleotide 1662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:25 from nucleotide 370 to nucleotide 1662, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:25 from nucleotide 370 to nucleotide 1662.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:26;
(b) a fragment of the amino acid sequence of SEQ ID N0:26, the fragment comprising eight contiguous amino acids of SEQ ID N0:26; and 2 0 (c) the amino acid sequence encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:26. In further preferred embodiments, the present invention provides a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:26, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 210 to amino acid 219 of SEQ ID N0:26.
3 0 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27 from nucleotide 105 to nucleotide 365;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:27 from nucleotide 147 to nucleotide 365;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;
(e) a polynucleoHde encoding the full-length protein encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
(f) a polynucleoride comprising the nucleotide sequence of a mature protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc39_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:28;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:28 having biological activity, the fragment 2 0 comprising eight contiguous amino acids of SEQ ID N0:28;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
2 5 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:27.
3 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:27 from nucleotide 105 to nucleotide 365; the nucleotide sequence of SEQ ID
N0:27 from nucleotide 147 to nucleotide 365; the nucleotide sequence of the full-length protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vc39_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID N0:28.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0~7.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:27, but excluding the poly(A) tail at the 2 0 3' end of SEQ ID N0:27; and (ab) the nucleotide sequence of the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and 2 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that 3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:27, but excluding the poly(A) tail at the 3' end of SEQ ID N0:27; and WO 00/11015 PC"T/US99/19351 (bb) the nucleotide sequence of the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:27 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:27 from nucleotide 105 to nucleotide 365, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:27 from nucleotide 105 to nucleotide 365, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:27 from nucleotide 105 to nucleotide 365. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:27 from nucleotide 147 to nucleotide 365, and extending contiguously from a 2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:27 from nucleotide 147 to nucleotide 365, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:27 from nucleotide 147 to nucleotide 365.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:28;
(b) a fragment of the amino acid sequence of SEQ ID N0:28, the fragment comprising eight contiguous amino acids of SEQ ID N0:28; and (c) the amino acid sequence encoded by the cDNA insert of clone 3 0 vc39_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:28. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:28, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID N0:28.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29 from nucleotide 35 to nucleotide 1066;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:29 from nucleotide 128 to nucleotide 1066;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature 2 0 protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862;
(g} a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc40_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid 2 5 sequence of SEQ ID N0:30;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ TD N0:30;
(j) a polynucleotide which is an allelic variant of a polynucleotide of 3 0 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-{i}; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:29.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:29 from nucleotide 35 to nucleotide 1066; the nucleotide sequence of SEQ ID
N0:29 from nucleotide 128 to nucleotide 1066; the nucleotide sequence of the full-length protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vc40_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 167 to amino acid 176 of SEQ ID N0:30.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:29.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:29, but excluding the poly(A) tail at the 3' end of SEQ ID N0:29; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vc40_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);

and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:29, but excluding the poly(A) tail at the 3' end of SEQ ID N0:29; and (bb) the nucleotide sequence of the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:29 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 0 corresponding to the cDNA sequence of SEQ ID N0:29 from nucleotide 35 to nucleotide 1066, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:29 from nucleotide 35 to nucleotide 1066, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:29 from nucleotide 35 to nucleotide 1066. Also preferably the polynucleotide isolated according to the above 2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:29 from nucleotide 128 to nucleotide 1066, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:29 from nucleotide 128 to nucleotide 1066, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:29 from nucleotide 128 to nucleotide 1066.
3 0 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:30;

(b) a fragment of the amino acid sequence of SEQ ID N0:30, the fragment comprising eight contiguous amino acids of SEQ ID N0:30; and (c) the amino acid sequence encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:30. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:30, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 167 to amino acid 176 of SEQ ID N0:30.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:31 from nucleotide 38 to nucleotide 553;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:31 from nucleotide 104 to nucleotide 553;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;
3 0 (g) a polynucieotide encoding a mature protein encoded by the cDNA
insert of clone vc46_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:32;
SO

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:32;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynudeotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynudeotide that hybridizes under stringent conditions to any one of the polynucieotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:31.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:31 from nucleotide 38 to nucleotide 553; the nucleotide sequence of SEQ ID
N0:31 from nucleotide 104 to nucleotide 553; the nucleotide sequence of the full-length protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 2 0 of clone vc46_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:32, or a polynucleotide 2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 81 to amino acid 90 of SEQ ID N0:32.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:31.
3 0 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
{a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:31, but excluding the poly(A) tail at the 3' end of SEQ ID N0:31; and (ab) the nucleotide sequence of the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and . (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID N0:31; and (bb) the nucleotide sequence of the cDNA insert of clone 2 0 vc46_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:31 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:31. Also preferably the 3 0 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:31 from nucleotide 38 to nucleotide 553, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:31 from nucleotide 38 to nucleotide 553, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:31 from nucleotide 38 to nucleotide 553: Also preferably the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:31 from nucleotide 104 to nucleotide 553, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:31 from nucleotide 104 to nucleotide 553, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:31 from nucleotide 104 to nucleotide 553.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:32;
(b) a fragment of the amino acid sequence of SEQ ID N0:32, the fragment comprising eight contiguous amino acids of SEQ ID N0:32; and (c) the amino acid sequence encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:32. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 2 0 of SEQ ID N0:32, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 81 to amino acid 90 of SEQ ID N0:32.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:33 from nucleotide 164 to nucleotide 2548;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:33 from nucleotide 242 to nucleotide 2548;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc49_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:34;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:34 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:34;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
{k) a polynudeotide which encodes a species homologue of the protein of {h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a~(i); and 2 0 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:33.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:33 from nucleotide 164 to nucleotide 2548; the nucleotide sequence of SEQ
ID N0:33 2 5 from nucleotide 242 to nucleotide 2548; the nucleotide sequence of the full-length protein rnding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of done vc49_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 3 0 of clone vc49_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 392 to amino acid 401 of SEQ ID N0:34.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:33.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:33, but excluding the poly(A) tail at the 3' end of SEQ ID N0:33; and (ab) the nucleotide sequence of the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:33, but excluding the poly(A) tail at the 3' end of SEQ ID N0:33; and (bb) the nucleotide sequence of the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in 3 0 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) . isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:33, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:33 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:33. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:33 from nucleotide 164 to nucleotide 2548, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:33 from nucleotide 164 to nucleotide 2548, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:33 from nucleotide 164 to nucleotide 2548. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:33 from nucleotide 242 to nucleotide 2548, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:33 from nucleotide 242 to nucleotide 2548, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:33 from nucleotide 242 to nucleotide 2548.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:34;
(b) a fragment of the amino acid sequence of SEQ ID N0:34, the 2 0 fragment comprising eight contiguous amino acids of SEQ ID N0:34; and (c) the amino acid sequence encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:34. In further preferred 2 5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:34, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:34 having biological activity, the fragment comprising the amino acid sequence 3 0 from amino acid 392 to amino acid 401 of SEQ ID N0:34.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35;

(b). a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:35 from nucleotide 150 to nucleotide 776;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:35 from nucleotide 246 to nucleotide 776;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc50_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:36;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:36 having biological activity, the fragment 2 0 comprising eight contiguous amino acids of SEQ ID N0:36;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a poiynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
2 S (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:35.
3 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:35 from nucleotide 150 to nucleotide 776; the nucleotide sequence of SEQ ID
N0:35 from nucleotide 246 to nucleotide 776; the nucleotide sequence of the full-length protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vc50_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID N0:36.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:35.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
{aa) SEQ ID N0:35, but excluding the poly(A) tail at the 2 0 3' end of SEQ ID N0:35; and (ab) the nucleotide sequence of the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and 2 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that 3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:35, but excluding the poly(A) tail at the 3' end of SEQ ID N0:35; and (bb) the nucleotide sequence of the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
S (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:35, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:35 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:35. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:35 from nucleotide 150 to nucleotide 776, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:35 from nucleotide 150 to nucleotide 776, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:35 from nucleotide 150 to nucleotide 776. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:35 from nucleotide 246 to nucleotide 776, and extending contiguously from a 2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:35 from nucleotide 246 to nucleotide 776, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:35 from nucleotide 246 to nucleotide 776.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:36;
(b) a fragment of the amino acid sequence of SEQ ID N0:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and (c) the amino acid sequence encoded by the cDNA insert of clone 3 0 vc50_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:36. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:36, or a protein comprising a fragment of the amino acid sequence of SEQ
ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID N0:36.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37 from nucleotide 139 to nucleotide 1308;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:37 from nucleotide 211 to nucleotide 1308;
(d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone vc51 1 deposited with the ATCC under 1 S accession number 98862;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc51 1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature 2 0 protein coding sequence of clone vc51 1 deposited with the ATCC under accession number 98862;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc51 1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid 2 5 sequence of SEQ ID N0:38;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:38 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:38;
(j) a polynucleotide which is an allelic variant of a polynucleotide of 3 0 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or {i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:37.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:37 from nucleotide 139 to nucleotide 1308; the nucleotide sequence of SEQ
ID N0:37 from nucleotide 211 to nucleotide 1308; the nucleotide sequence of the full-length protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vc51_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID N0:38.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:37.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:37, but excluding the poly(A) tail at the 3' end of SEQ ID N0:37; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vc51 1 deposited with the ATCC under accession number 98862;
(ii) hybridi2ing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);

and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from S the group consisting of:
(ba) SEQ ID N0:37, but excluding the poly(A) tail at the 3' end of SEQ ID N0:37; and (bb) the nucleotide sequence of the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:37, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:37 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:37. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 0 corresponding to the cDNA sequence of SEQ ID N0:37 from nucleotide 139 to nucleotide 1308, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:37 from nucleotide 139 to nucleotide 1308, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:37 from nucleotide 139 to nucleotide 1308. Also preferably the polynucleotide isolated according to the above 2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:37 from nucleotide 211 to nucleotide 1308, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:37 from nucleotide 211 to nucleotide 1308, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:37 from nucleotide 211 to nucleotide 1308.
3 0 In other embodiments, the present invention provides a composirion comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:38;

(b) a fragment of the amino acid sequence of SEQ ID N0:38, the fragment comprising eight contiguous amino acids of SEQ ID N0:38; and (c) the amino acid sequence encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:38. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:38 having biological ackivity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:38, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID N0:38.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:39 from nucleotide 21 to nucleotide 1142;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:39 from nucleotide 114 to nucleotide 1142;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc52_1 deposited with the ATCC under accession number 98862;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:40;

{i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:40;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a~(g) above;
(k) a polynudeotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:39.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:39 from nucleotide 21 to nucleotide 1142; the nucleotide sequence of SEQ ID
N0:39 from nucleotide 114 to nucleotide 1142; the nucleotide sequence of the full-length protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
or the nucleotide sequence of a mature protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 2 0 of clone vc52_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 182 to amino acid 191 of SEQ ID N0:40.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:39.
3 0 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:39, but excluding the poly(A) tail at the 3' end of SEQ ID N0:39; and (ab) the nucleotide sequence of the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98$62;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and {iii) isolating the DNA polynucleotides detected with the probe{s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:39, but excluding the poly(A) tail at the 3' end of SEQ ID N0:39; and (bb) the nucleotide sequence of the cDNA insert of clone 2 0 vc52_1 deposited with the ATCC under accession number 98862;
(ii) hybridizing said primers) tv human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:39 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:39. Also preferably the 3 0 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:39 from nucleotide 21 to nucleotide 1142, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:39 from nucleotide 21 to nucleotide 1142, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:39 from nucleotide 21 to nucleotide 1142. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:39 from nucleotide 114 to nucleotide 1142, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
NO:39 from nucleotide 114 to nucleotide 1142, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:39 from nucleotide 114 to nucleotide 1142.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:40;
(b) a fragment of the amino acid sequence of SEQ ID N0:40, the fragment comprising eight contiguous amino acids of SEQ ID N0:40; and (c) the amino acid sequence encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:40. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino and sequence of SEQ ID N0:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 2 0 of SEQ ID N0:40, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 182 to amino acid 191 of SEQ ID N0:40.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41;
(b} a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:41 from nucleotide 13 to nucleotide 1416;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:41 from nucleotide 346 to nucleotide 1416;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
{f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc33_1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:42;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:42;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and 2 0 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:41.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:41 from nucleotide 13 to nucleotide 1416; the nucleotide sequence of SEQ ID
N0:41 2 5 from nucleotide 346 to nucleotide 1416; the nucleotide sequence of the full-length protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 3 0 of clone vc33_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 229 to amino acid 238 of SEQ ID N0:42.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:41.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:41, but excluding the poly(A) tail at the 3' end of SEQ ID N0:41; and (ab) the nucleotide sequence of the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:41, but excluding the poly(A) tail at the 3' end of SEQ ID N0:41; and (bb) the nucleotide sequence of the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in 3 0 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:41, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:41 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:41 from nucleotide 13 to nucleotide 1416, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:41 from nucleotide 13 to nucleotide 1416, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:41 from nucleotide 13 to nucleotide 1416. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:41 from nucleotide 346 to nucleotide 1416, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:41 from nucleotide 346 to nucleotide 1416, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:41 from nucleotide 346 to nucleotide 1416.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:42;
(b) a fragment of the amino acid sequence of SEQ ID N0:42, the 2 0 fragment comprising eight contiguous amino acids of SEQ ID N0:42; and (c) the amino acid sequence encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:42. In further preferred 2 5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino ands of SEQ ID N0:42, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:42 having biological activity, the fragment comprising the amino acid sequence 3 0 from amino acid 229 to amino acid 238 of SEQ ID N0:42.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:43;

(b) a polynucleotide comprising the nucleotide sequence of SEQ TD
N0:43 from nucleotide 232 to nucleotide 1461;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:43 from nucleotide 280 to nucleotide 1461;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc34_1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:44;
(i) a polynudeotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:44 having biological activity, the fragment 2 0 comprising eight contiguous amino acids of SEQ ID N0:44;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
{k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
2 5 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynudeotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:43.
3 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:43 from nucleotide 232 to nucleotide 1461; the nucleotide sequence of SEQ
ID N0:43 from nucleotide 280 to nucleotide 1461; the nucleotide sequence of the full-length protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vc34_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 200 to amino acid 209 of SEQ ID N0:44.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:43.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:43, but excluding the poly(A) tail at the 2 0 3' end of SEQ ID N0:43; and (ab) the nucleotide sequence of the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at SO degrees C; and 2 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that 3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ 1D N0:43, but excluding the poly(A) tail at the 3' end of SEQ ID N0:43; and (bb) the nucleotide sequence of the cDNA insert of clone vc34_l deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:43, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:43 to a nucleotide sequence corresponding to the 3' end of SEQ TD N0:43 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:43. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:43 from nucleotide 232 to nucleotide 1461, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:43 from nucleotide 232 to nucleotide 1461, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:43 from nucleotide 232 to nucleotide 1461. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:43 from nucleotide 280 to nucleotide 1461, and extending contiguously from a 2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:43 from nucleotide 280 to nucleotide 1461, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:43 from nucleotide 280 to nucleotide 1461.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:44;
(b) a fragment of the amino acid sequence of SEQ ID N0:44, the fragment comprising eight contiguous amino acids of SEQ ID N0:44; and (c) the amino acid sequence encoded by the cDNA insert of clone 3 0 vc34_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:44, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 200 to amino acid 209 of SEQ ID N0:44.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45 from nucleotide 1922 to nucleotide 2350;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:45 from nucleotide 2237 to nucleotide 2350;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc47 1 deposited with the ATCC under accession number 98886;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc47 1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature 2 0 protein coding sequence of clone vc47 1 deposited with the ATCC under accession number 98886;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc47 1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid 2 5 sequence of SEQ ID N0:46;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:46 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:46;
(j) a polynucleotide which is an allelic variant of a polynucleotide of 3 0 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:45.
Preferably, such .polynucleotide comprises the nucleotide sequence of SEQ ID
N0:45 from nucleotide 1922 to nucleotide 2350; the nucleotide sequence of SEQ
ID N0:45 from nucleotide 2237 to nucleotide 2350; the nucleotide sequence of the full-length protein coding sequence of clone vc47 1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vc47 1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc47 1 deposited with the ATCC under accession number 98886.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID N0:46.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:45.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:45, but excluding the poly(A) tail at the 3' end of SEQ ID N0:45; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vc47 1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);

and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:45, but excluding the poly(A) tail at the 3' end of SEQ ID N0:45; and (bb) the nucleotide sequence of the cDNA insert of clone vc47 1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:45, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:45 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:45. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 0 corresponding to the cDNA sequence of SEQ ID N0:45 from nucleotide 1922 to nucleotide 2350, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:45 from nucleotide 1922 to nucleotide 2350, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:45 from nucleotide 1922 to nucleotide 2350. Also preferably the polynucleotide isolated according to the 2 5 above process comprises a nucleotide sequence corresponding to the cDNA
sequence of SEQ ID N0:45 from nucleotide 2237 to nucleotide 2350, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:45 from nucleotide 2237 to nucleotide 2350, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:45 from nucleotide 2237 to nucleotide 2350.
3 0 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:46;

(b) a fragment of the amino acid sequence of SEQ ID N0:46, the fragment comprising eight contiguous amino acids of SEQ ID N0:46; and (c) the amino acid sequence encoded by the cDNA insert of clone vc47 1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:46. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:46, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID N0:46.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:47 from nucleotide 111 to nucleotide 1337;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:47 from nucleotide 246 to nucleotide 1337;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone v~ 1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:48;

(i) a polynudeotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:48;
(j) a polynudeotide which is an allelic variant of a polynudeotide of (a)-{g) above;
(k) a polynudeotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynudeotide that hybridizes under stringent conditions to any one of the polynudeotides specified in (a)-(i); and (m) a polynudeotide that hybridizes under stringent conditions to any one of the polynudeotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:47.
Preferably, such polynudeotide comprises the nucleotide sequence of SEQ ID
N0:47 from nucleotide 111 to nucleotide 1337; the nucleotide sequence of SEQ
ID N0:47 from nucleotide 246 to nucleotide 1337; the nucleotide sequence of the full-length protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of done v~ 1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynudeotide encodes the full-length or a mature protein encoded by the cDNA
insert 2 0 of clone vc54_1 deposited with the ATCC under accession number 98$86. In further preferred embodiments, the present invention provides a poiynudeotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:48, or a polynudeotide 2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 199 to amino acid 208 of SEQ ID N0:48.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:47.
3 0 Further embodiments of the invention provide isolated polynudeotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:47, but excluding the poly(A) tail at the 3' end of SEQ ID N0:47; and (ab) the nucleotide sequence of the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:47, but excluding the poly{A) tail at the 3' end of SEQ ID N0:47; and (bb) the nucleotide sequence of the cDNA insert of clone 2 0 v~ 1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:47 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:47. Also preferably the 3 0 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:47 from nucleotide 111 to nucleotide 1337, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:47 from nucleotide 111 to nucleotide 1337, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:47 from nucleotide 111 to nucleotide 1337. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:47 from nucleotide 246 to nucleotide 1337, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:47 from nucleotide 246 to nucleotide 1337, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:47 from nucleotide 246 to nucleotide 1337.
1n other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:48;
(b) a fragment of the amino acid sequence of SEQ ID N0:48, the fragment comprising eight contiguous amino acids of SEQ ID N0:48; and (c) the amino acid sequence encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SBQ ID N0:48. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 2 0 of SEQ ID N0:48, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 199 to amino acid 208 of SEQ ID N0:48.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:49 from nucleotide 189 to nucleotide 1637;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:49 from nucleotide 270 to nucleotide 1637;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc57 1 deposited with the ATCC under accession number 98886;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc57 1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:50;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:50 having biological activity, the fragment comprising eight contiguous amino acids of SEQ TD N0:50;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and 2 0 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:49.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:49 from nucleotide 189 to nucleotide 1637; the nucleotide sequence of SEQ
ID N0:49 2 5 from nucleotide 270 to nucleotide 1637; the nucleotide sequence of the full-length protein coding sequence of clone vc57 1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of clone vc57 1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 3 0 of clone vc57 1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucieotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 236 to amino acid 245 of SEQ ID N0:50.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:49.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:49, but excluding the poly(A) tail at the 3' end of SEQ ID N0:49; and (ab) the nucleotide sequence of the cDNA insert of clone vc57 1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleoside sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:49, but excluding the poly(A) tail at the 3' end of SEQ ID N0:49; and (bb) the nucleotide sequence of the cDNA insert of clone vc57 1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in 3 0 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:49, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:49 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:49 from nucleotide 189 to nucleotide 1637, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:49 from nucleotide 189 to nucleotide 1637, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:49 from nucleotide 189 to nucleotide 1637. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:49 from nucleotide 270 to nucleotide 1637, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:49 from nucleotide 270 to nucleotide 1637, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:49 from nucleotide 270 to nucleotide 1637.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:50;
(b} a fragment of the amino acid sequence of SEQ ID N0:50, the 2 0 fragment comprising eight contiguous amino acids of SEQ ID N0:50; and (c) the amino acid sequence encoded by the cDNA insert of clone vc57 1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:50. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:50, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:50 having biological activity, the fragment comprising the amino acid sequence 3 0 from amino acid 236 to amino acid 245 of SEQ ID N0:50.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51 from nucleotide 15 to nucleotide 1934;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:51 from nucleotide 1704 to nucleotide 2934;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vel3_1 deposited with the ATCC under accession number 98886;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vel3_1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vel3_1 deposited with the ATCC under accession number 98886;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vel3_1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:52;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:52 having biological activity, the fragment 2 0 comprising eight contiguous amino acids of SEQ ID N0:52;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
2 5 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:51.
3 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:51 from nucleotide 15 to nucleotide 1934; the nucleotide sequence of SEQ ID
N0:51 from nucleotide 1704 to nucleotide 1934; the nucleotide sequence of the full-length protein coding sequence of clone vel3_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vel3_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vel3_1 deposited with the ATCC under accession number 98886.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 315 to amino acid 324 of SEQ ID N0:52.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:51.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:51, but excluding the poly(A) tail at the 2 0 3' end of SEQ ID N0:51; and (ab) the nucleotide sequence of the cDNA insert of clone vel3_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that 3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:51, but excluding the poly(A) tail at the 3' end of SEQ ID N0:51; and (bb) the nucleotide sequence of the cDNA insert of clone vel3_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:51, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:51 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:51. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:51 from nucleotide 15 to nucleotide 1934, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:51 from nucleotide 15 to nucleotide 1934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:51 from nucleotide 15 to nucleotide 1934. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:51 from nucleotide 1704 to nucleotide 1934, and extending contiguously from a 2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:51 from nucleotide 1704 to nucleotide 1934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:51 from nucleotide 1704 to nucleotide 1934.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino arid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:52;
(b) a fragment of the amino acid sequence of SEQ ID N0:52, the fragment comprising eight contiguous amino acids of SEQ ID N0:52; and (c) the amino acid sequence encoded by the cDNA insert of clone 3 0 vel3_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:52. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino and sequence of SEQ ID N0:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:52, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 315 to amino acid 324 of SEQ ID N0:52.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53 from nucleotide 240 to nucleotide 503;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:53 from nucleotide 318 to nucleotide 503;
(d) a polynucleotide comprising the nucleotide sequence of the full length protein coding sequence of clone vel6_1 deposited with the ATCC under accession number 98886;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vel6_1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature 2 0 protein coding sequence of clone vel6_2 deposited with the ATCC under accession number 98886;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vel6_1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid 2 5 sequence of SEQ ID N0:54;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence,of SEQ ID N0:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:54;
(j) a polynucleotide which is an allelic variant of a polynucleotide of 3 0 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:53.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:53 from nucleotide 240 to nucleotide 503; the nucleotide sequence of SEQ ID
N0:53 from nucleotide 318 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone vel6_1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of clone vel6_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vel6_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID N0:54.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:53.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:53, but excluding the poly(A) tail at the 3' end of SEQ ID N0:53; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vel6_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);

WO 00!11015 PCT/US99/19351 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:53, but excluding the poly(A) tail at the 3' end of SEQ ID N0:53; and (bb) the nucleotide sequence of the cDNA insert of clone vel6_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b){iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:53 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 0 corresponding to the cDNA sequence of SEQ ID N0~3 from nucleotide 240 to nucleotide 503, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:53 from nucleotide 240 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:53 from nucleotide 240 to nucleotide 503. Also preferably the polynucleotide isolated according to the above 2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:53 from nucleotide 318 to nucleotide 503, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:53 from nucleotide 318 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:53 from nucleotide 318 to nucleotide 503.
3 0 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:54;

(b) a fragment of the amino acid sequence of SEQ ID N0:54, the fragment comprising eight contiguous amino acids of SEQ ID N0:54; and (c) the amino acid sequence encoded by the cDNA insert of clone vel6_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:54. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:54, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID N0:54.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:55;
(b) a polynucleoHde comprising the nucleotide sequence of SEQ ID
N0:55 from nucleotide 11 to nucleotide 1063;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:55 from nucleotide 71 to nucleotide 1063;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;
(e) a polynucleotide encoding the full-length protein encoded by the 2 5 cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vf3_1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:56;

(i) a polynucieotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:56;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a poiynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(I) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:55.
Preferably, such polynucieotide comprises the nucleotide sequence of SEQ ID
N0:55 from nucleotide I1 to nucleotide 1063; the nucleotide sequence of SEQ ID
N0:55 from nucleotide 71 to nucleotide 1063; the nucleotide sequence of the full-length protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 2 0 of clone vf3_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:56 having biologicai activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:56, or a poiynucieotide 2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:56 having biological activity, the fragment comprising the amino acid sequence fram amino acid 170 to amino acid 179 of SEQ ID NO:56.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:55.
3 0 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:55, but excluding the poly(A) tail at the 3' end of SEQ ID N0:55; and (ab) the nucleotide sequence of the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probe{s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b} a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:55, but excluding the poly(A) tail at the 3' end of SEQ ID N0:55; and (bb) the nucleotide sequence of the cDNA insert of clone 2 0 vf3_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:55 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:55. Also preferably the 3 0 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:55 from nucleotide 11 to nucleotide 1063, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:55 from nucleotide 11 to nucleotide 1063, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:55 from nucleotide 11 to nucleotide 1063. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:55 from nucleotide 71 to nucleotide 1063, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:55 from nucleotide 71 to nucleotide 1063, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:55 from nucleotide 71 to nucleotide 1063.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:56;
(b) a fragment of the amino acid sequence of SEQ ID N0:56, the fragment comprising eight contiguous amino acids of SEQ ID N0:56; and (c) the amino acid sequence encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 2 0 of SEQ ID N0:56, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 170 to amino acid 179 of SEQ ID N0:56.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:57 from nucleotide 542 to nucleotide 886;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:57 from nucleotide 755 to nucleotide 886;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;
(g) a polynucleofide encoding a mature protein encoded by the cDNA
insert of clone vj2_1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:58;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:58 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:58;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a}-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and 2 0 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (ar(i) and that has a length that is at least 25% of the length of SEQ ID N0:57.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:57 from nucleotide 542 to nucleotide 886; the nucleotide sequence of SEQ ID
N0:57 from nucleotide 755 to nucleotide 886; the nucleotide sequence of the full-length protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 3 0 of clone vj2_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID N0:58.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:57.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:57, but excluding the poly(A) tail at the 3' end of SEQ ID N0:57; and (ab) the nucleotide sequence of the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:57, but excluding the poly(A) tail at the 3' end of SEQ ID N0:57; and (bb) the nucleotide sequence of the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
{ii) hybridizing said primers) to human genomic DNA in 3 0 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:57, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:57 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:57 from nucleotide 542 to nucleotide 886, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:57 from nucleotide 542 to nucleotide 886, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:57 from nucleotide 542 to nucleotide 886. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:57 from nucleotide 755 to nucleotide 886, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ TD
N0:57 from nucleotide 755 to nucleotide 886, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:57 from nucleotide 755 to nucleotide 886.
In other embodim~ts, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:58;
(b) a fragment of the amino acid sequence of SEQ ID N0:58, the 2 0 fragment comprising eight contiguous amino acids of SEQ ID N0:58; and (c) the amino acid sequence encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:58. In further preferred 2 5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:58, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:58 having biological activity, the fragment comprising the amino acid sequence 3 0 from amino acid 52 to amino acid 61 of SEQ ID N0:58.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ TD
N0:59;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59 from nucleotide 30 to nucleotide 344;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:59 from nucleotide 84 to nucleotide 344;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp7 1 deposited with the ATCC under accession number 98886;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp7 1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of done vp7 1 deposited with the ATCC under accession number 98886;
{g} a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vp7 1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:60;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment 2 0 comprising eight contiguous amino acids of SEQ ID NO:60;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
2 5 {1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:59.
3 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:59 from nucleotide 30 to nucleotide 344; the nucleotide sequence of SEQ ID
N0:59 from nucleotide 84 to nucleotide 344; the nucleotide sequence of the full-length protein coding sequence of clone vp7 1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of clone vp7 1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vp7 1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID N0:60.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:59.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:59, but excluding the poly(A) tail at the 2 0 3' end of SEQ ID N0:59; and (ab) the nucleotide sequence of the cDNA insert of clone vp7 1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human øenntr,;r nnra ;., conditions at least as stringent as 4X SSC at 50 degrees C; and 2 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that 3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:59, but excluding the poly(A) tail at the 3' end of SEQ ID N0:59; and (bb) the nucleotide sequence of the cDNA insert of done vp7 1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynudeotide products of step (b)(iii).
Preferably the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:59, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:59 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:59. Also preferably the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:59 from nucleotide 30 to nucleotide 344, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:59 from nucleotide 30 to nucleotide 344, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:59 from nucleotide 30 to nucleotide 344. Also preferably the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:59 from nucleotide 84 to nucleotide 344, and extending contiguously from a 2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:59 from nucleotide 84 to nucleotide 344, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:59 from nucleotide 84 to nucleotide 344.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group 2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:60;
(b) a fragment of the amino acid sequence of SEQ ID N0:60, the fragment comprising eight contiguous amino acids of SEQ ID N0:60; and (c) the amino acid sequence encoded by the cDNA insert of clone 3 0 vp7 1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:60. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:60, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID N0:60.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61 from nucleotide 23 to nucleotide 757;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:61 from nucleotide 119 to nucleotide 757;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
(f) a polynucleotide comprising the nucleotide sequence of a mature 2 0 protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vp8_1 deposited with the ATCC under accession number 98886;
(h) a polynucleotide encoding a protein comprising the amino acid 2 5 sequence of SEQ ID N0:62;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:62;
(j) a polynucleotide which is an allelic variant of a polynucleotide of 3 0 (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleodde that hybridizes under stringent conditions to any one of the polynucleotides specified in {a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:61.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:61 from nucleotide 23 to nucleotide 757; the nucleotide sequence of SEQ ID
N0:61 from nucleotide 119 to nucleotide 757; the nucleotide sequence of the full-length protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;
or the nucleotide sequence of a mature protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vp8_I deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:62, or a polynucleotide encoding a protein comprising a fragment of the amino and sequence of SEQ ID
N0:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID N0:62.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:61.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 2 5 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:61, but excluding the poly(A) tail at the 3' end of SEQ ID N0:61; and (ab) the nucleotide sequence of the cDNA insert of clone 3 0 vp8_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);

and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:61, but excluding the poly(A) tail at the 3' end of SEQ ID N0:61; and (bb) the nucleotide sequence of the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:61, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:61 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:61. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence 2 0 corresponding to the cDNA sequence of SEQ ID N0:61 from nucleotide 23 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:61 from nucleotide 23 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:61 from nucleotide 23 to nucleotide 757. Also preferably the polynucleotide isolated according to the above 2 5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:61 from nucleotide 119 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:61 from nucleotide 119 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:61 from nucleotide 119 to nucleotide 757.
3 0 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:62;

(b) a fragment of the amino acid sequence of SEQ ID N0:62, the fragment comprising eight contiguous amino acids of SEQ ID N0:62; and (c) the amino acid sequence encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:62. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:62, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID N0:62.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:63;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:63 from nucleotide 1048 to nucleotide 3726;
(c) a polynucleotide comprising the nucleotide sequence of the full 2 0 length protein coding sequence of clone vb22_1 deposited with the ATCC
under accession number 98933;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;
2 5 (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vb22_1 deposited with the ATCC under accession number 98933;
3 0 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:64;
(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:64 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:64;

(i) a polynucleotide which is an allelic variant of a polvnucleotide of (a)-(f) above;
(j) a polynucieotide which encodes a species homologue of the protein of (g) or (h) above.;
(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID N0:63.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:63 from nucleotide 1048 to nucleotide 3726; the nucleotide sequence of the full-length protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933; or the nucleotide sequence of a mature protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:64 having biological activity, the fragment preferably comprising eight (more preferably 2 0 twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 441 to amino acid 450 of SEQ ID N0:64.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 5 ID N0:63.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 3 0 in 6X SSC at 65 degrees C to a nucleofide sequence selected from the group consisting of:
(aa) SEQ ID N0:63, but excluding the poly(A) tail at the 3' end of SEQ ID N0:63; and (ab) the nucleotide sequence of the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:63, but excluding the poly(A) tail at the 3' end of SEQ ID N0:63; and (bb) the nucleotide sequence of the cDNA insert of done vb22_1 deposited with the ATCC under accession number 98933;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:63, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:63 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:63 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:63. Also preferably the 2 5 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:63 from nucleotide 1048 to nucleotide 3726, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:63 from nucleotide 1048 to nucleotide 3726, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:63 from nucleotide 3 0 1048 to nucleotide 3726.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:64;

(b) a fragment of the amino acid sequence of SEQ ID N0:64, the fragment comprising eight contiguous amino acids of SEQ ID N0:64; and (c) the amino acid sequence encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:64. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino and sequence of SEQ ID N0:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:64, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 441 to amino acid 450 of SEQ ID N0:64.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:65;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:65 from nucleotide 134 to nucleotide 667;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:65 from nucleotide 191 to nucleotide 667;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;
3 0 (g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc48_1 deposited with the ATCC under accession number 98933;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:66;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:66 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:66;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in {a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:65.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:65 from nucleotide 234 to nucleotide 667; the nucleotide sequence of SEQ ID
N0:65 from nucleotide 191 to nucleotide 667; the nucleotide sequence of the full-length protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;
or the nucleotide sequence of a mature protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 2 0 of clone vc48_1 deposited with the ATCC under accession number 98933. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:66, or a polynucleotide 2 5 encoding a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID N0:66.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:65.
3 0 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID NO:65, but excluding the poly{A) tail at the 3' end of SEQ ID N0:65; and (ab) the nucleotide sequence of the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:65, but excluding the poly(A) tail at the 3' end of SEQ ID N0:65; and (bb) the nucleotide sequence of the cDNA insert of clone 2 0 vc48_1 deposited with the ATCC under accession number 98933;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
2 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:65, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:65 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:65 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:65. Also preferably the 3 0 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:65 from nucleotide 134 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:65 from nucleotide 134 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:65 from nucleotide WO 00/11015 PCT'/US99/19351 134 to nucleotide 667. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:65 from nucleotide 191 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:65 from nucleotide 191 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:65 from nucleotide 191 to nucleotide 667.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:66;
(b) a fragment of the amino acid sequence of SEQ ID N0:66, the fragment comprising eight contiguous amino acids of SEQ ID N0:66; and (c) the amino acid sequence encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:66. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids 2 0 of SEQ ID N0:66, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID N0:66.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
2 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:67;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:67 from nucleotide 65 to nucleotide 457;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:67 from nucleotide 158 to nucleotide 457;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vp3_1 deposited with the ATCC under accession number 98933;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:68;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:68 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:68;
{j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and 2 0 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID N0:67.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:67 from nucleotide 65 to nucleotide 457; the nucleotide sequence of SEQ ID
N0:67 2 5 from nucleotide 158 to nucleotide 457; the nucleotide sequence of the full-length protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;
or the nucleotide sequence of a mature protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert 3 0 of clone vp3_1 deposited with the ATCC under accession number 98933. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:68, or a polynucieotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 60 to amino acid 69 of SEQ ID N0:68.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:67.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynudeotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:67, but excluding the poly(A) tail at the 3' end of SEQ ID N0:67; and (ab) the nucleotide sequence of the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
2 0 and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 5 (ba) SEQ ID N0:67, but excluding the poly(A) tail at the 3' end of SEQ ID N0:67; and (bb) the nucleotide sequence of the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
(ii) hybridizing said primers) to human genomic DNA in 3 0 conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:67, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:67 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:67 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:67. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:67 from nucleotide 65 to nucleotide 457, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:67 from nucleotide 65 to nucleotide 457, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:67 from nucleotide 65 to nucleotide 457. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:67 from nucleotide 158 to nucleotide 457, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:67 from nucleotide 158 to nucleotide 457, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:67 from nucleotide 158 to nucleotide 457.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:68;
(b) a fragment of the amino acid sequence of SEQ ID N0:68, the 2 0 fragment comprising eight contiguous amino acids of SEQ ID N0:68; and (c) the amino acid sequence encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:68. In further preferred 2 5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:68, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:68 having biological activity, the fragment comprising the amino acid sequence 3 0 from amino acid 60 to amino acid 69 of SEQ ID N0:68.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:69;

{b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:69 from nucleotide 29 to nucleotide 1387;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:69 from nucleotide 113 to nucleotide 1387;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc61 1 deposited with the ATCC under accession number 207012;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc61 1 deposited with the ATCC under accession number 207012;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vc61_1 deposited with the ATCC under accession number 207012;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:70;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:70 having biological activity, the fragment 2 0 comprising eight contiguous amino acids of SEQ ID N0:70;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
2 5 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-{i) and that has a length that is at least 25% of the length of SEQ ID N0:69.
3 0 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ
ID
N0:69 from nucleotide 29 to nucleotide 1387; the nucleotide sequence of SEQ ID
N0:69 from nucleotide 113 to nucleotide 1387; the nucleotide sequence of the full-length protein coding sequence of clone vc61 1 deposited with the ATCC under accession number 207012; or the nucleotide sequence of a mature protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:70, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 221 to amino acid 230 of SEQ ID N0:70.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:69.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a} a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:69, but excluding the poly(A) tail at the 2 0 3' end of SEQ ID NO:69; and (ab) the nucleotide sequence of the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;
(ii} hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and 2 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b} a process comprising the steps of:
{i) preparing one or more polynucleotide primers that 3 0 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
{ba) SEQ ID N0:69, but excluding the poly(A) tail at the 3' end of SEQ ID N0:69; and (bb) the nucleotide sequence of the cDNA insert of clone vc61 1 deposited with the ATCC under accession number 207012;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:69, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:69 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:69 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:69. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:69 from nucleotide 29 to nucleotide 1387, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:69 from nucleotide 29 to nucleotide 1387, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:69 from nucleotide 29 to nucleotide 1387. Also preferably the poIynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:69 from nucleotide 113 to nucleotide 1387, and extending contiguously from a 2 0 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:69 from nucleotide 113 to nucleotide 1387, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:69 from nucleotide 113 to nucleotide 1387.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:70;
(b) a fragment of the amino acid sequence of SEQ ID N0:70, the fragment comprising eight contiguous amino acids of SEQ ID N0:70; and (c) the amino acid sequence encoded by the cDNA insert of clone 3 0 vc61_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:70. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino ands of SEQ ID N0:70, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 221 to amino acid 230 of SEQ ID N0:70.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71 from nucleotide 44 to nucleotide 1513;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71 from nucleotide 92 to nucleotide 1513;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:71 from nucleotide 1 to nucleotide 458;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vpl5_1 deposited with the ATCC under accession number 207012;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vpl5_1 deposited with the ATCC under accession number 2 0 207012;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vpl5_1 deposited with the ATCC under accession number 207012;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vpl5_1 deposited with the ATCC under accession number 207012;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:72;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:72 having biological activity, the fragment 3 0 comprising eight contiguous amino acids of SEQ ID N0:72;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a~~); and (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in {a)-(j) and that has a length that is at least 25% of the Length of SEQ ID N0:71.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:71 from nucleotide 44 to nucleotide 1513; the nucleotide sequence of SEQ ID
N0:71 from nucleotide 92 to nucleotide 1513; the nucleotide sequence of SEQ ID N0:71 from nucleotide 1 to nucleotide 458; the nucleotide sequence of the full-length protein coding sequence of clone vpl5_1 deposited with the ATCC under accession number 207012; or the nucleotide sequence of a mature protein coding sequence of clone vpl5_1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vpl5_1 deposited with the ATCC under accession number 207012. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:72 from amino acid 1 to amino acid 139. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:72 having biological activity, the fragment preferably comprising eight (more 2 0 preferably twenty, most preferably thirty) contiguous amino acids of SEQ
ID N0:72, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID N0:72.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:71.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
{a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize 3 0 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID NO:71, but excluding the poly(A) tail at the 3' end of SEQ ID N0:71; and (ab) the nucleotide sequence of the cDNA insert of clone vpl5_1 deposited with the ATCC under accession number 207012;
(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:71, but excluding the poly(A) tail at the 3' end of SEQ ID N0:71; and (bb) the nucleotide sequence of the cDNA insert of clone vpl5_1 deposited with the ATCC under accession number 207012;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
2 0 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ TD N0:71, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:71 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:71 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:71. Also preferably the 2 5 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:71 from nucleotide 44 to nucleotide 1513, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:71 from nucleotide 44 to nucleotide 1513, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:71 from nucleotide 3 0 44 to nucleotide 1513. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:71 from nucleotide 92 to nucleotide 1513, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:71 from nucleotide 92 to nucleotide 1513, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:71 from nucleotide 92 to nucleotide 1513. Also preferably the ,polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:71 from nucleotide 1 to nucleotide 458, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:71 from nucleotide 1 to nucleotide 458, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID
N0:71 from nucleotide 1 to nucleotide 458.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:72;
(b) the amino acid sequence of SEQ ID N0:72 from amino acid I to amino acid 139;
(c) a fragment of the amino acid sequence of SEQ ID N0:72, the fragment comprising eight contiguous amino acids of SEQ ID N0:72; and (d) the amino acid sequence encoded by the cDNA insert of clone vpl5_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino and sequence of SEQ ID N0:72 or the amino acid sequence 2 0 of SEQ ID N0:72 from amino and 1 to amino acid 139. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:72, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:72 2 5 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID N0:72.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:73;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:73 from nucleotide 348 to nucleotide 743;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:73 from nucleotide 414 to nucleotide 743;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vpl7 1 deposited with the ATCC under accession number 207012;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vpl7 1 deposited with the ATCC under accession number 207012;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vpl7_1 deposited with the ATCC under accession number 207012;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vpl7 1 deposited with the ATCC under accession number 207012;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ TD N0:74;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:74 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:74;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynudeotide which encodes a species homologue of the protein 2 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 2 5 25% of the length of SEQ ID N0:73.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:73 from nucleotide 348 to nucleotide 743; the nucleotide sequence of SEQ TD
N0:73 from nucleotide 414 to nucleotide 743; the nucleotide sequence of the full-length protein coding sequence of clone vpl7 1 deposited with the ATCC under accession number 3 0 207012; or the nucleotide sequence of a mature protein coding sequence of clone vpl7 1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vpl7 1 deposited with the ATCC under accession number 207012. In further preferred embodiments, the present invention provides a WO 00/11015 PC1'NS99/19351 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:74, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID N0:74.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:73.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:73, but excluding the poly(A) tail at the 3' end of SEQ ID N0:73; and (ab) the nucleotide sequence of the cDNA insert of clone vpl7 1 deposited with the ATCC under accession number 207012;
(ii) hybridizing said probes) to human genomic DNA in 2 0 conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:73, but excluding the poly(A) tail at the 3' end of SEQ ID N0:73; and 3 0 (bb) the nucleotide sequence of the cDNA insert of clone vpl7 1 deposited with the ATCC under accession number 207012;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:73, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:73 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:73 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:73. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:73 from nucleotide 348 to nucleotide 743, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:73 from nucleotide 348 to nucleotide 743, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:73 from nucleotide 348 to nucleotide 743. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:73 from nucleotide 414 to nucleotide 743, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:73 from nucleotide 414 to nucleotide 743, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:73 from nucieotide 414 to nucleotide 743.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:74;
(b) a fragment of the amino acid sequence of SEQ ID N0:74, the fragment comprising eight contiguous amino acids of SEQ ID N0:74; and (c) the amino acid sequence encoded by the cDNA insert of clone vpl7_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:74. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:74 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:74, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID N0:74.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:75;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:75 from nucleotide 144 to nucleotide 461;
(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vpl9_1 deposited with the ATCC under accession number 207012;
(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vpl9_1 deposited with the ATCC under accession number 207012;
(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vpl9_1 deposited with the ATCC under accession number 207012;
(f) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vpl9_1 deposited with the ATCC under accession number 207012;
(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:76;
2 0 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:76 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:76;
(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
2 5 (j) a polynucleotide which encodes a speaes homologue of the protein of (g) or (h) above ;
(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any 3 0 one of the polynucleotides specified in (a~(h) and that has a length that is at least 25% of the length of SEQ ID N0:75.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:75 from nucleotide 144 to nucleotide 461; the nucleotide sequence of the full-length protein coding sequence of clone vpl9_1 deposited with the ATCC under accession number 207012; or the nucleotide sequence of a mature protein coding sequence of clone vpl9_1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vpl9_1 deposited with the ATCC under accession number 207012. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:76, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID N0:76.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:75.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
2 0 (aa) SEQ ID N0:75, but excluding the poly(A) tail at the 3' end of SEQ ID N0:75; and (ab) the nucleotide sequence of the cDNA insert of clone vpl9_I deposited with the ATCC under accession number 207012;
(ii) hybridizing said probes) to human genomic DNA in 2 5 conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
3 0 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:75, but excluding the poly(A) tail at the 3' end of SEQ ID N0:75; and (bb) the nucleotide sequence of the cDNA insert of clone vpl9_1 deposited with the ATCC under accession number 207012;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:75, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:75 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:75 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:75. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:75 from nucleotide 144 to nucleotide 461, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:75 from nucleotide 144 to nucleotide 461, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:75 from nucleotide 144 to nucleotide 461.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:76;
(b) a fragment of the amino acid sequence of SEQ ID N0:76, the fragment comprising eight contiguous amino acids of SEQ ID N0:76; and (c) the amino acid sequence encoded by the cDNA insert of clone vpl9_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:76. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:76 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:76, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID N0:76.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77 from nucleotide 54 to nucleotide 368;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77 from nucleotide 141 to nucleotide 368;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:77 from nucleotide 51 to nucleotide 332;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vql 1 deposited with the ATCC under accession number 207012;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vql_1 deposited with the ATCC under accession number 207012;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012;
2 0 (h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vql 1 deposited with the ATCC under accession number 207012;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:78;
(j) a polynucleotide encoding a protein comprising a fragment of the 2 5 amino acid sequence of SEQ ID N0:78 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:78;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein 3 0 of (i) or (j) above ;
(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID N0:77.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:77 from nucleotide 54 to nucleotide 368; the nucleotide sequence of SEQ ID
N0:77 from nucleotide 141 to nucleotide 368; the nucleotide sequence of SEQ ID N0:77 from nucleotide 51 to nucleotide 332; the nucleotide sequence of the full-length protein coding sequence of clone vql 1 deposited with the ATCC under accession number 207012;
or the nucleotide sequence of a mature protein coding sequence of clone vq1 1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone vql_1 deposited with the ATCC under accession number 207012. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:78 from amino acid 1 to amino acid 93. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:78, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence 2 0 of SEQ ID N0:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID N0:78.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:77.
Further embodiments of the invention provide isolated polynucleotides produced 2 5 according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
3 0 (aa) SEQ ID N0:77, but excluding the poly(A) tail at the 3' end of SEQ ID N0:77; and (ab) the nucleotide sequence of the cDNA insert of clone vql_1 deposited with the ATCC under accession number 207012;

(ii) hybridizing said probes) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
{ba) SEQ ID N0:77, but excluding the poly(A) tail at the 3' end of SEQ ID N0:77; and (bb) the nucleotide sequence of the cDNA insert of clone vql 1 deposited with the ATCC under accession number 207012;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:77, and 2 0 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:77 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:77 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:77. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:77 from nucleotide 54 to nucleotide 2 5 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:77 from nucleotide 54 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:77 from nucleotide 54 to nucleotide 368. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
3 0 N0:77 from nucleotide 141 to nucleotide 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:77 from nucleotide 141 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:77 from nucleotide 141 to nucleotide 368. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:77 from nucleotide 51 to nucleotide 332, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:77 from nucleotide 51 to nucleotide 332, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID
N0:77 from nucleotide 51 to nucleotide 332.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:78;
(b) the amino acid sequence of SEQ ID N0:78 from amino acid 1 to amino acid 93;
(c) a fragment of the amino acid sequence of SEQ ID N0:78, the fragment comprising eight contiguous amino acids of SEQ ID N0:78; and (d) the amino acid sequence encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:78 or the amino acid sequence of SEQ ID N0:78 from amino acid 1 to amino acid 93. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid 2 0 sequence of SEQ ID N0:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:78, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID N0:78.
2 5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:79;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
3 0 N0:79 from nucleotide 2 to nucleotide 1018;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:79 from nucleotide 53 to nucleotide 1018;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vpl4_1 deposited with the ATCC under accession number 207011;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vpl4_1 deposited with the ATCC under accession number 207011;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vpl4_1 deposited with the ATCC under accession number 207011;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone vpl4_1 deposited with the ATCC under accession number 207011;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:80;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:80 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID N0:80;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a~(g) above;
(k) a polynucleotide which encodes a species homologue of the protein 2 0 of (h) or (i) above ;
(1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i} and that has a length that is at least 2 5 25% of the length of SEQ ID N0:79.
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:79 from nucleotide 2 to nucleotide 1018; the nucleotide sequence of SEQ ID
N0:79 from nucleotide 53 to nucleotide 1018; the nucleotide sequence of the full-length protein coding sequence of clone vpl4_1 deposited with the ATCC under accession number 3 0 207011; or the nucleotide sequence of a mature protein coding sequence of clone vpl4_1 deposited with the ATCC under accession number 207011. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vpl4_1 deposited with the-ATCC under accession number 207011. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID
N0:80, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 164 to amino acid 173 of SEQ ID N0:80.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:79.
Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(aa) SEQ ID N0:79, but excluding the poly(A) tail at the 3' end of SEQ ID N0:79; and (ab) the nucleotide sequence of the cDNA insert of clone vpl4_1 deposited with the ATCC under accession number 207011;
(ii) hybridizing said probes) to human genomic DNA in 2 0 conditions at least as stringent as 4X SSC at 50 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
and (b) a process comprising the steps of:
2 5 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(ba) SEQ ID N0:79, but excluding the poly(A) tail at the 3' end of SEQ ID N0:79; and 3 0 {bb) the nucleotide sequence of the cDNA insert of clone vpl4_1 deposited with the ATCC under accession number 207011;
(ii) hybridizing said primers) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
(iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:79, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
ID N0:79 to a nucleotide sequence corresponding to the 3' end of SEQ ID N0:79 , but excluding the poly(A) tail at the 3' end of SEQ ID N0:79. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID N0:79 from nucleotide 2 to nucleotide 1018, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID N0:79 from nucleotide 2 to nucleotide 101$, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:79 from nucleotide 2 to nucleotide 1018. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
N0:79 from nucleotide 53 to nucleotide 1018, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID
N0:79 from nucleotide 53 to nucleotide 1018, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID N0:79 from nucleotide 53 to nucleotide 1018.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:80;
(b) a fragment of the amino acid sequence of SEQ ID N0:80, the fragment comprising eight contiguous amino acids of SEQ ID N0:80; and (c) the amino acid sequence encoded by the cDNA insert of clone vpl4_1 deposited with the ATCC under accession number 207011;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:80. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:80 having biological activity, the fragment preferably 3 0 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID N0:80, or a protein comprising a fragment of the amino acid sequence of SEQ
ID N0:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 164 to amino acid 173 of SEQ ID N0:80.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.
Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the genes) corresponding to the polynucleotide sequences disclosed herein.
Processes are also provided for producing a protein, which comprise:
(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and (b) purifying the protein from the culture.
The protein produced according to such methods is also provided by the present invention.
Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.
Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.
BR_1~F DESCRIP'TTON OF THE DRAWIN~C;S
Figures 1A and 18 are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

ISOLATED PROTEINS AND POLYNUCLEOTIDES
Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone 3 0 in accordance with known methods. The predicted amino acid sequence {both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.
As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
Clone "vbll 1"
A polynucleotide of the present invention has been identified as clone "vbll l".
vbll_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vbll_1 is a full-length clone, including the entire coding sequence of a secreted protein {also referred to herein as "vbll 1 protein").
The nucleotide sequence of vbll 1 as presently determined is reported in SEQ
ID
N0:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vbll 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:2.
Another 2 0 potential vbl l_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 84 to 236 of SEQ ID NO:1 is reported in SEQ ID N0:121. Amino acids 13 to of SEQ ID N0:121 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26 of SEQ ID N0:121. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a 25 transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID N0:121.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vbll 1 should be approximately 1751 bp.
The nucleotide sequence disclosed herein for vbll 1 was searched against the 3 0 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vbll 1 demonstrated at least some similarity with sequences identified as N94870 (yy63bO5.r1 Homo sapiens cDNA clone 278193 5'). Based upon sequence similarity, vbl l 1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the vbll 1 protein sequence centered around amino acid 27 of SEQ
ID
N0:2.
Clone"vbl2 1"
A polynucleotide of the present invention has been identified as clone "vbl2 1".
vbl2_I was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vbl2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vbl2_1 protein').
The nucleotide sequence of vbl2_1 as presently determined is reported in SEQ
ID
N0:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vbl2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:4.
Amino acids 34 to 46 of SEQ ID N0:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vbl2_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 2 0 vbl2_1 should be approximately 2289 bp.
The nucleotide sequence disclosed herein for vbl2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vbl2_1 demonstrated at least S(1n'1P Cimilarifcr wi~A
~o""e.,..,...
identified as AA426009 (zw49e1 l.sl Soares total fetus Nb2HF8 9w Homo sapiens cDNA
2 5 clone 773420 3', mRNA sequence). Based upon sequence similarity, vbl2_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three additional potential transmembrane domains within the vbl2 1 protein sequence, centered around amino acids 11, 60, and 104 of SEQ ID N0:4, respectively. The nucleotide sequence of vbl2_1 indicates that it may contain a THE1B
3 0 repeat sequence.
vbl2_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 17 kDa was detected in membrane fractions using SDS
polyacrylamide gel electrophoresis.

Clone "vbl4 1"
A polynucleotide of the present invention has been identified as clone "vbl4_1".
vbl4_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vbl4_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vbl4_1 protein").
The nucleotide sequence of vbl4_1 as presently determined is reported in SEQ
ID
N0:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vbl4_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:6.
Amino acids 79 to 91 of SEQ ID N0:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 92. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vbl4_1 protein. Another potential vbl4_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 182 to 484 of SEQ ID N0:5 is reported in SEQ ID N0:122.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vbl4_1 should be approximately 2377 bp.
2 0 The nucleotide sequence disclosed herein for vbl4_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vbl4_1 demonstrated at least some similarity with sequences identified as AF007149 (Homo Sapiens clone 23568, 23621, 23795, 23873 and mRNA sequences), AF0706I2 (Homo sapiens clone 24771 mRNA sequence), T23635 2 5 (Human gene signature HUMGS05495; standard; cDNA to mRNA), and W02197 (za57e04.r1 Soares fetal liver spleen INFI,S Homo sapiens cDNA clone 296670 5', mRNA
sequence). Based upon sequence similarity, vbl4_1 proteins and each similar protein or peptide may share at least some activity.
3 0 Clone "yell 1"
A polynucleotide of the present invention has been identified as clone "vell 1".
vel l_1 was isolated from a human adult brain (Alzheimer s hippocampus level 7) cDNA
library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yell 1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yell 1 protein").
The nucleotide sequence of vel l_1 as presently determined is reported in SEQ
ID
N0:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yel l 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:8. Amino acids 1 to 9 of SEQ ID N0:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino and 10. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vell_1 protein.
The EcolZI/NotI restriction fragment obtainable from the deposit containing clone vell_1 should be approximately 984 bp.
The nucleotide sequence disclosed herein for vell_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vell_1 demonstrated at least some similarity with sequences identified as F22745 (H.sapiens EST sequence (LL,45/C09) from skeletal muscle, mRNA
sequence) and Q60824 (Human brain Expressed Sequence Tag EST00928; standard;
DNA). Based upon sequence similarity, yell 1 proteins and each similar protein or 2 0 peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the yell 1 protein sequence centered around amino acid 35 of SEQ ID N0:8.
Clone "vf2 1"
2 5 A polynucleotide of the present invention has been identified as clone "vf2 1".
vf2_1 was isolated from a human adult heart cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vf2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vf2_1 protein").
3 0 The nucleotide sequence of vf2_1 as presently determined is reported in SEQ ID
N0:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vf2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Amino acids 20 to 32 of SEQ ID NO:10 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 33. Due to the hydrophobic nature of the predicted Ieader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vf2_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ~ 1 should be approximately 1162 bp.
The nucleotide sequence disclosed herein for vf2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vf2_1 demonstrated at least some similarity with sequences identified as AA605037 (no68h 10.s 1 NCI_CGAP_AA 1 Homo sapiens cDNA clone IMAGE:1112035 similar to contains Alu repetitive element;contains element THR
repetitive element; mRNA sequence). Based upon sequence similarity, vf2_1 proteins and each similar protein or peptide may share at least some activity. The TopPredlI computer program predicts two potential transmembrane domains within the vf2_1 protein sequence, one centered around amino acid 30 and another around amino acid 70 of SEQ
ID NO:10. The nucleotide sequence of vf2_1 indicates that it may contain an Alu repetitive element.
2 0 Clone "vg2 1"
A polynucleotide of the present invention has been identified as clone "vg2_1".
vg2_1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vg2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vg2_1 protein").
The nucleotide sequence of vg2_1 as presently determined is reported in SEQ ID
N0:11, and includes a poIy(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vg2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:12. Amino acids 34 to 4b 3 0 of SEQ ID N0:12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature of the predicted Ieader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vg2_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vg2_1 should be approximately 1993 bp.
The nucleotide sequence disclosed herein for vg2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLAST7C and FASTA search protocols. vg2_1 demonstrated at least some similarity with sequences identified as AA830272 (oc45gll.sl NCI CGAP_GCB1 Homo sapiens cDNA clone TMAGE 1352708 3' similar to TR Q92853 Q92853 HU-K4; mRNA sequence) and D31740 (Homo sapiens DNA, CpG island). The predicted amino acid sequence disclosed herein for vg2_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vg2_1 protein demonstrated at least some similarity to sequences identified as AF026124 (schwannoma-associated protein [Mus musculus]) and U60644 (HU-K4 [Homo sapiens]). Based upon sequence similarity, vg2_1 proteins and each similar protein or peptide may share at least some activity.
Profile hidden markov model analysis (Eddy, S. R., 1996, Curr. Opin. Struct.
Biol. 6(3):
361-365; incorporated by reference herein) of the predicted vg2_1 protein revealed two phospholipase D active sites (amino acid residues 209 to 236 and 423 to 449 of SEQ ID
N0:12). Phospholipase D (PLD) genes are members of a superfamily that is defined by 2 0 several highly conserved motifs. In mammals, it has been proposed that phospholipase D
plays a role in membrane vesicular trafficking and in signal transduction.
Using site-directed mutagenesis, twenty-five point mutants have been made in human (hPLDl) and then characterized (Sung et al., 1997, EMBO J. 16(15): 4519-4530;
which is incorporated by reference herein). Sung et al. found that a motif (HxKxxxxD;
see for 2 5 example amino acids 214-221 of SEQ ID N0:12) and a serine/threorune conserved in all members of the PLD superfamily are critical for PLD biochemical activity, suggesting a possible catalytic mechanism. The vg2_1 clone appears to encode a membrane protein that may be a phospholipase related to the phospholipase D family. The TopPredII
computer program predicts four potential transmembrane domains within the vg2_1 3 0 protein sequence, centered around amino acids 40, 305, 330, and 455 of SEQ
ID N0:12, respectively.

Clone "vjl 1"
A polynudeotide of the present invention has been identified as clone "vjl 1".
vjl 1 was isolated from a human fetal brain cDNA library (enriched for Gprotein-coupled receptors) and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
vjl 1 is a full-length done, including the entire coding sequence of a secreted protein (also referred to herein as "vjl_1 protein").
The nucleotide sequence of vjl 1 as presently determined is reported in SEQ ID
N0:13. What applicants presently believe to be the proper reading frame and the predicted amino add sequence of the vjl 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:14. Amino acids 1 to 12 of SEQ ID
N0:14 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 13. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vjl 1 protein. Another potential vjl_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 1795 to 2064 of SEQ ID N0:13 is reported in SEQ ID N0:123.
The EcoRI/NotI restriction fragment obtainable from the deposit containing done vjl_1 should be approximately 2895 bp.
2 0 The nucleotide sequence disclosed herein for vj1 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/B1..ASTX and FASTA search protocols. vjl_1 demonstrated at least some similarity with sequences identified as AA410352 (zvllfOl.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 753337 5', mRNA sequence). Based upon sequence similarity, vj2 1 proteins and each 2 5 similar protein or peptide may share at least some activity. The TopPredII
computer program predicts a potential transmembrane domain within the vj1 1 protein sequence centered around amino acid 70 of SEQ ID N0:14. The nucleotide sequence of vjl indicates that it may contain repetitive elements.
3 0 Clone "vll 1"
A polynudeotide of the present invention has been identified as clone "v11 I".
vll_1 was isolated from a human fetal cartilage cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. v11_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vll 1 protein").
The nucleotide sequence of vll 1 as presently determined is reported in SEQ ID
NOaS, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vll 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:16. Amino acids 187 to 199 of SEQ ID N0:16 are a predicted Ieader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 200. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vll_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone v11 1 should be approximately 1936 bp.
The nucleotide sequence disclosed herein for vll 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vll_1 demonstrated at least some similarity with sequences identified as AA464362 (zx81b12.r1 Soares ovary tumor NbHOT Homo Sapiens cDNA
clone 810143 5', mRNA sequence), M90089 (Mouse inositol 1,4,5-triphosphate receptor mRNA sequence), and T21689 (Human gene signature HUMGS03131; standard; cDNA
2 0 to mRNA). The predicted amino acid sequence disclosed herein for vll_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX
search protocol. The predicted vh_1 protein demonstrated at least some similarity to the sequence identified as U80846 (partial CDS jCaenorhabditis elegansJ). Based upon sequence similarity, vll_1 proteins and each similar protein or peptide may share at least 2 5 some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vll_1 protein sequence, one centered around amino acid 192 and another around amino acid 234 of SEQ ID N0:16.
vll_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 37 kDa was detected in membrane fractions using SDS
3 0 polyacrylamide gel electrophoresis.

Clone "vk2 1"
A polynucleotide of the present invention has been identified as clone "vk2 1".
vk2_1 was isolated from a human adult brain cDNA library (enriched for G-protein-coupled receptors) and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
vk2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vk2_1 protein').
The nucleotide sequence of vk2_1 as presently determined is reported in SEQ ID
N0:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vk2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:18. Amino acids 10 to 22 of SEQ ID N0:18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signai sequence not be separated from the remainder of the vk2_1 protein. Basepairs 416 to 418 of SEQ ID N0:17 may represent the site of an alternatively spliced exon that is not present in clone vk2_1.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vk2_1 should be approximately 1284 bp.
2 0 The nucleotide sequence disclosed herein for vk2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vk2_1 demonstrated at least some similarity with sequences identified as AA152101 (z149f09.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA
clone 505289 3', mRNA sequence) and Q78696 (Sequence encoding therapeutic 2 5 polypeptide from glioblastoma cell line; standard; cDNA to mRNA). The predicted amino acid sequence disclosed herein for vk2_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vk2_1 protein demonstrated at least some similarity to the sequence identified as (Therapeutic polypeptide from glioblastoma cell line). Based upon sequence similarity, 3 0 vk2_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vk2_1 protein sequence, one centered around amino acid 61 and another around amino acid 97 of SEQ ID N0:18.

Clone"vb21 1"
A polynucleotide of the present invention has been identified as clone "vb2l 1".
vb21 1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb21 1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb21 1 protein").
The nucleotide sequence of vb21 1 as presently determined is reported in SEQ
ID
N0:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb21_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID
N0:20. Amino acids 296 to 308 of SEQ ID N0:20 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 309. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb21_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing done vb21 1 should be approximately 4159 bp.
The nucleotide sequence disclosed herein for vb21 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and 2 0 FASTA search protocols. vb21 1 demonstrated at least some similarity with sequences identified as AA026150 (zj99c10.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA
clone 469170 3', mlZIVA sequence), T72108 (Human semaphorin Z gene; standard;
cDNA
to mRNA), U52840 (Human semaphorin F homology, X97817 (M. musculus mRNA for semaphorin F}, and X97818 (M. musculus mRNA for semaphorin G). The predicted 2 5 amino acid sequence disclosed herein for vb21 1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vb21_1 protein demonstrated at least some similarity to sequences identified as W19857 (Human semaphorin Z) and X97818 (samaphorin G [Mus musculus]).
Semaphorins are important membrane proteins involved in axonal guidance in the 3 0 embryonic stage, and may also have a role in nerve regeneration after injury. Based upon sequence similarity, vb21_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four additional potential transmembrane domains within the vb21 1 protein sequence, centered around amino acids 237, 523, 769, and 895 of SEQ ID N0:20, respectively.

'lone "vc35 1"
A polynucleotide of the present invention has been identified as clone "vc35 1".
vc35_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc35_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc35_I protein").
The nucleotide sequence of vc35_1 as presently determined is reported in SEQ
ID
N0:21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc35_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:22. Amino acids 38 to 50 of SEQ ID N0:22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 51. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc35_1 1 5 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc35_1 should be approximately 3042 bp.
The nucleotide sequence disclosed herein for vc35_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BIrASTN/BLASTX and 2 0 FASTA search protocols. vc35_1 demonstrated at least some similarity with sequences identified as AA532364 (nj12a08.s1 NCI_CGAP_Pr22 Homo Sapiens cDNA clone IMAGE:986102, mltNA sequence), AF029343 (human protocadherin 68), and T22263 (Human gene signature HUMGS03835; standard; cDNA to mIZNA). The predicted amino acid sequence disclosed herein for vc35_1 was searched against the GenPept and GeneSeq 2 5 amino acid sequence databases using the B1.ASTX search protocol. The predicted vc35_1 protein demonstrated at least some similarity to sequences identified as (protocadherin-4 [Mus musculus)). Based upon sequence similarity, vc35_1 proteins and each similar protein or peptide may share at least some activity.
3 0 Clone "vc36 1"
A polynucleotide of the present invention has been identified as clone "vc36_1".
vc36_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc36_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc36_1 protein").
The nucleotide sequence of vc36_1 as presently determined is reported in SEQ
ID
N0:23, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc36_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:24. Amino acids 24 to 36 of SEQ ID N0:24 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 37. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc36 1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc36_1 should be approximately 1395 bp.
The nucleotide sequence disclosed herein for vc36_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc36_1 demonstrated at least some similarity with sequences identified as AA259070 (zs33c04.r1 NCI_CGAP_GCBl Homo sapiens cDNA clone IMAGE
686982 5', mRNA sequence) and W67508 (zd40f11.s1 Soares fetal heart NbHHI9W
Homo sapiens cDNA clone 343149 3', mRNA sequence). Based upon sequence similarity, vc36_1 2 0 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vc36_1 indicates that it may contain repetitive elements.
Clone "vc38 1"
A polynucleotide of the present invention has been identified as clone "vc38 1".
2 5 vc38_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc38_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc38_1 protein").
The nucleotide sequence of vc38_1 as presently determined is reported in SEQ
ID
3 0 N0:25, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc38_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:26.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc38_1 should be approximately 2468 bp.

The nucleotide sequence disclosed herein for vc38_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc38_1 demonstrated at least some similarity with sequences identified as AF03740t? (neuropeptide Y/peptide YY receptor Ya [Danio rerioJ).
Motifs analysis and profile hidden markov model analysis of the predicted vc38_1 protein both reveal the presence of the G-protein-coupled receptor signature. G-protein-coupled receptors (also called R7G) are an extensive group of hormones, neurotransmitters, odorants, and light receptors which transduce extracellular signals by interaction with guanine nucleotide-binding (G) proteins. Most G-protein-coupled receptors lack a signal peptide, as does the predicted vc38_1 protein. Based upon sequence similarity, vc38_1 proteins and each similar protein or peptide may share at least some activity.
The TopPredII computer program predicts seven potential transmembrane domains within the vc38_1 protein sequence, centered around amino acids 60, 90,130, 170, 225, 280, and 318 of SEQ ID N0:26, respectively.
vc3S_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 71 kDa was detected in conditioned medium using SDS
polyacrylamide gel electrophoresis.
Clone "vc39 1"
2 0 A polynucleotide of the present invention has been identified as clone "vc39_i".
vc39_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc39_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc39_1 protein").
2 5 The nucleotide sequence of vc39_1 as presently determined is reported in SEQ ID
N0:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc39_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:28. Amino acids 2 to 14 of SEQ ID N0:28 are a predicted leader/signal sequence, with the predicted mature 3 0 amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc39_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc39_1 should be approximately 2048 bp.
The nucleotide sequence disclosed herein for vc39_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc39_1 demonstrated at least some similarity with sequences identified as AA631722 (np79d04.s1 NCI_CGAP_Pr2 Homo Sapiens cDNA clone IMAGE:1132519 similar to gb:M21121 T-CELL SPECIFIC RANTES PROTEIN
PRECURSOR (I-iIJMAN); contains Alu repetitive element; mRNA sequence). Based upon sequence similarity, vc39_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vc39_1 protein sequence centered around amino acid 40 of SEQ ID N0:28. The nucleotide sequence of vc39_1 indicates that it may contain an Alu/SVA repetitive element.
Clone "vc40 1"
A polynucleotide of the present invention has been identified as clone "vc40 1".
vc40_I was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc40_1 is a full-length clone, including the 2 0 entire coding sequence of a secreted protein (also referred to herein as "vc40_1 protein").
The nucleotide sequence of vc40_1 as presently determined is reported in SEQ
ID
N0:29, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc40_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:30. Amino acids 19 to 31 2 5 of SEQ ID N0:30 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc40_1 protein.
3 0 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc40_1 should be approximately 2297 bp.
The nucleotide sequence disclosed herein for vc40_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc40_1 demonstrated at least some similarity with sequences identified as AA143014 {z148g04.r1 Scares pregnant uterus NbHPtJ Homo sapiens cDNA
clone 505206 5', mRNA sequence) and T20006 (Human gene signature HUMGS01143;
standard; cDNA to mRNA). Based upon sequence similarity, vc40_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII
computer program predicts three additional potential transmembrane domains within the vc40_1 protein sequence, centered around amino acids 101, 136, and 182 of SEQ ID
N0:30, respectively.
Clone "vc46 1"
A polynucleotide of the present invention has been identified as clone "vc46_1".
vc46_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino and sequence of the encoded protein. vc46_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc46_1 protein").
The nucleotide sequence of vc4b_1 as presently determined is reported in SEQ
ID
N0:31, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc46_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:32. Amino acids 10 to 22 of SEQ ID N0:32 are a predicted leader/signal sequence, with the predicted mature 2 0 amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc46 1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 2 5 vc46_1 should be approximately 2938 bp.
The nucleotide sequence disclosed herein for vc46_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc46_1 demonstrated at least some similarity with sequences identified as AA029404 (ze94e06.r1 Scares fetal heart NbHHI9W Homo sapiens cDNA
3 0 clone 366658 5', mRNA sequence) and AQ071029 (human genomic fragment).
Based upon sequence similarity, vc46_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vc46_1 protein sequence, one centered around amino acid 70 and another around amino acid 130 of SEQ ID N0:32.

vc46_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 19 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone"vc49 1"
A polynucleotide of the present invention has been identified as clone "vc49 1".
vc49_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc49_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc49_1 protein").
The nucleotide sequence of vc49_1 as presently determined is reported in SEQ
ID
N0:33, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc49_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:34. Amino acids 14 to 26 of SEQ ID N0:34 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc49_1 protein.
2 0 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc49_1 should be approximately 3471 bp.
The nucleotide sequence disclosed herein for vc49_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc49_1 demonstrated at least some similarity with sequences 2 5 identified as AI075929 (ov46h11.x1 Soares_testis_NHT Homo sapiens cDNA
clone IMAGE
16404213' similar to TR Q63418 Q63418 PROTOCADHERIN-3; mRNA sequence), I79964 (Sequence 109 from patent US 5708143), and T03572 (Human protocadherin pc3 coding sequence; standard; cDNA). The predicted amino acid sequence disclosed herein for vc49_1 was searched against the GenPept and GeneSeq amino acid sequence databases 3 0 using the BLASTX search protocol. The predicted vc49_1 protein demonstrated at least some similarity to sequences identified as L43592 (protocadherin-3 [Rattus norvegicus]) and 886865 (Human protocadherin pc3). Based upon sequence similarity, vc49_1 proteins and each similar protein or peptide may share at least some activity. The TopPredlT
computer program predicts two potential transmembrane domains within the vc49 WO 00/11015 PC'T/US99/19351 protein sequence, one definite transmembrane domain centered around amino acid and another possible transmembrane domain centered around amino acid 260 of SEQ ID
N0:34. Profile hidden markov model and motifs analyses of the predicted vc49_1 protein sequence have revealed it to contain five cadherin extracellular repeated domain signatures at amino acids 142 to 242, 251 to 347, 356 to 451, 460 to 561, and 576 to 67I of SEQ ID N0:34. Cadherins are a family of animal glyco-proteins responsible for calcium-dependent cell-cell adhesion. Cadherins preferentially interact with themselves in a homophilic manner in connecting cells; thus acting as both receptor and ligand.
Structurally, cadherins are built of the following domains: a signal sequence, followed by a propeptide of about 130 residues, then an extracellular domain of around 600 residues, then a transmembrane region, and finally a C-terminal cytoplasmic domain of about 150 residues. The predicted vc49_1 protein sequence almost exactly follows this structure (its cytoplasmic domain being approximately 100 amino acids). Clearly, vc49_1 protein appears to represent a novel member of the cadherin superfamily.
Clone "vc50 1"
A polynucleotide of the present invention has been identified as clone "vc50 I".
vc50_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the 2 0 amino acid sequence of the encoded protein. vc50_l is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc50_1 protein").
The nucleotide sequence of vc50_1 as presently determined is reported in SEQ
ID
N0:35, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc50_I protein corresponding 2 5 to the foregoing nucleotide sequence is reported in SEQ ID N0:36. Amino acids 20 to 32 of SEQ ID N0:36 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 33. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc50_1 3 0 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc50_1 should be approximately 3819 bp.
The nucleotide sequence disclosed herein for vc50_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. v~ 1 demonstrated at least some similarity with sequences identified as AA193122 (zr39d05.r1 Soares NhHMPu Sl Homo Sapiens cDNA clone 665769 5', mRNA sequence), T26031 (Human gene signature HIJMGS08267; standard;
cDNA to mRNA), 231718 (H.sapiens gene for myelin protein zero), and 299943 (Human DNA sequence from PAC 313L4 on chromosome 1q24). The predicted amino acid sequence disclosed herein for vc50_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted v~ 1 protein demonstrated at least some similarity to the sequence identified as K03242 (rat PO
myelin prepeptide), L24893 (myelin protein zero [Homo sapiensJ), and M62860 (mouse peripheral myelin protein) . Based upon sequence similarity, vc50_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII
computer program predicts an additional potential transmembrane domain within the vc50_1 protein sequence centered around amino acid 181 of SEQ ID N0:36.
vc50_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 26 kDa was detected in membrane fractions using SDS
polyacrylamide gel electrophoresis.
Clone"vc51 1"
A polynucleotide of the present invention has been identified as clone "vc5l I".
2 0 vc51_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc51 1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc51 I protein").
The nucleotide sequence of vc51 1 as presently determined is reported in SEQ
ID
2 5 N0:37, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc51_1 protein corresponding to the foregoing nucleoside sequence is reported in SEQ ID N0:38. Amino acids 12 to 24 of SEQ ID N0:38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 25. Due to the hydrophobic nature of the 3 0 predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc51 1 protein. If the "G" residue at position 388 of SEQ ID N0:37 were deleted, two alternative potential vc51_1 reading frames and predicted amino acid sequences that could be encoded by basepairs 333 to 1310 of SEQ ID N0:37 and by basepairs 139 to 522 of SEQ ID
N0:37 are reported in SEQ ID N0:124 and SEQ ID N0:125, respectively.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc51_1 should be approximately 1992 bp.
The nucleotide sequence disclosed herein for vc51 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc51 1 demonstrated at least some similarity with sequences identified as T21514 (Human gene signature HUMGS02887; standard; cDNA to mRIVA) and W52782 (zd13h06.r1 Soares fetal heart NbHHI9W Homo sapiens cDNA clone 5', mRNA sequence). The predicted amino acid sequence disclosed herein for vc51_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc51_1 protein demonstrated at least some similarity to sequences identified as U90716 (human cell surface protein HCAR), Y07593 (coxsackie and adenovirus receptor protein [Homo sapiens]), Y10320 (mouse coxsackie and adenovirus receptor homology, and W 14146 (Human A33 antigen). Based upon sequence similarity, vc51 1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four additional potential transmembrane domains within the vc51 1 protein sequence centered around amino acids 17, 216, 260, and 373 of SEQ ID NO:38, respectively.
Clone"vc52 1"
A polynucleotide of the present invention has been identified as clone "vc52 1".
vc52_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the 2 5 amino acid sequence of the encoded protein. vc52_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc52_1 protein").
The nucleotide sequence of vc52_1 as presently determined is reported in SEQ
ID
N0:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc52_1 protein corresponding 3 0 to the foregoing nucleotide sequence is reported in SEQ ID N0:40. Amino acids 19 to 31 of SEQ ID N0:40 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc52_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc52_1 should be approximately 2018 bp.
The nucleotide sequence disclosed herein for vc52_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc52_1 demonstrated at least some similarity with sequences identified as AA075627 (zm89a01.s1 Stratagene ovarian cancer (#937219) Homo Sapiens cDNA clone 545064 3', mRNA sequence) and T24879 (Human gene signature HUMGS06985; standard; cDNA to mRNA). The predicted amino acid sequence disclosed herein for vc52_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc52_1 protein demonstrated at least some similarity to sequences identified as AL021890 (putative protein [Arabidopsis thaliana]), L47993 (ORF YJR072c [Saccharomyces cerevisiaej), and (undefined protein (Caenorhabditis elegans]). Based upon sequence similarity, vc52_1 proteins and each similar protein or peptide may share at least some activity.
The TopPredII computer program predicts a potential transmembrane domain within the vc52_1 protein sequence centered around amino acid 145 of SEQ ID N0:40.
vc52_1 protein was expressed in a COS cell expression system, and an expressed 2 0 protein band of approximately 44 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone "vc33 1"
A polynucleotide of the present invention has been identified as clone "vc33 1".
2 5 vc33_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc33_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc33_1 protein").
The nucleotide sequence of vc33_1 as presently determined is reported in SEQ
ID
3 0 N0:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc33_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:42. Amino acids 99 to 111 of SEQ ID N0:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 112. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc33_I
protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc33_1 should be approximately 2877 bp.
The nucleotide sequence disclosed herein for vc33_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLAST7C and FASTA search protocols. vc33_1 demonstrated at least some similarity with sequences identified as AA846599 (aj97g02.s1 Soares parathyroid tumor NbHPA Homo Sapiens cDNA clone IMAGE:1404434 3' similar to gb:M95549 SODIUM/GLUCOSE
COTRANSPORTER-LIKE (HUMAN); mRNA sequence), M95549 (Homo sapiens sodium/glucose cotransporter-like protein mRNA, complete cds), and Q89779 (Cotransporter protein SNSTl cDNA; standard; cDNA). The predicted amino acid sequence disclosed herein for vc33_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc33_1 protein demonstrated at least some similarity to sequences identified as (sodium/glucose cotransporter-like protein [Homo sapiens]) and 873593 (Cotransporter protein SNST1). Based upon sequence similarity, vc33_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts 2 0 three additional potential transmembrane domains within the vc33_1 protein sequence, centered around amino acids 186, 260, and 324 of SEQ ID N0:42, respectively.
vc33_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 45 kDa was detected in membrane fractions using SDS
polyacrylamide gel electrophoresis.
Clone"vc34 1"
A polynucleotide of the present invention has been identified as clone "vc34_1".
vc34_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the 3 0 amino acid sequence of the encoded protein. vc34_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc34_1 protein").
The nucleotide sequence of vc34_1 as presently determined is reported in SEQ
ID
N0:43, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc34_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:44. Amino acids 4 to 16 of SEQ ID N0:44 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc34_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc34_1 should be approximately 3062 bp.
The nucleotide sequence disclosed herein for vc34_Z was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc34_1 demonstrated at least some similarity with sequences identified as AA927558 (om71e04.s1 NCI CGAP_GC4 Homo sapiens cDNA clone IMAGE
1552638 3', ml2NA sequence) and U79281 (Human clone 23588 mRNA sequence).
Based upon sequence similarity, vc34_1 proteins and each similar protein or peptide rilay share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vc34_1 protein sequence, one centered around amino acid 251 and another around amino acid 283 of SEQ ID N0:44.
vc34_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 72 kDa was detected in conditioned medium using SDS
2 0 polyacrylamide gel electrophoresis.
Clone"vc47 1"
A polynucleotide of the present invention has been identified as clone "vc47 1".
vc47 1 was isolated from a human fetal brain cDNA library and was identified as 2 5 encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc47 1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc47_1 protein').
The nucleotide sequence of vc47 1 as presently determixied is reported in SEQ
ID
N0:45, and includes a poly(A) tail. What applicants presently believe to be the proper 3 0 reading frame and the predicted amino acid sequence of the vc47 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:46. Amino acids 93 to 105 of SEQ ID N0:46 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 106. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc47 1 protein.
Another potential vc47 1 reading frame and predicted amino acid sequence that could be encoded by basepairs 1047 to 1322 of SEQ ID N0:45 is reported in SEQ
ID
N0:126. Amino acids 11 to 23 of SEQ ID N0:126 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of this predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID N0:126.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc47_1 should be approximately 3676 bp.
The nucleotide sequence disclosed herein for vc47_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc47_1 demonstrated at least some similarity with sequences identified as AA339320 (EST44392 Fetal brain I Homo sapiens cDNA 5' end, mRNA
sequence) and 802462 (ye82h04.r1 Homo sapiens cDNA clone 124279 5'). Based upon sequence similarity, vc47 1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vc47 1 indicates that it may contain one or more of the following repetitive elements: Alu, L1MB7.
Clone "vc54 1"
A polynucleotide of the present invention has been identified as clone "vc54_1".
v~ 1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc54_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc54_1 protein").
The nucleotide sequence of vc54_1 as presently determined is reported in SEQ
ID
N0:47, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the v~ 1 protein corresponding 3 0 to the foregoing nucleotide sequence is reported in SEQ ID N0:48. Amino acids 33 to 45 of SEQ ID N0:48 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 46. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc54_1 protein.
The EcolZI/NotI restriction fragment obtainable from the deposit containing clone v~ 1 should be approximately 2083 bp.
The nucleotide sequence disclosed herein for vc54_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. v~ 1 demonstrated at least some similarity with sequences identified as AF007152 (Homo Sapiens clone 23649 and 23755 unknown mRNA, partial cds), Q76901 (Human genome fragment (Preferred); standard; DNA), and T46905 (EST014 BL29 Burkitt's lymphoma, Pascalis Sideras Homo sapiens cDNA clone BL29-14 5', mlZIVA
sequence). The predicted amino acid sequence disclosed herein for vc54_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX
search protocol. The predicted vc54_1 protein demonstrated at least some similarity to the sequence identified as AF007152 (unknown (Homo sapiens]). Based upon sequence similarity, vc54_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vc54_1 protein sequence, one centered around amino acid 220 and another around amino acid 247 of SEQ ID N0:48.
v~ 1 protein was expressed in a COS cell expression system, and an expressed 2 0 protein band of approximately 44 kDa was detected in membrane fractions using SDS
polyacrylamide gel electrophoresis.
Clone"vc57 1"
A polynucleotide of the present invention has been identified as clone "vc57 1".
2 5 vc57 1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc57_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc57 1 protein").
The nucleotide sequence of vc57 1 as presently determined is reported in SEQ
ID
3 0 N0:49, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc57 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ TD N0:50. Amino acids 15 to 27 of SEQ ID N0:50 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc57_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc57 1 should be approximately- 2564 bp.
The nucleotide sequence disclosed herein for vc57 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc57 1 demonstrated at least some similarity with sequences identified as AA156231 (z150a11.s1 Scares pregnant uterus NbHPU Homo sapiens cDNA
clone 505340 3', mRNA sequence). The predicted amino acid sequence disclosed herein for vc57 1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc57 1 protein demonstrated at least some similarity to the sequence identified as U41635 (OS-9 precursor [Homo Sapiens]).
Based upon sequence similarity, vc57 1 proteins and each similar protein or peptide may share at least some activity.
vc57 1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 51 kDa was detected in conditioned medium using SDS
polyacrylamide gel electrophoresis.
2 0 Clone "vela 1"
A polynucleotide of the present invention has been identified as clone "vela 1 ".
vel3_1 was isolated from a human adult brain (Alzheimer's hippocampus level 7) cDNA
library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vel3_1 is a full-2 5 length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vel3_1 protein").
The nucleotide sequence of vel3_1 as presently determined is reported in SEQ
ID
N0:51, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vel3_1 protein corresponding 3 0 to the foregoing nucleotide sequence is reported in SEQ ID N0:52. Amino acids 551 to 563 of SEQ ID N0:52 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 564. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vela 1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vel3_1 should be approximately 3046 bp.
The nucleotide sequence disclosed herein for vel3_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vel3_1 demonstrated at least some similarity with sequences identified as AA587395 (nn82h06.s1 NCI_CGAP Co9 Homo Sapiens cDNA clone IMAGE:1090427 similar to contains element THR repetitive element; mltNA
sequence) and Q76778 (Human genome fragment (Preferred); standard; DNA). The predicted amino acid sequence disclosed herein for vel3_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vel3_1 protein demonstrated at least some similarity to the sequence identified as U50828 (sel-1 gene product [Caenorhabditis elegans]). Based upon sequence similarity, vel3_1 proteins and each similar protein or peptide may share at least some activity.
Clone "ve 6 1"
A polynucleotide of the present invention has been identified as clone "vel6_1".
vel6_1 was isolated from a human adult brain (Alzheimer's hippocampus level 7) cDNA
2 0 library and was identified as encoding a secreted or transmembrane protein on the basis of rnmputer analysis of the amino acid sequence of the encoded protein. vel6_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vel6_1 protein").
The nucleotide sequence of vel6_1 as presently determined is reported in SEQ
ID
N0:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vel6_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:54. Amino acids 14 to 26 of SEQ ID N0:54 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the 3 0 predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vel6 1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vel6_1 should be approximately 2033 bp.

The nucleotide sequence disclosed herein for vel6_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the databases. The nucleotide sequence of vel6_1 indicates that it may contain one or more of the following repetitive elements:
Alu, MER.
Clone "vf3 1"
A polynucleotide of the present invention has been identified as clone "vf3 1".
vf3_1 was isolated from a human adult heart cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vf3_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vf3_1 protein").
The nucleotide sequence of vf3_1 as presently determined is reported in SEQ ID
N0:55, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vf3_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:56. Amino acids 8 to 20 of SEQ ID N0:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should 2 0 the predicted leader/signal sequence not be separated from the remainder of the vf3_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vf3_1 should be approximately 2987 bp.
The nucleotide sequence disclosed herein for vf3_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vf3_1 demonstrated at least some similarity with sequences identified as 278394 (H.sapiens mRNA, expressed sequence tag ICRFp507K11187 (5'), mRNA sequence). The predicted amino acid sequence disclosed herein for vf3_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the 3 0 BLASTX search protocol. The predicted vf3_1 protein demonstrated at least some similarity to the sequence identified as U41558 (K02B2.3 gene product [Caenorhabditis elegans]). Based upon sequence similarity, vf3_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vf3_1 protein sequence, one centered around amino acid 242 and another around amino acid 275 of SEQ ID
N0:56.
vf3_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 39 kDa was detected in membrane fractions using SDS
S polyacrylamide gel electrophoresis.
Clone "~~ 1"
A polynucleotide of the present invention has been identified as clone "vj2_I".
vj2_1 was isolated from a human fetal brain (whole brain, enriched for Gprotein-coupled I O receptors) cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vj2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vj2_1 protein").
The nucleotide sequence of vj2_1 as presently determined is reported in SEQ ID
15 N0:57, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vj2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:58. Amino acids 59 to 71 of SEQ ID N0:58 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 72. Due to the hydrophobic nature of the 2 0 predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vj2_1 protein.
Another potential vj2_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 146 to 400 of SEQ ID N0:57 is reported in SEQ ID
N0:127.
2 5 The TopPredlT computer program predicts two potential transmembrane domains within the amino acid sequence of SEQ ID N0:127.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vj2_1 should be approximately 1762 bp.
The nucleotide sequence disclosed herein for vj2_1 was searched against the 3 0 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and PASTA search protocols. vj2_1 demonstrated at least some similarity with sequences identified as N36445 (yx83c04.r1 Homo Sapiens cDNA clone 268326 5'). Based upon sequence similarity, vj2_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the vj2_1 protein sequence, centered around amino acids 30, 67, and 90 of SEQ ID N0:58, respectively. The nucleotide sequence of vj2_1 indicates that it may contain one or more repetitive elements.
Clone "vp7 1"
A polynucleotide of the present invention has been identified as done "vp7 1".
vp7 1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp7_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp7 1 protein").
The nucleotide sequence of vp7_1 as presently determined is reported in SEQ ID
N0:59, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp7 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:60. Amino acids 6 to 18 of SEQ ID N0:60 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp7 1 protein. Another potential vp7 1 reading frame and predicted amino acid sequence that 2 0 could be encoded by basepairs 2071 to 2430 of SEQ ID N0:59 is reported in SEQ ID
N0:128.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp7 1 should be approximately 2638 bp.
The nucleotide sequence disclosed herein for vp7_1 was searched against the 2 5 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp7 1 demonstrated at least some similarity with sequences identified as N49433 (yv21e12.r1 Homo sapiens cDNA clone 243406 5') and Q63862 (AP2 sequence obtained by PCR for tumour specific DNA; standard; cDNA). Based upon sequence similarity, vp7 1 proteins and each similar protein or peptide may share at least 3 0 some activity. The TopPredlT computer program predicts an additional potential transmembrane domain within the vp7_1 protein sequence centered around amino acid 75 of SEQ ID N0:60. The nucleotide sequence of vp7 1 indicates that it may contain one or more Alu repeat sequences.

Clone "vn8 1 "
A polynucleotide of the present invention has been identified as clone "vp8_1".
vp8_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp8_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp8_1 protein").
The nucleotide sequence of vp8_1 as presently determined is reported in SEQ ID
N0:61, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp8_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:62. Amino acids 20 to 32 of SEQ ID N0:62 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 33. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp8_1 protein. If two insertions of "C" residues were made in the nucleotide sequence of SEQ
ID N0:61, one after the "A" at position 380 and another after the "G" at position 382, the resulting nucleotide sequence would be predicted to encode the amino acid sequence reported in SEQ ID N0:129.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone 2 0 vp8_1 should be approximately 1513 bp.
The nucleotide sequence disclosed herein for vp8_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp8_1 demonstrated at least some similarity with sequences identified as AA284421 (zs59c10.r1 NCI_CGAP_GCBl Homo sapiens cDNA clone IMAGE
2 5 701778 5' similar to contains AIu repetitive element; mltNA sequence) and (Human PAC clone DJ525N14 from Xq23, complete sequence). Based upon sequence similarity, vp8_1 proteins and each similar protein or peptide may share at least some activity. Profile hidden markov model analysis reveals the presence of an SH2 domain in the predicted vp8_1 protein (SEQ ID N0:62). SH2 domains function as regulatory 3 0 modulators of infra-cellular signalling cascades by interacting with high affinity to phosphotyrosine-containing target peptides in a sequence-specific and strictly phosphoryiation-dependent manner. The nucleotide sequence of vp8_1 indicates that it may contain one or more AIu repeat sequences.

vp8_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 34 kDa was detected in membrane fractions using SDS
polyacrylamide gel electrophoresis. ' Clone"vb22 1"
A polynucleotide of the present invention has been identified as clone "vb22_1".
vb22_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb22_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb22_1 protein").
The nucleotide sequence of vb22_1 as presently determined is reported in SEQ
ID
N0:63, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb22_I protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID
N0:64.
Another potential vb22_1 reading frame and predicted amino acid sequence is encoded by basepairs 152 to 1006 of SEQ ID N0:63 and is reported in SEQ ID N0:130.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb22_1 should be approximately 4176 bp.
The nucleotide sequence disclosed herein for vb22_1 was searched against the 2 0 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb22_1 demonstrated at least some similarity with sequences identified as L10335 (Homo sapiens neuroendocrine-specific protein C (NSP) mRNA, complete cds), N21304 (yx53f07.s1 Homo sapiens cDNA clone 265477 3' similar to SP:A60021 A60021 TROPOMYOSIN-RELATED PROTEIN, NEURONAL), and V23695 2 5 (Human NSPLP protein A coding sequence; standard; cDNA). The predicted amino acid sequence disclosed herein for vb22_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vb22_1 protein demonstrated at least some similarity to sequences identified as (nueroendocrine-speciEc protein A [Homo sapiens]) and W53947 {Human NSPLP
protein 3 0 A). Based upon sequence similarity, vb22_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the vb22_1 protein sequence, one centered around amino acid 730 and another around amino acid 846 of SEQ ID N0:64. The nucleotide sequence of vb22_1 appears to contain a short simple nucleotide repeat ("GGA") region.

Clone "vc48 1"
A polynucleotide of the present invention has been identified as clone "vc48_I".
vc48_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc48_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc48_I protein").
The nucleotide sequence of vc48_1 as presently determined is reported in SEQ
ID
N0:65, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc48_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:66. Amino acids 7 to 19 of SEQ ID N0:66 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc48_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc48_1 should be approximately 3096 bp.
The nucleotide sequence disclosed herein for vc48_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and 2 0 FASTA search protocols. vc48_1 demonstrated at least some similarity with sequences identified as AA292779 (zt56c06.s1 Soares ovary tumor NbHOT Homo sapiens cDNA
clone 726346 3', mRNA sequence). The predicted amino acid sequence disclosed herein for vc48_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc48_1 protein demonstrated at least 2 5 some sirrularity to sequences identified as AL031765 (Drosophila genomic product 22E5.z) and 281058 {F11E6.e [Caenorhabditis elegans]). Based upon sequence similarity, vc48_1 proteins and each similar protein or peptide may share at least some activity.
The TopPredII computer program predicts four potential transmembrane domains within the vc48_1 protein sequence, one centered around amino acid 39 and others around amino 3 0 acids 69,107 and 134 of SEQ ID N0:66, respectively. The nucleotide sequence of vc48_1 appears to contain a simple nucleotide repeat ("AC") and one or more of the following repetitive elements: Alu and MIR.

WO 00/11015 PC1'/US99/19351 Clone "vp3 1"
A polynucleotide of the present invention has been identified as clone "vp3_1".
vp3_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp3_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp3_1 protein").
The nucleotide sequence of vp3_1 as presently determined is reported in SEQ ID
N0:67, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp3_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:68. Amino acids 19 to 32 of SEQ ID N0:68 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp3_1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp3_1 should be approximately 552 bp.
The nucleotide sequence disclosed herein for vp3_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and 2 0 FASTA search protocols. vp3_1 demonstrated at least some similarity with sequences identified as AA225045 (nc34c06.r1 NCI_CGAP_Pr2 Homo Sapiens cDNA clone IMAGE
1010026, mRNA sequence), M18157 (Human glandular kallikrein gene, complete cds), and T35868 (Prostate-specific antigen gene partial sequence; standard; DNA). Based upon sequence similarity, vp3_1 proteins and each similar protein or peptide may share at least 2 5 some activity.
Clone "vc61 1"
A polynucleotide of the present invention has been identified as clone "vc61 1".
vc61_1 was isolated from a human fetal brain cDNA library and was identified as 3 0 encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc61 1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc61 1 protein").
The nucleotide sequence of vc61 1 as presently determined is reported in SEQ
ID
N0:69, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc61_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:70. Amino acids 16 to 28 of SEQ ID N0:70 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 29. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc61 1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc61_1 should be approximately 3199 bp.
The nucleotide sequence disclosed herein for vc61 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc61 1 demonstrated at least some similarity with sequences identified as AI028115 (ow51d09.x1 Soares_parathyroid tumor_NbHPA Homo Sapiens cDNA clone IMAGE 1650353 3' similar to gb S67859 TRANSCRIPT ION I1VTTIA'I'ION
FACTOR IIE-ALPHA CHAIN (HUMAN); m,~A), V20913 (Human induced tumour protein cDNA), and 299129 (Human DNA sequence from clone 425C14 on chromosome 6q22 Contains the HSF2 gene for Heat Shock Factor 2 (Heat Shock Transcription Factor 2, HST'F 2) and an unknown gene similar to the placental protein D1FF33 gene;
Contains ESTs, ST'Ss and GSSs, complete sequence). Tie predicted amino acid sequence disclosed 2 0 herein for vc61 1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLAST7C search protocol. The predicted vc62_1 protein demonstrated at least some similarity to sequences identified as W52812 (Human induced tumour protein) and 299129 (dJ425C14.2 (Placental protein D1FF33 LIKE) [Homo sapiens]). The deduced vc61 1 protein has amino acid similarity to human and mouse diff33 protein.
2 5 Diff33 is a transmembrane protein which is overexpressed in testicular tumors from polyomavirus large T-antigen transgenic mice. Based upon sequence similarity, vc61_1 proteins and each similar protein or peptide may share at least some activity.
The TopPredII computer program predicts nine additional potential transmembrane domains within the vc61_1 protein sequence, centered around amino acids 50,100,150, 210, 240, 3 0 270, 320, 390, and 430 of SEQ ID N0:70, respectively. The nucleotide sequence of vc61_1 indicates that it may contain an Alu repetitive element.

Clone "vpl5 1"
A polynucleotide of the present invention has been identified as clone "vpl5_1".
vpl5_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vpl5_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vpl5_1 protein").
The nucleotide sequence of vpl5_1 as presently determined is reported in SEQ
ID
N0:71, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vpl5_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID
N0:72. Amino acids 4 to 16 of SEQ ID N0:72 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17. Due to the hydrophobic nature of the predicted Ieader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vpl5_1 protein. If a "C" residue were inserted between nucleotides 458 and 459 of SEQ
ID N0:71, nucleotides 44 to 568 of the resulting nucleotide sequence would encode a protein having an amino acid sequence reported as SEQ ID N0:131.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vpl5_1 should be approximately 2033 bp.
2 0 The nucleotide sequence disclosed herein for vpl5_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vpl5_1 demonstrated at least some similarity with sequences identified as AI033082 (ow97g04.s1 Soares_fetal_Iiver_spleen_1NFLS Sl Homo Sapiens cDNA clone IMAGE 1654806 3', mRNA sequence) and T21877 (Human gene signature HUMGS03418). The predicted amino acid sequence disclosed herein for vpl5_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vpl5_1 protein demonstrated at least some similarity to sequences identified as 845335 (Thrombomodulin analogue Q336N, Q365E) and U94333 (ClqR(p) (Homo sapiens]). The predicted vpl5_1 protein shows some amino 3 0 acid similarity to multiple thrombomodulin analogues (such as GeneSeq accession number 845335), and shows some end-to-end similairity to GenPept accession number U94333, which is described as a "... human Clq/MBL/SPA receptor that mediates enhanced phagocytosis in vitro" (Nepomuceno et al., 1997, Immunity 6(2):119-129, which is incorporated by reference herein). Based upon sequence similarity, vpl5_1 proteins and each similar protein or peptide may share at least some activity.
vpl5_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 24 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.
Clone "vol7 1"
A polynucleotide of the present invention has been identified as clone "vpl7 1".
vpl7 1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vpl7 1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vpl7 1 protein").
The nucleotide sequence of vpl7 1 as presently determined is reported in SEQ
ID
N0:73, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vpl7 1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID
N0:74. Amino ands 10 to 22 of SEQ ID N0:74 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain 2 0 should the predicted leader/signal sequence not be separated from the remainder of the vpl7 1 protein.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vpl7 1 should be approximately 3150 bp.
The nucleotide sequence disclosed herein for vpl7 1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vpl7 1 demonstrated at least some similarity with sequences identified as AI056890 (oz03g07.x1 Soares_fetal_Iiver_spleen_1NFLS_Sl Homo sapiens cDNA clone IMAGE 1674300 3', mRNA sequence) and T64815 (Tumour suppressor activated pathway gene TSAP6). Based upon sequence similarity, vpl7_1 proteins and 3 0 each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vpl7 1 protein sequence, one centered around amino acid 50 and another around amino acid 80 of SEQ ID N0:74.

Clone "vnl9 1 "
A polynucleotide of the present invention has been identified as clone "vpl9_1".
vpl9_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vpl9_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vpl9_1 protein').
The nucleotide sequence of vpl9_1 as presently determined is reported in SEQ
ID
N0:75, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vpl9_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID
N0:76.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vpl9_1 should be approximately 971 bp.
The nucleotide sequence disclosed herein for vpl9_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and PASTA search protocols. vpl9_1 demonstrated at least some similarity with sequences identified as AA716408 (Zg64b02.s1 Soares fetal heart NbHHI9W Homo sapiens cDNA
clone 398091 3', mRNA sequence) and T20711 (Human gene signature HUMGS01928).
Based upon sequence similarity, vpl9_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential 2 0 transmembrane domain within the vpl9_1 protein sequence centered around amino acid 23 of SEQ ID N0:76; due to its hydrophobic nature, this region (amino acids 20 to 32) could also be a leader/signal sequence, with the mature protein beginning at amino acid 33 of SEQ ID N0:76.
Clone "val 1"
A polynucleotide of the present invention has been identified as clone "vql 1".
vql 1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vql_1 is a full-length clone, including the 3 0 entire coding sequence of a secreted protein (also referred to herein as "vql 1 protein").
The nucleotide sequence of vql 1 as presently determined is reported in SEQ ID
N0:77, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq1_I protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:78. Amino acids 17 to 29 of SEQ ID N0:78 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vql_1 protein. If a "T" residue were inserted between nucleotides 332 and 333 of SEQ
ID
N0:77, nucleotides 54 to 496 of the resulting nucleotide sequence would encode a protein having an amino acid sequence reported as SEQ ID N0:132.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vql 1 should be approximately 873 bp.
The nucleotide sequence disclosed herein for vql_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/gL~~ ~d FASTA search protocols. vql_1 demonstrated at least some similarity with sequences identified as No hits were found in the databases. The TopPredII computer program predicts an additional potential transmembrane domain within the vq1_1 protein sequence, extending from about amino acid 36 to about amino acid 76 of SEQ ID
N0:78.
The nucleotide sequence of vq1 1 indicates that it may contain an Alu repetitive element.
Clone "vul4 1"
2 0 A polynucleotide of the present invention has been identified as clone "vpl4_1".
vpl4_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vpl4_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vpl4_I protein").
The nucleotide sequence of vpl4_1 as presently determined is reported in SEQ
ID
N0:79, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vpl4_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID
N0:80. Amino acids 5 to 17 of SEQ ID N0:80 are a predicted leader/signal sequence, with the predicted 3 0 mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vpl4_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vpl4_1 should be approximately 1355 bp.
The nucleotide sequence disclosed herein for vpl4_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vpl4_1 demonstrated at least some similarity with sequences identified as AI052724 (oz27a12.x1 Soares total_fetus Nb2HF8 9w Homo Sapiens cDNA clone IMAGE:1676542 3' similar to SW:yQIQ_BACSU P54554 HYPOTHETICAL OXIDOREDUCTASE IN GLNQ-ANSR INTERGENIC REGION;
mRNA sequence) and T20001 (Human gene signature HUMGS01138). The predicted amino acid sequence disclosed herein for vpl4_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vpl4_1 protein demonstrated at least some similarity to sequences identified as 861477 (Clavulanic acid dehydrogenase sequence) and 299116 (similar to ketoacyI
reductase [Bacillus subtilis]). The predicted vpl4_1 protein shows some amino acid similarity to various dehydrogenases due to the presence of a short-chain alcohol dehydrogenase family signature at amino acids 51 to 240 of SEQ 1D NO:80, as detected by motifs and hidden markov model analysis. Based upon sequence similarity, vpl4_1 proteins and each similar protein or peptide may share at least some activity.
The TopPredII computer program predicts four additional potential transmembrane domains within the vpl4_1 protein sequence, centered around amino acids 55, 195, 230, and 300 of SEQ ll~ N0:80, respectively.
Deposit of Clones Clones vbll_l, vbl2_1, vbl4_l, yell 1, vf2_l, vg2_l, vjl_l, and vll_1 were 2 5 deposited on August 20,1998 with the ATCC (American Type Culture Collection,10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98846, from which each clone comprising a particul~. polynucleotide is obtainable.
Clone vk2_1 was deposited on August 20,1998 with the ATCC (American Type 3 0 Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 98838, from which the vk2_1 clone comprising a particular polynucleotide is obtainable.

Clones vb21_l, vc35_l, vc36_l, vc38_l, vc39_1, vc40_l, vc46_1, vc49_l, vc50 1, vc51 1, and vc52_1 were deposited on September 2,1998 with the ATCC (American Type Culture Collection,10801 University Boulevard, Mantissas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98862, from which each clone comprising a particular polynucleotide is obtainable.
Clones vc33_l, vc34_l, vc47 1,, vc54_l, vc57 1, vel3_1, vel6_I, vf3_1, vj2_l, vp7 1, and vp8_1 were deposited on September 22,1998 with the ATCC (.American Type Culture Collection, 10801 University Boulevard, Mantissas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98886, from which each clone comprising a particular polynucleotide is obtainable.
Clones vb22_l, vc48_l, and vp3_1 were deposited on October 16,1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Mantissas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98933, from which each clone comprising a particular polynucleotide is obtainable.
Clones vc61_l, vpl5_l, vpl7 1, vpl9_1, and vql_1 were deposited on December 23,1998 with the ATCC (American Type Culture Collection,10801 University Boulevard, Mantissas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 207012, from which each clone comprising a 2 0 particular polynucleotide is obtainable.
Clone vpl4_1 was deposited on December 23, 1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Mantissas, Virginia 20110-U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 207011, from which the vpl4_1 clone comprising a particular polynucleotide is 2 5 obtainable.
All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. ~ L808(b), and the term of the deposit will comply with 37 C.F.R.
~ 1.806.
3 0 Each clone has been transfected into separate bacterial cells (E. colt' in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al., 1991, Nucleic Acids Res.19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman et al.,1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the CIaI site. In some instances, the deposited clone can become "flipped"
(i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.
Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:
An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.
Cl-ne Probe SeduellCP

2 0 vbl l_1 SEQ ID N0:81 vbl2_1 SEQ ID N0:82 vbl4_1 SEQ ID N0:83 vell_1 SEQ ID N0:84 vf2_1 SEQ ID N0:85 2 5 vg2_1 SEQ ID N0:86 vj1 1 SEQ ID N0:87 vll_1 SEQ ID N0:88 vk2_1 SEQ ID N0:89 vb21_1 SEQ ID N0:90 3 0 vc35_1 SEQ ID N0:91 vc36_1 SEQ ID N0:92 vc38_1 SEQ ID N0:93 vc39_1 S EQ ID N0:94 vc40_1 SEQ ID N0:95 vc46_1 SEQ ID N0:96 vc49_1 SEQ ID N0:97 vc5t1_1 SEQ ID N0:98 vc51_1 SEQ ID N0:99 vc52_1 SEQ ID N0:100 vc33_1 SEQ ID N0:101 vc34_1 SEQ ID N0:102 vc47 1 SEQ ID N0:103 vc54_1 SEQ ID N0:104 vc57 1 S EQ ID N0:105 vel3_1 SEQ ID N0:106 vel6_1 SEQ ID N0:107 vf3_1 SEQ ID N0:108 vj2_1 SEQ ID N0:109 vp7 1 SEQ ID N0:110 ~'8 1 SEQ ID NO:111 vb22_1 SEQ ID N0:112 vc48_1 SEQ ID N0:113 vp3_1 SEQ ID N0:114 2 0 vc61_1 SEQ ID N0:115 vpl5_1 SEQ ID N0:116 vpl7 1 SEQ ID NO:I17 vpl9_1 SEQ ID N0:118 vql_1 SEQ ID N0:119 vpl4_i SEQ ID N0:120 In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-3 0 dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramadite) (Glen Research, cat. no.10-1953)).
The design of the oligonucleotide probe should preferably follow these parameters:

(a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
(b) It should be designed to have a T°, of approx. 80 ° C
(assuming 2° for each A or T and 4 degrees for each G or C).
The oligonucleotide should preferably be labeled with y 32P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used.
Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.
The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 lzl of the stock used to inoculate a sterile culture flask containing 25 m1 of sterile L-broth containing ampicillin at 100 ug/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 ug/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other 2 0 known methods of obtaining distinct, well-separated colonies can also be employed.
Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.
The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCI/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with 2 5 NaOH) containing 0.5% SDS,100 ug/ml of yeast RNA, and 10 mM EDTA
(approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to le+6 dprn/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed 3 0 by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes.
A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.
Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al., Bio/Technology ,~Q, 773-778 (1992) and in R.S.
McDowell, et al., J. Amer. Chem. Soc. ,1~4, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker"
sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.
The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature forms) of such protein may be obtained by expression of the disclosed full-length 2 0 polynucleotide (preferably those deposited with the ATCC) in a suitable mammalian cell or other host cell. The sequences) of the mature forms) of the protein may also be determinable from the amino acid sequence of the full-length form.
The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that 2 5 are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can 3 0 be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.
The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes in situ. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number.
Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address http://www.ncbi.nlm.nih.gov/UruGene/, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UruGene clusters"
so identified will already have been mapped to particular chromosomal sites.
Organisms that have enhanced, reduced, or modified expression of the genes) corresponding to the polynucleotide sequences disclosed herein are provided.
The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris,1994, Trends Phurma~col. Sci.15(7): 250-254; Lavarosky et al.,1997, Biochem. Mol. Med. 62(1):11-22; and Hampel,1998, Prog. Nucleic Acid Res. Mol.
Biol. 58: 1-39; all of which are incorporated by reference herein). The desired change in gene expression can also be achieved through the use of double-stranded ribonucleotide molecules having some complementarity to the mRNA transcribed from the gene, and which interfere with the transcription, stability, or expression of the mRNA
("RNA
intereference" or "RNAi"; Fire et al.,1998, Nature 391 (6669): 806-811;
Montgomery et al., 1998, Proc. Natl. Acad. Sci. LISA 95 (26): 15502-15507; and Sharp,1999, Genes Dev.13 (2):
139-141; all of which are incorporated by reference herein). Transgenic animals that have 3 0 multiple copies of the genes) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided.
Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 $1, incorporated by reference herein).
In addition, organisms are provided in which the genes) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding genes) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk,1992, Bioessays 14(9): 629-633; Zwaal et al.,1993, Proc. Natl.
Acad. Sci. LISA 90(16): 7431-7435; Clark ef al.,1994, Proc. Natl. Acad. Sci.
LISA 91(2): 719-722;
all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al.,1988, Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059;
5,631,153; 5,614, 396;
5,616,491; and 5,679,523; all of which are incorporated by reference herein).
These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein products) of the corresponding gene(s).
Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part 2 0 or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.
For example, the TopPredII computer program can be used to predict the location of 2 5 transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmsmbrane domain, with at least ten transmembrane amino acids on each side of the reported central residue{s).
Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most 3 0 preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity {more preferably, at least 75% identity; mast preferably at least 90%
or 95%
identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity;
most preferably at least 95% identity) with any such segment of any of the disclosed proteins.
In particular, sequence identity may be determined using WU-BLAST
(Washington University BLAST) version 2.0 software, which builds upon WU-BLAST
version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266: 460-480; Altschul et al., 1990, Basic local alignment search tool, Journal of Molecular Biology 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, Nature Genetics 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, Proc. Natl. Acad Sci. USA 90: 5873-5877; all of which are incorporaxed by reference herein). WU-BLAST version 2.0 executable programs for several UNIX
platforms can be downloaded from ftp://blast.wustl.edu/blast/executables. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any forrn or manner without the express written consent of the author; hut the posted executables may otherwise be freely 2 0 used for commercial, nonprofit, or academic purposes. In all search programs in the suite -- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length 2 5 one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, 3 0 seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps.

T'he default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.
Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity {more preferably, at least 75% identity; most preferably at least 90%
identity) with the given polynucleotide, and protein species homologues have at least 30%
sequence identity (more preferably, at least 45% identity; most preferably at least 60%
identity} with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while rrunimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian speties. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, Pan troglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulatta, Papio papio, Papio hamadryas, Cercopithecus aethiops, Cebus capucinus, 2 0 Aotus trivirgatus, Sanguinus Oedipus, Microcebus murinus, Mus musculus, Rattus norvegicus, Cricetulus griseus, Fells catus, Mustela vison, Canis familuxris, Oryctolagus cuniculus, Bos taurus, Ovis cries, Sus scrofa, and Eguus caballus, for which genetic maps have been created allowing the identification of synteruc relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species 2 5 (O'Brien and Seuanez, 1988, Ann. Rev. Genet. 22: 323-351; O'Brien et al., 1993, Nature Genetics 3:103-112; Johansson et al.,1995, Genomics 25: 682-690; Lyons et al.,1997, Nature Genetics 15: 47-56; O'Brien et al.,1997, Trends in Genetics 13(10): 393-399;
Carver and Stubbs, 1997, Genome Research 7:1123-1137; all of which are incorporated by reference herein).
The invention also encompasses allelic variants of the disclosed polynucleotides 3 0 or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90%

identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.
The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.
The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

StringencyPolynucleotideHybridHybridization TemperatureWash and ConditionHybrid LengthBuffer' T~p~~re t and Buffer' A DNA:DNA x 50 65C; lxSSC -or- 65C; 0.3xSSC

42C; lxSSC, 50% formamide B DNA:DNA <50 TB*; lxSSC TB*; lxSSC

C DNA:RNA x 50 67C; lxSSC -or- 67C; 0.3xSSC

45C; lxSSC, 50% formamide D DNA:RNA <50 Tp*; lxSSC TD*; lxSSC

E RNA:RNA x 50 70C; lxSSC -or- 70C; 0.3xSSC

50C; lxSSC, 50% formamide F RNA:RNA <50 TF*; lxSSC TF*; lxSSC

G DNA:DNA x 50 65C; 4xSSC -or- 65C; lxSSC

42C; 4xSSC, 50% formamide H DNA:DNA <50 TH*; 4xSSC *
T

;
H

I DNA:RNA x 50 67C; 4xSSC -or- 67'C; lxSSC

45C; 4xSSC, 50% formamide 1 DNA:RNA <50 T~*; 4xSSC T~'; 4xSSC

RNA:RNA x 50 70C; 4xSSC -or- 67C; lxSSC

50C; 4xSSC, 50% formamide L RNA:RNA <50 T~*; ~ T~*; ~

M DNA:DNA x 50 50C; 4xSSC -or- 50C; 2xSSC

40C; 6xSSC, 50% formamide N DNA:DNA <50 TN*; 6xSSC TN*; 6xSSC

DNA:RNA x 50 55C; 4xSSC -or- 55C; 2xSSC

42C; 6xSSC, 50% formamide P DNA:RNA <50 Tp*; 6xSSC Tp*; 6xSSC

C2 RNA:RNA x 50 60C; 4xSSC -or- 6p 45C; 6xSSC, 50% formamide 2 R RNA:RNA <50 TR*; 4xSSC Ts*; 4xSSC

;: The hybrid length is that anticipated for the hybridized regions) of the hybridizing polynudeotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the 2 5 hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.
': SSPE (ixSSPE is 0.15M NaCI, lOmM NaHZPO" and 1.25mM EDTA, pH 7.4) can be substituted for SSC
(lxSSC is 0.15M NaCI and lSmM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.
3 0 "TB - TR: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (Tm) of the hybrid, where Tm is determined according to the following equations. For hybrids less than 18 base pairs in length, T°,(°C) = 2(# of A + T bases) + 4(# of G +
C bases). For hybrids between 18 and 49 base pairs in length, Tm(°C) =
81.5 + 16.6(log~o[Na']) + 0.41(%G+C) (600/N), where N is the number of bases in the hybrid, and [Na'] is the concentration of sodium ions in the 3 5 hybridization buffer ([Na'] for lxSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and Current Protocols in Molecular Biology,1995, F.M.
Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.
Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60%
sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.
The isolated polynucleotide endcoing the protein of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 9 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 1~5, 537-566 (1990). As defined 2 0 herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.
A number of types of cells may act as suitable host cells for expression of the 2 5 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Co1o205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vi o culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.
3 0 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac RO kit), and such methods are well known in the art, as described in Summers and Smith, Texas A~~ricultural Experiment Station Bulletin No 15.55 (L9871 incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."
The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column 2 0 containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl~ or Cibacrom blue Sepharose~; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.
2 5 Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (T1ZX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and 3 0 lnvitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."
The protein of the invention rnay also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.
The protein may also be produced by known conventional chemical synthesis.
Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.
2 0 The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA
sequences can be made by those skilled in the art using known techniques.
Modifications of interest in the protein sequences may include the alteration, substitution, replacement, 2 5 insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, 3 0 insertion or deletion retains the desired activity of the protein.
Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the presentinvention.
USES AND BIOLOGI~ai. A~y~y The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
Research Uses and Utilities The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare 2 0 with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive I'CR primers for genetic fingerprinting; as a probe to "subtract-out"
known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for 2 5 examination of expression patterns; to raise anti-protein antibodies using DNA
immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those 3 0 described in Gyuris et al.,1993, Cell 75: 791-803 and in Rossi et al.,1997, Proc. Natl. Acad.
Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.
Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to 2 0 Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R.
Kimmel eds.,1987.
Nutrition 1 Uses Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein 2 5 or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention 3 0 can be added to the medium in or on which the microorganism is cultured.
Cvtokine and Cell Proliferation/Differentiation Activity A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RBS, DA1,123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by j. E. Coligan, A.M.
Kruisbeek, D.H.
Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986;
Bertagnolli et al., J. lmmunol.145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327 341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992;
Bowman et al., J.
Immunol. 152: 1756-1761, 1994.
Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in:
Polyclonal T cell 2 0 stimulation, Kruisbeek, A.M, and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a.
Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon y, Schreiber, R.D. In Current Protocols in Immunology, j.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto.1994.
Assays for proliferation and differentiation of hematopoietic and lymphopoietic 2 5 cells include, without limitation, those described in: Measurement of Human and Murine InterIeukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current Protocols in Immunology. j.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983;
3 0 Measurement of mouse and human interleukin 6 - Nordan, R. In Current ProEocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Whey and Sons, Toronto.1991;
Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11- Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;

Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C.
and Turner, K.J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.
Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in:
Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H.
Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Lmmunologic studies in Humans);
Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. j.
Immun.
11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol.
140:508-512, 1988.
Immune Stimulatin ~r SunnreSS,'n_~ Activity A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may ho "~ac,.~ :.- ~L.. ~__~__ _ . ~ . _ deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., 2 0 in regulating (up or down) growth and proliferation of T and/or B
lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations.
These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a 2 5 protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.
3 0 Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease.

WO 00/11015 PC'T/US99/19351 Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.
Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both.
Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent.
Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.
Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B~), eg., preventing 2 0 high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys 2 5 the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (eg., B7 1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the 3 0 molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.
The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad.
Sci USA, 89:11102-11105 (1992). In addition, marine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. $46-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.
Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases.
Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.
2 0 Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T
cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include marine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/Ipr/Ipr mice or NZB hybrid mice, marine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB
rats, and 3 0 marine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York,1989, pp. 840-856).
Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy.
Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B
lymphocyte antigens systemically.
Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.
In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present 2 0 invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides.
For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7 2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7 3-like activity. The 2 5 transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alten~atively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.
The presence of the peptide of the present invention having the activity of a B
lymphocyte antigens) on the surface of the tumor cell provides the necessary 3 0 costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II
molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC
class II
molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I a chain protein and (3Z

microglobulin protein or an MHC class II a chain protein and an MHC class II
~i chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (eg., B7-1, B7-2, B7-3) induces a T
cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated 1.0 immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E.
Coligan, A.M.
Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1 3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl.
Acad. Sci.
USA 78:2488-2492,1981; Herrmann et al., J. Immunol.128:1968-1974,1982; Handa et aL, 2 0 J. Immunol.135:1564-1572,1985; Takai et al., J. Immunol.137:3494-3500,1986; Takai et al., J. lmmunol.140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA
78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J.
Immunol.
135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J.
Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988;
Bertagnolli et al., 2 5 Cellular Immunology 133:327 341,1991; Brown et al., J. Immunol. 153:3079-3092, 1994.
Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033,1990; and Assays for B cell function: In vitro 3 0 antibody production, Mond, J.j. and Brunswick, M. In Current Protocols in Immunology.
J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto.1994.
Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thl and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M.
ICruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500,1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol.
149:3778-3783,1992.
Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079,1995; Porgador et al., Journal of Experimental Medicine 182:255-260,1995;
Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264,1989;
Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640,1990.
Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in:
Darzynkiewicz et al., Cytometry 13:795-808,1992; Gorczyca et al., Leukemia 7:659-670,1993;
Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991;
Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993;
2 0 Gorczyca et al., International Journal of Oncology 1:639-648,1992.
Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778,1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551,1991.
HematopoieSis Re lating Achvit~r A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies.
Even marginal biological activity in support of colony forming cells or of factor-dependent cell 3 0 lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF
activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.
Assays for embryonic stem cell differentiation (which will identify, among others, 2 0 proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151,1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915,1993.
Assays for stem cell survival and differentiation (which will identify, among 2 5 others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematapoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992;
Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, i.K. and 3 0 Briddell, R.A. In Culture of Hematopoietic Cells. R.I. Freshney, et al.
eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY.1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. l-21, Wiley-Liss, Inc.., New York, NY.1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY.1994; Long term culture initiating cell assay, Sutherland, H.j. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.
T~sue Growth Activity A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.
A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals.
Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogeruc agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.
A protein of this invention may also be used in the treatment of periodontal 2 0 disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue 2 5 destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.
Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/Iigament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in 3 0 circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.
The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, 2 0 Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the 2 5 invention.
Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.
It is expected that a protein of the present invention may also exhibit activity for 3 0 generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation WO 00/11015 Pty'T/US99/19351 of fiibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.
A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. W095/16035 (bone, cartilage, tendon);
International Patent Publication No. W095/05846 (nerve, neuronal);
International Patent Publication No. W091 /07491 (skin, endothelium ).
Assays for wound healing activity include, without limitation, those described in:
Winter, Epidermal Wound Hea ,n pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J.
Invest.
Dermatol 71:382-84 (1978).
Activin/Inhibin Activity A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present 2 5 invention, alone or in heterodimers with a member of the inhibin a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-3 0 p group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary.
See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

WO 00/11015 PC'T/US99/19351 The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for activin/inhibin activity include, without limitation, those described in:
Vale et al., Endocrinology 91:562-572,1972; Ling et al., Nature 321:779-782,1986; Vale et al., Nature 321:776-779,1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc.
Natl. Acad. Sci. USA 83:3091-3095,1986.
Chemotactic/Chemokin t~'c Activity A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.
Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.
A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell 2 0 population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.
The activity of a protein of the invention may, among other means, be measured 2 5 by the following methods:
Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion 3 0 include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. ICruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub.
Greene Publishing Associates and Wiley-lnterscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376,1995; Lied et al.

APMIS 103:140-146,1995; Muller et al Eur. J. Immunol. 25: 174ø1748; Gruber et al. J. of Immunol. 152:5860-5867,1994; Johnston et al. J. of Immunol. 153:1762-1768,1994.
Hemostatic and Thrombol r~tnc A protein of the invention may also exhibit hemostatic or thrombolytic activity.
As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Olin. Pharmacol. 26:131-140,1986; Burdick et al., Thrombosis Res. 45:413-419,1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474,1988.
Recgp or/Ligand Ac~vi~
A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions.
Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, 2 5 receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant 3 0 receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.
The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M.
Kruisbeek, D.H.
Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987;
Bierer et al., J. Exp. Med.168:1145-1156, 1988; Rosenstein et al., J. Exp.
Med.169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68,1994; Stitt et al., Cell 80:661-670, 1995.
Anti-Inflammator3r Activi Proteins of the present invention may also exhibit anti-inflammatory activity.
The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions}, including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic 2 0 inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.
Cadherin/Tumor Invasion Suvpressor Activity Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to 3 0 tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.
The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself; the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.
E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed 2 0 in these cells by providing normal cadherin expression.
Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the 2 5 inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.
Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block 3 0 the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherirt-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and poly-nucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.
Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995;
Miyaki et al. Oncogene 11: 2547-2552,1995; Ozawa et al. Cell 63: 1033-1038,1990.
Tumor Inhibition Activit~"~
In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities.
A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by 2 0 inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.
Other Activiiieg 2 5 A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ 3 0 or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms;
effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or cornponent(s);

effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects;
promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.
ADMINISTRATION AND DOSING
A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable Garner.
Such a composition may also contain (in addition to protein and a Garner) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the 2 0 carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IIr9, IIrlO, IL-11, IL-12, IL-13, IL-14, I1r15, IFN, TNFO, TNF1, TIVF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other 2 5 agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoieHc factor, 3 0 thromboiytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.
A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.
The pharmaceutical composition of the invention may be in the form of a complex of the proteins) of present invention along with protein or peptide antigens.
The protein and/or peptide antigen will deliver a stimulatory signal to both B and T
lymphocytes. B
lymphocytes will respond to antigen through their surface immunoglobulin receptor. T
lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MI~iC genes on host cells will serve to present the peptide antigens) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.
The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers 2 0 in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monogIycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No.
4,501,728; U.S.
Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein 2 5 by reference.
As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, 3 0 prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytolcines, lymphokines or other hematopoietic factors. When co-administered with one or more cytolcines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytolcine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytolcine(s), lympholcine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.
Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carned out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection.
Intravenous administration to the patient is preferred.
When a therapeutically effective amount of protein of the present invention is 2 0 administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95%
protein of the present invention, and preferably from about 25 to 90% protein of the present invention.
2 5 When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oii, or sesame oii, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid 3 0 form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.
When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A
preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art.
The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.
Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 ug to about 100 2 0 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 pg to about 1 mg) of protein of the present invention per kg body weight.
The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient.
It is 2 5 contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration.
Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
Protein of the invention may also be used to immunize animals to obtain 3 0 polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein.

Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.
Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, Monoclonal antibodies: principles and practice, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in Current Protocols in Immunology, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons).
Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the relevant protein or fragments thereof in accordance with known methods.
Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, supra; and Andrew et ai., 1992, "Fragmentation of Immunoglobulins" in Current Protocols in Immunology, Unit 2.8, Greene Publishing Assoc. and John Whey & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding marine antibodies in accordance with well known methods (see for example, U.S.
Patent Nos. 5,530,101, S,S85,089, and 5,693,762). Additionally, human antibodies may be 2 0 produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild et al., 1996, Nature Biotechnology 14: 84S-851; Mendez et al., 1997, Nature Genetics 15: 146-1S6 (erratum Nature Genetics 16: 410); and U.S. Patents 5,877,397 and S,62S,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an imrnunogen. The peptide 2 5 immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P.
Merrifield, J.
Amer.Chem.Soc. $5, 2149-2154 (1963); j.L. Krstenansky, et al., FEBS Lett.
21,10 {198.
Monoclonal antibodies binding to the protein of the invention may be useful 3 0 diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.
For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device.
When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body.
Such matrices may be formed of materials presently in use for other implanted medical 2 0 applications.
The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation.
Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defmed, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other 3 0 ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.
In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.
A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose {CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly{ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and polyvinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in 2 0 question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-a and TGF (3), and insulin-like growth factor (IGF).
The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to 2 5 humans, are desired patients for such treatment with proteins of the present invention.
The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of 3 0 a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor n, to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.
Polynucleotides of the present invention can also be used for gene therapy.
Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynudeotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
Cells may also be cultured ex vivo in the presence of proteins of the present 14 invention in order to proliferate or to produce a desired effect on or activity in such cells.
Treated cells can then be introduced in vivo for therapeutic purposes.
Patent and literature references cited herein are incorporated by reference as if fully set forth.

SEQUENCE LISTING
<110> Valenzuela, Dario Yuan, Olive Hoffman, Heidi Hall, Jeff Rapiejko, Peter <120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
<130> GI 6908X
<140>
<141>
<160> 132 <170> PatentIn Ver. 2.0 <210> 1 <211> 1738 <212> DNA
<213> Homo Sapiens <400> 1 acttagtgta gcaccaggga gccctagagc tggaggatat cgaatagatt aaattttgct 60 cgtctcttcc acaagcccta accatgggtc ttaaaaacag cagattctgg gagccttcca 120 tgctctctct ctctcctctt ttatctactt ccctcccasa tgagagagtg acagagaatt 180 gtttttttat aaatcgaagt ttcttaatag tatcaggttt tgatacgtca gtggtctaaa 240 atgctatagt gcaattacta gcagttactg cacggagtgc caccgtgcca atagaggact 300 gttgttttaa taagggaact cttagcccat ttcctccctc ccgccatctc tacccttgct 360 caatgaaata tcatttaaat ttcttttaaa aaaaatcagt ttaattctta ctgtgtgccc 420 aacacgaagg ccttttttga aagaaaaata gaatgttttg cctcaaagta gtccatataa 480 aatgtcttga atagaagaaa aaactaccaa accaaaggtt actatttttg aaacatcgtg 540 tgttcattcc agcaaggcag aagactgcac cttctttcca gtgacatgct gtgtcatttt 600 ttttaagtcc tcttaatttt tagacacatt tttggtttat gttttaacaa tgtatgccta 660 accagtcatc ttgtctgcac caatgcaaag gtttctgaga ggagtattct ctatccctgt 720 ggatatgaag acactggcat ttcatctatt tttccctttc ctttttaaag gatttaactt 780 tggaatcttc caaaggaagt ttggccaatg ccagatcccc aggaatttgg ggggttttct 840 ttcttttcaa ctgaaattgt atctgattcc tactgttcat gttagtgatc atctaatcac 900 agagccaaac acttttctcc cctgtgtgga aaagtaggta tgctttacaa taaaatctgt 960 cttttctggt agaaacctga gccactgaaa ataaaagaga caactagaag cacagtagag 1020 tcccagactg agatctacct ttgagaggct ttgaaagtaa tccctggggt ttggattatt 1080 ttcacaaggg ttatgccgtt ttattcaagt ttgttgctcc gttttgcacc tctgcaataa 1140 aagcaaaatg acaaccagta cataaggggt tagcttgaca aagtagactt ccttgtgtta 1200 atttttaagt ttttttttcc ttaactatat ctgtctacag gcagatacag atagttgtat 1260 gaaaatctgc ttgcctgtaa aatttgcatt tataaatgtg ttgccgatgg atcacttggg 1320 cctgtacaca taccaattag cgtgaccact tccatcttaa aaacaaacct aaaaaacaaa 1380 atttattata tatatatata tatatatata aaggactgtg ggttgtatac aaactattgc 1440 aaacacttgt gcaaatctgt cttgatataa aggaaaagca aaatctgtat aacattatta 1500 ctacttgaat gcctctgtga ctgatttttt ttttcatttt aaatataaac ttttttgtga 1560 aaagtatgct caatgttttt tttccctttc cccattccct tgtaaataca ttttgttcta 1620 tgtgacttgg tttggaaata gttaactggt actgtaattt gcattaaata aaaagtaggt 1680 tagcctggaa atgaaattaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1738 <210> 2 <211> 84 <212> PRT
<213> Homo sapiens <400> 2 Met Gln Arg Phe Leu Arg Gly Val Phe Ser Ile Pro Val Asp Met Lys Thr Leu Ala Phe His Leu Phe Phe Pro Phe Leu Phe Lys Gly Phe Asn Phe Gly Ile Phe Gln Arg Lys Phe Gly Gln Cys Gln Ile Pro Arg Asn Leu Gly Gly Phe Leu Ser Phe Gln Leu Lys Leu Tyr Leu Ile Pro Thr Val His Val Ser Asp His Leu Ile Thr Glu Pro Asn Thr Phe Leu Pro Cys Val Glu Lys <210> 3 <211> 2198 <212> DNA
<213> Homo Sapiens <400> 3 gctctgtgga ttctggccag gccgggttcg gcggttgctg tgagagcggg cttcccaaca 60 ccatgccgtc cgccttctct gtcagctctt tccccgtcag catcccagcc gtgctcacgc 120 agacggactg gactgagccc tggctcatgg ggctggccac cttccacgcg ctctgcgtgc 180 tcctcacctg cttgtcctcc cgaagctaca gactacagat cgggcacttt ctgtgtctag 240 tcatcttagt ctactgtgct gaatacatca atgaggcggc tgcgatgaac tggagattat 300 tttcgaaata ccagtatttc gactccaggg ggatgttcat ttctatagta ttttcagccc 360 cactgctggt gaatgccatg atcattgtgg ttatgtgggt atggaagact ttgaatgtga 420 tgactgacct gaagaatgca caagagagaa gaaaggaaaa gaaaaggaga aggaaagaag 480 actgaggggc agcagctgct tggagtttgc gtccttcccg tccacccagt gcagctccca 540 gtgctgcagt gtgcgtggcg tgggcatcct tccagctgac tcatggtttg aaaaaccgtt 600 gttttattta aatatccaca gtggtagggc acacactgaa gttggctttt cagccagcac 660 tgaatgtatc catcaggaca tgcgtcttca ggtgcctgat ctttgtagtc aggctgtggg 720 aacggtctct gcagagcttc ataactggga atttgatttg aagaagtcca tgtcatatgt 780 gtaactagta ctaattataa atataaaata cacaatataa aatatgaaac tcaataataa 840 acagtgccac ctgtacatgg gcaccatgcc ctcctcctcg tgctgtgttt tctagtgcat 900 gccacagttc gcagtagagg gtgttttcac cttccaagac atggggcaaa gtttggagac 960 acctggttgt cactggaggg ggtggtgctc ctggcttctc ctgtggagcc cggggtgatg 1020 cataaaatcc tgtgtgcctg ggtcagccgc atcacagaca atgacttgac atgaaatgtc 1080 agctgtgctg gggcagagag accttggaag gaagctcttg gaaaatacgt tgtatctcag 1140 tttgatgaac caattcacaa gaggctaggc cctctctagc aaagttatgg gctgctttac 1200 tgaaaacaga atggaagccc tgaagtcaac actccatgga gaagcgtgtc tttcctaatg 1260 tcctggtgtt ctgttgattt aggtgcttgg gaacacaatg ctcccagttc tgttaggaca 1320 ggcatactgt tactttgcaa tatccacttt ataaaatagc tcctgcccag tggctcttgg 1380 ttcctgtcaa atgtggacct gtagtttaag aatgacaggt ggttagagac ccagatattt 1440 aaaaataggt gttcaataag ggaatactga ttgtgcattg tatctggata gcatgcctaa 1500 ttgtgcattt ctgaaagtta ccaattcaaa atgtaattgg aacagttatc tttgattaga 1560 caagcctggg aagagaatgt tgaggtgcag agctcaccag ccaagttcat gcccctctcg 1620 ggcctttgtg gctgagaagt gggacagaaa gatgattaag gtaatgtgtc ctccctgtag 1680 cattgtccag ggccgttgtg tagatatttg acttcactga cagaaaagaa accagggagt 1740 ttgtagagac tgtgcatttt tagtataaca ttttcaccat ctgatatggt ttggctttgt 1800 gtccccaccc aaattgcatc tcaaattgta atccccatgt gtcaagggag ggacctgatg 1860 ggaggtgatg ggatcatggg ggtggtttcc cctatgttgt tatcataata gagagggagt 1920 tctcacaaga tctgctcgtt ttaaagacag cagtttcccc tgctgtcact gtctctctcc 1980 tgctgccttg tgaagaaggt gcttgtttct ccctctgcca tgattgtaag tttcccgagg 2040 cctccccggc catgtggaac tgagtcaatt aaacttcttg tttataaagt aaaaaaaaaa 2100 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2160 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 2198 <~210> 4 <211> 140 <212> PRT
<213> Homo sapiens <400> 9 Met Pro Ser Ala Phe Ser Val Ser Ser Phe Pro Val Ser Ile Pro Ala Val Leu Thr Gln Thr Asp Trp Thr Glu Pro Trp Leu Met Gly Leu Ala Thr Phe His Ala Leu Cys Val Leu Leu Thr Cys Leu Ser Ser Arg Ser Tyr Arg Leu Gln Ile Gly His Phe Leu Cys Leu Val Ile Leu Val Tyr Cys Ala Glu Tyr Ile Asn Glu Ala Ala Ala Met Asn Trp Arg Leu Phe Ser Lys Tyr Gln Tyr Phe Asp Ser Arg Gly Met Phe Ile Ser Ile Val Phe Ser Ala Pro Leu Leu Val Asn Ala Met Ile Ile Val Val Met Trp Val Trp Lys Thr Leu Asn Val Met Thr Asp Leu Lys Asn Ala GIn Glu Arg Arg Lys Glu Lys Lys Arg Arg Arg Lys Glu Asp <210> 5 <211> 2229 <212> DNA
<213> Homo sapiens <400> 5 ggagccgggc aaccagtgga aggagcctgg gagaggccag gcctccccgg actgctagcc 60 tgcttttcct ggggtccctg gagccggagg aagaaccagg atgttgctgc ctgcagaagc 120 tcagctcagg aagacttcca ggaacctgag gaggagctgc cactaacagc catatttccc 180 aatggagact gtgatgacct tggaaggggg tcaaaagcct gtgatggagt cgtacacact 240 cctgctgagc ccaccggaga ctcaagatga aggctggacc cttgcgctgt ccctggctct 300 aacctacaga ctggggcctg gctccgtctt actggccccc aggtctccat ggagactgca 360 gaaacccccg cctgctggag gcctgccaca ctcacagtta ccagctagac agtggggctt 420 actaagacaa gcaggaccta aaacagtgtc tcccctggga acctactccc cacccagcat 480 ttgctaagtc tgatcacagg gaggttattt tgtctctctg tctcggtttc tctgagccac 540 tgagacagat ggctgtccgc tttgaggctc tgcagagctg tggcacccca tggtgtgtct 600 gcagtgttct gggcacatgc atgggcaccc atcgttgaga gtgcagctgg gaagaactct 660 gaaccagaag tcatcagagc tgaggcatgg ccttgaacat gtcactcagt ctctggggct 720 tctgtttcac aaatgcatga gggggccacc agcccagtgg ctttaaacca ggggcaggtt 780 gtccctccag gcagcattgg aaatgtgtgt gtgttgaggg ggtcacagtg actgtggggg 840 cacccctggc atctagtggg catcccacaa tgtgcagaac agtctctgac agcaaagaat 900 tggtccattc aatgccaatt gtagtacctt tgagacattc tggctgagcc aatgccttct 960 Ccctgtcaga gtcccccaga gcagagaggg tcaggcttcc ctggaccttg gctcccagag 1020 caagccaaaa taaagactac actgttgcct tgggggcttg tcgggccagg gccaagacgg 1080 tctgcgtgct gcagggccag gacagaaata gccacacatg ccggtgagaa caaagagcct 1140 ctttctttct catgttgaca tcgactttct gtgccaagtc ctttgggtat aaggatgcta 1200 gggaattcct ataggcacca aacagaagga aagctagggg cttggactac tgggtatagg 1260 acttgctcta gctctcaggt cctagcccaa gctcaatgca aacacagccc ctccgggctc 1320 tctgtttctg tgaggttctg gaatcccttc ctctgtgtcc gtgagtctga cagaatcgat 1380 gatgttccct tagagctggg aaatccatgt gtttattcac ggagggaact caccattacc 1440 tcccttgtct tctttgcctg ccttggagaa atccagagtc ttcggaatgg caaaggcagc 1500 tcctggattt ccctggaggg gaggcactag ctgagggaag tagctccctt cattcatgat 1560 gcacagttta cgcagcagac acacaactgc gcctactatt tgctcggtgc cctgcaaggt 1620 gctgcctaac tttgatttgt tatttcagct ctctccagga tagtgccaaa tggtgcaatg 1680 ggaaacctgt tttgctgggg ggctctagat cactggctcc agaactcccg gctgccaggg 1740 tagcccctac ccccagcccc ttgctcctgg acagcagtgg gtctcacctt tagcctctgc 1800 ccccagttct ggtctgaccc aacagagggg ctctatgata ttaagaaggg gcccttcctg 1860 ctctgtgcct caacctattc tccataatag ggagtctaat cctattcctt ccctgcctga 1920 tgaggatggt gtgaggatga ggaggacggc atctcatttg gggctttttg gcagtgggcc 1980 tcattttaat cctgcagggc tgcctgccag tggatctatc cagctgcttc cttgtagcca 2040 agaatgagtt caatgaattg tgattcactg attttattga ttttgtttta aaacagggag 2100 actggtattt ttgaagctgc tatcattttc tatttcttta ttaatttctt tgtaatcatc 2160 ttattaaagt tttcttattt agtggaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2220 aaaaaaaaa 2229 <210> 6 <211> 111 <212> PRT
<213> Homo sapiens <400> 6 Met Leu Gly Asn Ser Tyr Arg His Gln Thr Glu Gly Lys Leu Gly Ala Trp Thr Thr Gly Tyr Arg Thr Cys Ser Ser Ser Gln Val Leu Ala Gln Ala Gln Cys Lys His Ser Pro Ser Gly Leu Ser Val Ser Val Arg Phe Trp Asn Pro Phe Leu Cys Val Arg Glu Ser Asp Arg Ile Asp Asp Val Pro Leu Glu Leu Gly Asn Pro Cys Val Tyr Ser Arg Arg Glu Leu Thr Ile Thr Ser Leu Val Phe Phe Ala Cys Leu Gly Glu Ile Gln Ser Leu Arg Asn Gly Lys Gly Ser Ser Trp Ile Ser Leu Glu Gly Arg His <210> 7 <211> 915 <212> DNA
<213> Homo sapiens <400> 7 gcgtgagcac cctatctcag ctgctattcg ggcatgatgc tttgtagagg gtagagtaga 60 cagccccctc ccctactcac catggtattt ctccttgaat tcctctttct tgttttcttt 120 cctggttgtg tgaaccagtt gctgctgtca tacccctggc agggccaggg gacctctctt 180 tggtcatttc tgtcctttca ctggctgctg ccccaggaag actcctctag gctctccatc 240 tttcccttga gagctggctc cccaccccaa cctgctcagg caccaccgag gatctaggtc 300 tctggctccc catacctgga cccacatggg tgggtgcctg ttgcatgttt aagagagagg 360 ggctgtgagg tgacagggca ctagggcctt cactcctttc tccccttcca tcctttcttt 920 accagtgcca cccatgtccc tagctcccgg gtattggggc tgaggctctg gggcctgtct 480 ccctgccagc gtgagggcaa gaccccagag ccttagctga gcaagcccag aggggcagcg 540 tggcccctcc ctcccctttt cctgccccgt cccatgcctc agcttgctgc ttgtgccagt 600 tgcctgtttc gcttcagtgt ttgattctag cacttacatg tgtcctcccc accaagccct 660 ctatctcctt ctaatccttc aacccctggc cccctcccca taacagtgac ttttccaggg 720 aggaagaggc agcaggagct gttggccttg gtttgcacag agcgggtagg gctgtaggga 780 aagcgggtga gctgttgtgc tgctgggcct ccctttggcc ctcgcttccc accctacgat 840 gtatgaaatg tatgtacaga ccagagatgt ttatacagcc gataaagatg gaaaaaaaaa 900 aaaaaaaaaa aaaaa 915 <210> 8 <211> 71 <212> PRT
<213> Homo Sapiens <400> 8 Met Val Phe Leu Leu Glu Phe Leu Phe Leu Val Phe Phe Pro Gly Cys Val Asn Gln Leu Leu Leu Ser Tyr Pro Trp Gln Gly Gln Gly Thz Ser Leu Trp Ser Phe Leu Ser Phe His Trp Leu Leu Pro Gln Glu Asp Ser Ser Arg Leu Ser Ile Phe Pro Leu Arg Ala Gly Ser Pro Pro Gln Pro Ala Gln Ala Pro Pro Arg Ile <210> 9 <211> 1100 <212> DNA
<213> Homo Sapiens <400> 9 tgacccccaa gacggaagag gatggccgcg gcggctctga ggagattttg gtcccggcgc 60 cgcgcagagg cggggcgcgc cgctgtgtat gtgggtctgc tgggcggcgc ggcggcctgc 120 ttcacgctgg cgcccagcga gggtgccttc gaggaggcgc tgctggaggc gtcggggacc 180 ctcctgctgc tggcgccggc cacccgcaac cgcgggtcct ggacgtgggc ttcgtgggtc 240 gctggtgggt gctgggggcc tggatgcgcg actgcgacat caacgacgac gaattcctgc 300 acctgccggc gcatttgcgg gtggtcgggc cccagcagct gcattccgag accaacgagc 360 ggctcttcga tgagaagtac aagcctgtcg tgctcaccga cgatcaggtg gaccaggcgc 420 tgtgggagga gcaggtcttg cagaaggaga agaaggacag gctcgccctg agccaggccc 480 actcgctggt gcaggcggag gccccgagat gaaaccctga ggcccccgag tcctggcaaa 540 ctgcttgcct ggggtggtgc agttctgagt gtgcctcacc tgcagaacag ctgagacaga 600 tgatgtgcaa agtgttttct cactggattt gcacaagttt ggggagcctt tctgcccccc 660 gtctttgttc tttattagct gaagctaatt cagagccacc tgggtccggg agttggggac 720 agcagaacga cttgacacat gttcatcact ggcagagctg gtcatgagcc ttttatataa 780 gcctttttca tcgggcctca gaggccctcc ttaaggaggt accacattgg tcagctgact 840 tgcaaactct tctaaggcca cttagatttt ctttttcaag tttgggttgt ggcctggcat 900 ggtgatgtct gtaatcccag cagtttgcaa actgaggcaa gagaatcgct tgaggccagg 960 agtttgaggc cagctagagt gacatagcaa gactccgatg ctacaaaaaa gaataataat 1020 agtaattaac taaataaaat ttgagctgaa atgttaaaaa aaaaaaaaaa aaaaaaaaaa 1080 S

aaaaaaaasa aaaaaaaaaa 1100 <210> 10 <211> 149 <212> PRT
<213> Homo Sapiens <400> 10 Met Ala Ala Ala Ala Leu Arg Arg Phe Trp Ser Arg Arg Arg Ala Glu Ala Gly Arg Ala Ala Val Tyr Val Gly Leu Leu Gly Gly Ala Ala Ala Cys Phe Thr Leu Ala Pro Ser Glu Gly Ala Phe Glu Glu Ala Leu Leu Glu Ala Ser Gly Thr Leu Leu Leu Leu Ala Pro Ala Thr Arg Asn Arg Gly Ser Trp Thr Trp Ala Ser Trp Val Ala Gly Gly Cys Trp Gly Pro Gly Cys Ala Thr Ala Thr Ser Thr Thr Thr Asn Ser Cys Thr Cys Arg Arg Ile Cys Gly Trp Ser Gly Pro Ser Ser Cys Ile Pro Arg Pro Thr Ser Gly Ser Ser Met Arg Ser Thr Ser Leu Ser Cys Ser Pro Thr Ile Arg Trp Thr Arg Arg Cys Gly Arg Ser Arg Ser Cys Arg Arg Arg Arg Arg Thr Gly Ser Pro <210> 11 <211> 2010 <212> DNA
<213> Homo sapiens <400> 11 tggtgagctg cagagaagag gaggttggtg tggagcacag gcagcaccga gcctgccccg 60 tgagctgagg gcctgcagtc tgcggctgga atcaggatag acaccaaggc aggaccccca 120 gagatgctga agcctctttg gaaagcagca gtggccccca catggccatg ctccatgccg 180 ccccgccgcc cgtgggacag agaggctggc acgttgcagg tcctgggagc gctggctgtg 240 ctgtggctgg gctccgtggc tcttatctgc ctcctgtggc aagtgccccg tcctcccacc 300 tggggccagg tgcagcccaa ggacgtgccc aggtcctggg agcatggctc cagcccagct 360 tgggagcccc tggaagcaga ggccaggcag cagagggact cctgccagct tgtccttgtg 420 gaaagcatcc cccaggacct gccatctgca gccggcagcc cctctgccca gcctctgggc 480 caggcctggc tgcagctgct ggacactgcc caggagagcg tccacgtggc ttcatactac 540 tggtccctca cagggcctga catcggggtc aacgactcgt cttcccagct gggagaggct 600 cttctgcaga agctgcagca gctgctgggc aggaacattt ccctggctgt ggccaccagc 660 agcccgacac tggccaggac atccaccgac ctgcaggttc tggctgcccg aggtgcccat 720 gtacgacagg tgcccatggg gcggctcacc aggggtgttt tgcactccaa attctgggtt 780 gtggatggac ggcacatata catgggcagt gccaacatgg actggcggtc tctgacgcag 840 gtgaaggagc ttggcgctgt catctataac tgcagccacc tggcccaaga cctggagaag 900 accttccaga cctactgggt actgggggtg cccaaggctg tcctccccaa aacctggcct 960 cagaacttct catctcactt caaccgtttc cagcccttcc acggcctctt tgatggggtg 1020 cccaccactg cctacttctc agcgtcgcca ccagcactct gtccccaggg ccgcacccgg 1080 gacctggagg cgctgctggc ggtgatgggg agcgcccagg agttcatcta tgcctccgtg 1140 atggagtatt tccccaccac gcgcttcagc caccccccga ggtactggcc ggtgctggac 1200 aacgcgctgc gggcggcagc cttcggcaag ggcgtgcgcg tgcgcctgct ggtcggctgc 1260 ggactcaaca cggaccccac catgttcccc tacctgcggt ccctgcaggc gctcagcaac 1320 cccgcggcca acgtctctgt ggacgtgaaa gtcttcatcg tgccggtggg gaaccattcc 1380 aacatcccat tcagcagggt gaaccacagc aagttcatgg tcacggagaa ggcagcctac 1440 ataggcacct ccaactggtc ggaggattac ttcagcagca cggcgggggt gggcttggtg 1500 gtcacccaga gccctggcgc gcagcccgcg ggggccacgg tgcaggagca gctgcggcag 1560 ctctttgagc gggactggag ttcgcgctac gccgtcggcc tggacggaca ggctccgggc 1620 caggactgcg tttggcaggg ctgagggggg cctctttttc tctcggcgac cccgccccgc 1680 acgcgccctc ccctctgacc ccggcctggg cttcagccgc ttcctcccgc aagcagcccg 1740 ggtccgcact gcgccaggag ccgcctgcga ccgcccgggc gtcgcaaacc gcccgcctgc 1800 tctctgattt ccgagtccag ccccccctga gccccacctc ctccagggag ccctccagga 1860 agccccttcc ctgactcctg gcccacaggc caggcctaaa aaaaactcgt ggcttaaaaa 1920 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2010 <210> 12 <211> 506 <212> PRT
<213> Homo sapiens <400> 12 Met Leu Lys Pro Leu Trp Lys Ala Ala Val Ala Pro Thr Trp Pro Cys Ser Met Pro Pro Arg Arg Pro Trp Asp Arg Glu Ala Gly Thr Leu Gln Val Leu Gly Ala Leu Ala Val Leu Trp Leu Gly Ser Val Ala Leu Ile Cys Leu Leu Trp Gln Val Pro Arg Pro Pro Thr Trp Gly Gln Val Gln Pro Lys Asp Val Pro Arg Ser Trp Glu His Gly Ser Ser Pro Ala Trp Glu Pro Leu Glu Ala Glu Ala Arg Gln Gln Arg Asp Ser Cys Gln Leu Val Leu Val Glu Ser Ile Pro Gln Asp Leu Pro Ser Ala Ala Gly Ser Pro Ser Ala Gln Pro Leu Gly Gln Ala Trp Leu Gln Leu Leu Asp Thr Ala Gln Glu Ser Val His Val Ala Ser Tyr Tyr Trp Ser Leu Thr Gly Pro Asp Ile Gly Val Asn Asp Ser Ser Ser Gln Leu Gly Glu Ala Leu Leu Gln Lys Leu Gln Gln Leu Leu Gly Arg Asn Ile Ser Leu Ala Val Ala Thr Ser Ser Pro Thr Leu Ala Arg Thr Ser Thr Asp Leu Gln Val Leu Ala Ala Arg Gly Ala His Val Arg Gln Val Pro Met Gly Arg Leu Thr Arg Gly Val Leu His Ser Lys Phe Trp Val Val Asp Gly Arg His Ile Tyr Met Gly Ser Ala Asn Met Asp Trp Arg Ser Leu Thr Gln Val Lys Glu Leu Gly Ala Val Ile Tyr Asn Cys Ser His Leu Ala Gln Asp Leu Glu Lys Thr Phe Gln Thr Tyr Trp Val Leu Gly Val Pro Lys Ala Val Leu Pro Lys Thr Trp Pro Gln Asn Phe Ser Ser His Phe Asn Arg Phe Gln Pro Phe His Gly Leu Phe Asp Gly Val Pro Thr Thr Ala Tyr Phe Ser Ala Ser Pro Pro Ala Leu Cys Pro Gln Gly Arg Thr Arg Asp Leu Glu Ala Leu Leu Ala Val Met Gly Ser Ala Gln Glu Phe Ile Tyr Ala Ser Val Met Glu Tyr Phe Pro Thr Thr Arg Phe Ser His Pro Pro Arg Tyr Trp Pro Val Leu Asp Asn Ala Leu Arg Ala Ala Ala Phe Gly Lys Gly Val Arg Val Arg Leu Leu Val Gly Cys Gly Leu Asn Thr Asp Pro Thr Met Phe Pro Tyr Leu Arg Ser Leu Gln Ala Leu Ser Asn Pro Ala Ala Asn Val Ser Val Asp Val Lys Val Phe Ile Val Pro Val Gly Asn His Ser Asn Ile Pro Phe Ser Arg Val Asn His Ser Lys Phe Met Val Thr Glu Lys Ala Ala Tyr Ile Gly Thr Ser Asn Trp Ser Glu Asp Tyr Phe Ser Ser Thr Ala Gly Val Gly Leu Val Val Thr Gln Ser Pro Gly Ala Gln Pro Ala Gly Ala Thr Val Gln Glu Gln Leu Arg Glri Leu Phe Glu Arg Asp Trp Ser Ser Arg Tyr Ala Val Gly Leu Asp Gly Gln Ala Pro Gly Gln Asp Cys Val Trp Gln Gly g <210> 13 <211> 2830 <212> DNA
<213> Homo sapiens <400> 13 ggcagaggca tgctcatggt gctccttccc cagcagcaat cctatgctcc ccttccaggt 60 cttctcttcc ttcttttcct cagccagctg gctgctggta agagaggtct ggcgagagtg 120 tgtcccagta gctgctgcta tggatggaac ggagcgggca ggacgtaggc tggaggagtc 180 tgtcttcccg gcatctttac gagatcgctg ctgcaggacc ttaatcatag catctttctc 240 tatgattttg gcatggagat ttttaatagt gtattccatg tcctgacacc ttctgttggc 300 ctgcaccacc tcctcctcct cttgccagat gtgggcctcc agcgagctct ctccgtagct 360 gccattccgt gagtggttga tgatcgtggt gtccctctca gctgctgcag tggctgcggc 420 attcatggca aagtgtcgga tggtgctctc ctccaggtac ttctgctccc actttgtcat 480 gtcggcctcc agggccagga tccgctcctc cttctcccgc acaagttcca ggagggctgg 540 ggcattgtat tccggcatgt tggctggctg gccatttcca tgtttctgct gggttctcag 600 tgcatccagc tctctctcca gccaagtccg cagtctccgc tccatctgtt ctcgcttctc 660 acatgcagac tgcagctggg tcagggcctg ctgcagcttc tcaactttct caacatatgc 720 ttgcttctct cgtaactcct cttccagctt gatgaccctg gcctgggcgt tgctcaaagc 780 ctggtccagg atctcgatgt gtctccgatg gtcctcactt gcagtccgca ctgctgctaa 840 ctccatttct aatttctcct tttccttcaa gaattctttg ttctgggaag cataatgccc 900 ctctgcagct ttgtcttcat gcccttcgta ttccctgctg gatagttgcc tgttagcagt 960 ctctagtcga tctcggaggt ctctgttgaa atcatgaagt cttctaatct cgccttccaa 1020 tttgtttctc atggccttgt ccagcgattc tcgcttggtg gtagacttga ccagactttc 1080 ataggcttcc gaaattctct gaagttcttt ttcaaacttg tggagcttgt cggcattgtc 1140 gtagtaaccc tgaagttcct ggtgaagcac ccggttctcc tctgttaata tctccaccat 1200 ttgctgggct cgctccacaa tcgcasaggc atctggacca agctgctggc tgggggaggc 1260 ggcaggcggg ggctgtggag cacccagggc catcgggagt ggaagcggca gggagacaga 1320 gtgcagtggc ccgctggcgg aagaggtctg ggaggacatg gggctgtgct gctgcatggt 1380 tgatgggaac ggaagttggc atgggcggct cgttacccca tactcagggg gtggctggta 1440 ccgcaggacg gccacatctg ttctcacagg ctgaggagca gggtagggct tgaccatctc 1500 gtggagcatc ccggggtgct ggtcaccata aaaaagtccg tgctcctggg tcttgctgac 1560 tggggacatc atttgcttgg tcttgaaggg gtactcaggt ggaggacccc gagggtccag 1620 cactttacct gcaggctggg caggggaggg cccccctcct actttgaagc cctttccatt 1680 ccccgagccg ggaaggtgtt gcttggcccc attcctctcc agggacagct gcatgattct 1740 ctcgctgagc gagcggacgt ggccctgctt cagttccttc agcgcctcgt ccttatgcgc 1800 ctgtccactg ttggcacggt tcacagtggg cctcccctca gttcgggact tctgactggt 1860 gccccctgcc atgtagtaac catggcccac cgccccctgc tgctgttgct gctgctgctg 1920 ccccctgaag aactgcgact gtgctttggc ctcctcgtaa gtgggcagtt cctcgttgtt 1980 ctgctgaggc tgcgtggacc ggacctgttt ctccatcact gtattgtcca cctggtgttc 2040 ttgaccctgc ggttcttggc gtgctgactg gtagaccatt tgtgggtctt cttgagtgag 2100 gttttccgtg gaagaaaagt tgtttgtagg atgggctggt cctgcactcc ctgtggcctg 2160 gtgctgaatg gccagcaagt tcatgttctc ggttggggtg ccataccgca gttgttcctg 2220 gatcagccgc tgcaatactg ttccagctgc cgcatcctcg gaacctctca tttccacctc 2280 tgagatcctc aggaagtttg gggagtggaa gttacaaaga ggatcttcaa caactttttc 2340 cctgatgcta ctggttgcct ccaccgtcaa agcagatgtt tcatgcctcc cagaatagag 2400 ctgaaagtct ggggaaaagt aggtggagtc ttctagaacc tggacaggac tactggggct 2460 ataacaagca gaaggggacc ctaactcgtc tgggctgtag gatgcgggcg aggcttccac 2520 aaactcactg tctgggggag aagaaaagca gaaaacaact cgaatcgcta ccattcagga 2580 cgaacccgcc aagcaccagc tcaagcgcag gtccccggga aaagcgcggg cttctctctc 2640 ccagcgctca gaatccctga gccggaggcc ccgcgggatt cagaccgcca gatccccagg 2700 gagtgacaaa tcgccgcaga aacttggggg acaactcggc cctggcaccg cgcggcttcc 2760 aggcgcggtc aggcgcgcgc caactttccc cgcgtgccac cccgcggctc ccccggccgg 2820 gcgctgggcc <210> 14 <211> 171 <212> PRT
<213> Homo sapiens <400> 14 Met Ile Val Val Ser Leu Ser Ala Ala Ala Val Ala Ala Ala Phe Met Ala Lys Cys Arg Met Val Leu Ser Ser Arg Tyr Phe Cys Ser His Phe Val Met Ser Ala Ser Arg Ala Arg Ile Arg Ser Ser Phe Ser Arg Thr Ser Ser Arg Arg Ala Gly Ala Leu Tyr Ser Gly Met Leu Ala Gly Trp Pro Phe Pro Cys Phe Cys Trp Val Leu Ser Ala Ser Ser Ser Leu Ser Ser Gln Val Arg Ser Leu Arg Ser Ile Cys Ser Arg Phe Ser His Ala Asp Cys Ser Trp Val Arg Ala Cys Cys Ser Phe Ser Thr Phe Ser Thr Tyr Ala Cys Phe Ser Arg Asn Ser Ser Ser Ser Leu Met Thr Leu Ala Trp Ala Leu Leu Lys Ala Trp Ser Arg Ile Ser Met Cys Leu Arg Trp Ser Ser Leu Ala Val Arg Thr Ala Ala Asn Ser Ile Ser Asn Phe Ser Phe Ser Phe Lys Asn Ser Leu Phe Trp Glu Ala <210> 15 <211> 2000 <212> DNA
<213> Homo sapiens <400> 15 gcagaagctg tacgggctcc aggctgacat taccatcagc ctggacggcg tgcccttcct 60 catgcatgac accaccctgc ggcgcaccac caacgtggag gaggagttcc cggagctggc 120 ccgcaggcct gcctccatgc ttaactggac caccctgcag agactcaacg ctggccagtg 180 gttcctgaag actgacccct tctggacagc cagctccctg tcaccctccg accacagaga 240 ggcccagaac cagtccatct gcagcctggc agagctcctg gagctggcca agggcaatgc 300 cacactgctg ctcaacctgc gtgacccgcc ccgggagcac ccctaccgca gcagttttat 360 caacgtgact ctggaggccg tgctgcactc cggcttcccc cagcaccagg tcatgtggct 420 gcctagcagg cagaggcccc tggtgcggaa ggtggctccc ggcttccaac agacatcagg 480 ctccaaggag gcagtcgcca gcctgcggag aggccacatc cagcggctga acctgcgcta 540 cactcaggtg tcccgccagg agctcaggga ctacgcgtcc tggaacctga gtgtgaacct 600 ctacacagtc aacgcaccgt ggctcttctc cctgctgtgg tgtgcggggg tcccatccgt 660 cacctctgac aactcccaca ccctgtccca ggtgccttcc cccctctgga tcatgccccc 720 ggacgagtac tgtctcatgt gggtcactgc cgacctggtc tccttcaccc tcatcgtggg 780 catcttcgtg ctccagaagt ggcgcctggg tggcatacgg agctacaacc ctgagcagat 840 catgctgagt gctgcggtgc gccggaccag ccgggacgtc agcatcatga aggagaagct 900 tattttctca gagatcagcg atggtgtaga ggtctccgat gtgctctccg tatgttcaga 960 1~

caacagttat gacacatatg ccaacagcac cgccacccct gtgggccccc gagggggtgg 1020 cagccacacc aagaccctca tagagcggag tgggcgttag ctgaagacat gtctgtccca 1080 cctgtacctg acacagaagc tggggagcct aggagagctg gtggaagtgt gtctgaactc 1140 ggagtgctct gggagcgggc tccacagcct ccttgtgggc tccagcccct tgtcagccgc 1200 agcctctctt gagggggact ccctgtcccc tgaggcccag ctgggccagg actccatcct 1260 ttcagatgcc cctgcaggcc tggggctcct tctgggaagt atggggccta gggcttggtc 1320 cccctcttct gaggccctct cctgtatccc gacctggaag ctttgatggg tcatgggcca 1380 tgccataccc cctgtggcaa tggagtgtgt ggatgctcac ctgtgccatc tgtcctcctg 1440 tctgtgccag gaggcacctg agttctctgc tgttatcctg ccccaagggc ctgggccgag 1500 cctctacctg aagcaactct gctcttcctg tcagtctcaa agcacaagga ggttcagccc 1560 aggaggaagc cagctgcaat gtggagacac gtcctcctcc ccaacccacc tcatgccacc 1620 gccaaccccc tgccccagga gcgggcctga gccacgtccc ctaggagcag ctggagatgg 1680 ccaaaagagt gagctcaagg actactggga tcccaatgcc agtgtccagc agacctcaag 1740 gcagaagggt cacctaaccc aggagtccac agactgatgt gacctcaggt tcccacatca 1800 gtggccacag ggcagggccc acctggtaga agtgttctgg atatggccag ggtgggtgtg 1860 tggctaagtg ggcctgaaca gagggaacct agggcccttg gcccaatgtg attaaaggct 1920 gccatcttga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980 aaaaaaaaaa aaaaaaaaaa 2000 <210> 16 <211> 332 <212> PRT
<213> Homo sapiens <400> 16 Met His Asp Thr Thr Leu Arg Arg Thr Thr Asn Val Glu Glu Glu Phe Pro Glu Leu Ala Arg Arg Pro Ala Ser Met Leu Asn Trp Thr Thr Leu Gln Arg Leu Asn Ala Gly Gln Trp Phe Leu Lys Thr Asp Pro Phe Trp Thr Ala Ser Ser Leu Ser Pro Ser Asp His Arg Glu Ala Gln Asn Gln Ser Ile Cys Ser Leu Ala Glu Leu Leu Glu Leu Ala Lys Gly Asn Ala Thr Leu Leu Leu Asn Leu Arg Asp Pro Pro Arg Glu His Pro Tyr Arg Ser Ser Phe Ile Asn Val Thr Leu Glu Ala Val Leu His Ser Gly Phe Pro Gln His Gln Val Met Trp Leu Pro Ser Arg Gln Arg Pro Leu Val Arg Lys Val Ala Pro Gly Phe Gln Gln Thr Ser Gly Ser Lys Glu Ala Val Ala Ser Leu Arg Arg Gly His Ile Gln Arg Leu Asn Leu Arg Tyr Thr Gln Val Ser Arg Gln Glu Leu Arg Asp Tyr Ala Ser Trp Asn Leu Ser Val Asn Leu Tyr Thr Val Asn Ala Pro Trp Leu Phe Ser Leu Leu Trp Cys Ala Gly Val Pro Ser Val Thr Ser Asp Asn Ser His Thr Leu Ser Gln Val Pro Ser Pro Leu Trp Ile Met Pro Pro Asp Glu Tyr Cys Leu Met Trp Val Thr Ala Asp Leu Val Ser Phe Thr Leu Ile Val Gly Ile Phe Val Leu Gln Lys Trp Arg Leu Gly Gly Ile Arg Ser Tyr Asn Pro Glu Gln Ile Met Leu Ser Ala Ala Val Arg Arg Thr Ser Arg Asp Val Ser Ile Met Lys Glu Lys Leu Ile Phe Ser Glu Ile Ser Asp Gly Val Glu Val Ser Asp Val Leu Ser Val Cys Ser Asp Asn Ser Tyr Asp Thr Tyr Ala Asn Ser Thr Ala Thr Pro Val Gly Pro Arg Gly Gly Gly Ser His Thr Lys Thr Leu Ile Glu Arg Ser Gly Arg <210> 17 <211> 1170 <212> DNA
<213> Homo Sapiens <400> 17 aagtttgttc cccgagttcg gagcctagga gccccccgcg gctgcggcgc aggtgccctc 60 ggcctgagtc gggatggagc tgcctgctgt gaacctgaag gtgattctcc taggtcactg 120 gctgctgaca acctggggct gcattgtatt ctcaggctcc tatgcctggg ccaacttcac 180 catcctggcc ttgggcgtgt gggctgtggc tcagcgggac tccatcgacg ccataagcat 240 gtttctgggt ggcttgctgg ccaccatctt cctggacatc gtgcacatca gcatcttcta 300 cccgcgggtc agcctcacgg acacgggccg ctttggcgtg ggcatggcca tcctcagctt 360 gctgctcaag ccgctctcct gctgcttcgt ctaccacatg taccgggagc gcgggggttt 420 ccttgggtct tctcaggacc gtagtgccta ccagacgatt gactcagcag aggcgcccgc 480 agatcccttt gcagtcccag agggcaggag tcaagatgcc cgagggtact gaagccagcc 540 acgctgcgcc cggccctgcc ccgggccttc ctcgtgcctg ggaggtcgtt ctagggatgc 600 tcctgacctc cgtctcttgg acctaagatg gaatgtgtcc ccagctcagg gattgcctga 660 accaagaggc caggagcccc catgggccgc ccagtaccat gcacactcct gtcccgaact 720 ccctgaggcc tcccctccct tcagggcacc cactggttcc caggctggaa ccagggtctc 780 tctttacctc ctaccccatg gtggcaccac agaggccctc agccgagtcc tgcctgagtg 840 ttgcaagctc aggcctttaa ggactgctga tgccccctca ggcctccccc aagtttgctg 900 ggctttggtg gaagccctga gagcttcagg tcctgctcag cccgaggagc agtctgacat 960 gggagtgagg ccctgtcctt ctcactgcct ggtcacatgg tgcctaggga tgcagggctg 1020 gaggccagag gtgtcagcaa cactgtgacc caccacaacc tccagcctcc cttttcagag 1080 cacagcatta aagtttgggg aattctgtaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1140 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1170 <210> 18 <211> 152 <212> PRT
<213> Homo Sapiens <400> 18 Met Glu Leu Pro Ala Val Asn Leu Lys Val Ile Leu Leu Gly His Trp Leu Leu Thr Thr Trp Gly Cys Ile Val Phe Ser Gly Ser Tyr Ala Trp Ala Asn Phe Thr Ile Leu Ala Leu Gly Val Trp Ala Val Ala Gln Arg Asp Ser Ile Asp Ala Ile Ser Met Phe Leu Gly Gly Leu Leu Ala Thr Ile Phe Leu Asp Ile Val His Ile Ser Ile Phe Tyr Pro Arg Val Ser Leu Thr Asp Thr Gly Arg Phe Gly Val Gly Met Ala Ile Leu Ser Leu Leu Leu Lys Pro Leu Ser Cys Cys Phe Val Tyr His Met Tyr Arg Glu Arg Gly Gly Phe Leu Gly Ser Ser Gln Asp Arg Ser Ala Tyr Gln Thr Ile Asp Ser Ala Glu Ala Pro Ala Asp Pro Phe Ala Val Pro Glu Gly Arg Ser Gln Asp Ala Arg Gly Tyr <210> 19 <211> 4144 <212> DNA
<213> Homo sapiens <400> 19 ctccttgggc aggtgaggat aacagccctg tggcgagctg gtcctgagca tctgagtgag 60 cagtgatgcg gagaaatgac cttggtggga ggggacgtcc acagacgtga cccggacgtc 120 gggacaggtg gatctggggt caaggggagt gtttagaata cttgttggca tccatgacgc 180 agtggtgtga gcgtgagata tccagcatcg cacctggaga gctgtgctgt ctgctccttt 240 ccttcctgcc tcaggaggag tgtcagaact acgtgcgagt cctgatcgtc gccggccgga 300 aggtgttcat gtgtggaacc aatgcctttt cccccatgtg caccagcaga caggtgggga 360 acctcagccg gactattgag aagatcaatg gtgtggcccg ctgcccctat gacccacgcc 420 acaactccac agctgtcatc tcctcccagg gggagctcta tgcagccacg gtcatcgact 480 tctcaggtcg ggaccctgcc atctaccgca gcctgggcag tgggccaccg cttcgcactg 540 cccaatataa ctccaagtgg cttaatgagc caaacttcgt ggcagcctat gatattgggc 600 tgtttgcata cttcttcctg cgggagaacg cagtggagca cgactgtgga cgcaccgtgt 660 actctcgcgt ggcccgcgtg tgcaagaatg acgtgggggg ccgattcctg ctggaggaca 720 catggaccac attcatgaag gcccggctca actgctcccg cccgggcgag gtccccttct 780 actataacga gctgcagagt gccttccact tgccggagca ggacctcatc tatggagttt 840 tcacaaccaa cgtaaacagc attgcggctt ctgctgtctg cgccttcaac ctcagtgcta 900 tctcccaggc tttcaatggc ccatttcgct accaggagaa ccccagggct gcctggctcc 960 ccatagccaa ccccatcccc aatttccagt gtggcaccct gcctgagacc ggtcccaacg 1020 agaacctgac ggagcgcagc ctgcaggacg cgcagcgcct cttcctgatg agcgaggccg 1080 tgcagccggt gacacccgag ccctgtgtca cccaggacag cgtgcgcttc tcacacctcg 1140 tggtggacct ggtgcaggct aaagacacgc tctaccatgt actctacatt ggcaccgagt 1200 cgggcaccat cctgaaggcg ctgtccacgg cgagccgcag cctccacggc tgctacctgg 1260 aggagctgca cgtgctgccc cccgggcgcc gcgagcccct gcgcagcctg cgcatcctgc 1320 acagcgcccg cgcgctcttc gtggggctga gagacggcgt cctgcgggtc ccactggaga 1380 ggtgcgccgc ctaccgcagc cagggggcat gcctgggggc ccgggacccg tactgtggct 1440 gggacgggaa gcagcaacgt tgcagcacac tcgaggacag ctccaacatg agcctctgga 1500 cccagaacat caccgcctgt cctgtgcgga atgtgacacg ggatgggggc ttcggcccat 1560 ggtcaccatg gcaaccatgt gagcacttgg atggggacaa ctcaggctct tgcctgtgtc 1620 gagctcgatc ctgtgattcc cctcgacccc gctgtggggg ccttgactgc ctggggccag 1680 ccatccacat cgccaactgc tccaggaatg gggcgtggac cccgtggtca tcgtgggcgc 1740 tgtgcagcac gtcctgtggc atcggcttcc aggtccgcca gcgaagttgc agcaaccctg 1800 ctccccgcca cgggggccgc atctgcgtgg gcaagagccg ggaggaacgg ttctgtaatg 1860 agaacacgcc ttgcccggtg cccatcttct gggcttcctg gggctcctgg agcaagtgca 1920 gcagcaactg tggagggggc atgcagtcgc ggcgtcgggc ctgcgagaac ggcaactcct 1980 gcctgggctg cggcgtggag ttcaagacgt gcaaccccga gggctgcccc gaagtgcggc 2040 gcaacacccc ctggacgccg tggctgcccg tgaacgtgac gcagggcggg gcacggcagg 2100 agcagcggtt ccgcttcacc tgccgcgcgc cccttgcaga cccgcacggc ctgcagttcg 2160 gcaggagaag gaccgagacg aggacctgtc ccgcggacgg ctccggctcc tgcgacaccg 2220 acgccctggt ggaggacctc ctgcgcagcg ggagcacctc cccgcacacg gtgagcgggg 2280 gctgggccgc ctggggcccg tggtcgtcct gctcccggga ctgcgagctg ggcttccgcg 2340 tccgcaagag aacgtgcact aacccggagc cccgcaacgg gggcctgccc tgcgtgggcg 2400 atgctgccga gtaccaggac tgcaaccccc aggcttgccc agttcggggt gcttggtcct 2460 gctggacctc atggtctcca tgctcagctt cctgtggtgg gggtcactat caacgcaccc 2520 gttcctgcac cagccccgca ccctccccag gtgaggacat ctgtctcggg ctgcacacgg 2580 aggaggcact atgtgccaca caggcctgcc cagaaggctg gtcgccctgg tctgagtgga 2640 gtaagtgcac tgacgacgga gcccagagcc gaagccggca ctgtgaggag ctcctcccag 2700 ggtccagcgc ctgtgctgga aacagcagcc agagccgccc ctgcccctac agcgagattc 2760 ccgtcatcct gccagcctcc agcatggagg aggccaccgg ctgtgcaggg ttcaatctca 2820 tccacttggt ggccacgggc atctcctgct tcttgggctc tgggctcctg accctagcag 2880 tgtacctgtc ttgccagcac tgccagcgtc agtcccagga gtccacactg gtccatcctg 2940 ccacccccas ccatttgcac tacaagggcg gaggcacccc gaagaatgaa aagtacacac 3000 ccatggaatt caagaccctg aacaagaata acttgatccc tgatgacaga gccaacttct 3060 acccattgca gcagaccaat gtgtacacga ctacttacta cccaagcccc ctgaacaaac 3120 acagcttccg gcccgaggcc tcacctggac aacggtgctt ccccaacagc tgataccgcc 3180 gtcctgggga cttgggcttc ttgccttcat aaggcacaga gcagatggag atgggacagt 3240 ggagccagtt tggttttctc cctctgcact aggccaagaa cttgctgcct tgcctgtggg 3300 gggtcccatc cggcttcaga gagctctggc tggcattgac catgggggaa agggctggtt 3360 tcaggctgac atatggccgc aggtccagtt cagcccaggt ctctcatggt tatcttccaa 3420 cccactgtca cgctgacact atgctgccat gcctgggctg tggacctact gggcatttga 3480 ggaattggag aatggagatg gcaagagggc aggcttttaa gtttgggttg gagacaactt 3540 cctgtggccc ccacaagctg agtctggcct tctccagctg gccccaaaaa aggcctttgc 3600 tacatcctga ttatctctga aagtaatcaa tcaagtggct ccagtagctc tggattttct 3660 gccagggctg ggccattgtg gtgctgcccc agtatgacat gggaccaagg ccagcgcagg 3720 ttatccacct ctgcctggaa gtctatactc tacccagggc atccctctgg tcagaggcag 3780 tgagtactgg gaactggagg ctgacctgtg cttagaagtc ctttaatctg ggctggtaca 3840 ggcctcagcc ttgccctcaa tgcacgaaag gtggcccagg agagaggatc aatgccatag 3900 gaggcagaag tctggcctct gtgcctctat ggagactatc ttccagttgc tgctcaacag 3960 agttgttggc tgagacctgc ttgggagtct ctgctggccc ttcatctgtt caggaacaca 4020 cacacacaca cactcacaca cgcacacaca atcacaattt gctacagcaa csaaaaagac 4080 attgggctgt ggcattatta attaaagatg atatccagtc aaaaaaaaaa aaaaaaaaaa 4140 aaaa 4144 <210> 20 <211> 999 <212> PRT
<213> Homo sapiens <400> 20 Met Thr Gln Trp Cys Glu Arg Glu Ile Ser Ser Ile Ala Pro Gly Glu Leu Cys Cys Leu Leu Leu Ser Phe Leu Pro Gln Glu Glu Cys Gln Asn Tyr Val Arg Val Leu Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly Thr Asn Ala Phe Ser Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu Ser Arg Thr Ile Glu Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp Pro Arg His Asn Ser Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr Ala Ala Thr Val Ile Asp Phe Ser Gly Arg Asp Pro Ala~Ile Tyr Arg Ser Leu Gly Ser Gly Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys Trp Leu Asn Glu Pro Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe Ala Tyr Phe Phe Leu Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg Thr Val Tyr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly Arg Phe Leu Leu Glu Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu Asn Cys Ser Arg Pro Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln Ser Ala Phe His Leu Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr Thr Asn Val Asn Ser Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu Ser Ala Ile Ser Gln Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn Pro Arg Ala Ala Trp Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln Cys Gly Thr Leu Pro Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg Ser Leu Gln Asp Ala Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln Pro Val Thr Pro Glu Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser His Leu Val Val Asp Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val Leu Tyr Ile Gly Thr Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr Ala Ser Arg Ser Leu His Gly Cys Tyr Leu Glu Glu Leu His Val Leu Pro Pro Gly Arg Arg Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser Ala Arg Ala Leu Phe Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro Leu Glu Arg Cys Ala Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala Arg Asp Pro Tyr Cys Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr Leu Glu Asp Ser Ser Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala Cys Pro Val Arg Asn Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser Pro Trp Gln Pro Cys Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys Leu Cys Arg Ala Arg Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly Leu Asp Cys Leu Gly Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn Gly Ala Trp Thr Pro Trp Ser Ser Trp Ala Leu Cys Ser Thr Ser Cys Gly Ile Gly Phe Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro Arg His Gly Gly Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe Cys Asn Glu Asn Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp Gly Ser Trp Ser Lys Cys Ser Ser Asn Cys Gly Gly Gly Met Gln Ser Arg Arg Arg Ala Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val Glu Phe Lys Thr Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn Thr Pro Trp Thr Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala Arg Gln Glu Gln Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp Pro His Gly Leu Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys Pro Ala Asp Gly Ser Gly Ser Cys Asp Thr Asp Ala Leu Val Glu Asp Leu Leu Arg Ser Gly Ser Thr Ser Pro His Thr Val Ser Gly Gly Trp Ala Ala Trp Gly Pro Trp Ser Ser Cys Ser Arg Asp Cys Glu Leu Gly Phe Arg Val Arg Lys Arg Thr Cys Thr Asn Pro Glu Pro Arg Asn Gly Gly Leu Pro Cys Val Gly Asp Ala Ala Glu Tyr Gln Asp Cys Asn Pro Gln Ala Cys Pro Val Arg Gly Ala Trp Ser Cys Trp Thr Ser Trp Ser Pro Cys Ser Ala Ser Cys Gly Gly Gly His Tyr Gln Arg Thr Arg Ser Cys Thr Ser Pro Ala Pro Ser Pro Gly Glu Asp Ile Cys Leu Gly Leu His Thr Glu Glu Ala Leu Cys Ala Thr Gln Ala Cys Pro Glu Gly Trp Ser Pro Trp Ser Glu Trp Ser Lys Cys Thr Asp Asp Gly Ala Gln Ser Arg Ser Arg His Cys Glu Glu Leu Leu Pro Gly Ser Ser Ala Cys Ala Gly Asn Ser Ser Gln Ser Arg Pro Cys Pro Tyr Ser Glu Ile Pro Val Ile Leu Pro Ala Ser Ser Met Glu Glu Ala Thr Gly Cys Ala Gly Phe Asn Leu Ile His Leu Val Ala Thr Gly Ile Ser Cys Phe Leu Gly Ser Gly Leu Leu Thr Leu Ala Val Tyr Leu Ser Cys Gln His Cys Gln Arg Gln Ser Gln Glu Ser Thr Leu Val His Pro Ala Thr Pro Asn His Leu His Tyr Lys Gly Gly Gly Thr Pro Lys Asn Glu Lys Tyr Thr Pro Met Glu Phe Lys Thr Leu Asn Lys Asn Asn Leu Ile Pro Asp Asp Arg Ala Asn Phe Tyr Pro Leu Gln Gln Thr Asn Val Tyr Thr Thr Thr Tyr Tyr Pro Ser Pro Leu Asn Lys His Ser Phe Arg Pro Glu Ala Ser Pro Gly Gln Arg Cys Phe Pro Asn Ser <210> 21 <211> 2820 <212> DNA
<213> Homo Sapiens <400> 21 agaatgggag ctgtcagtta tcattcagga caaaggcaat cctcagctac ataccaaagt 60 ccttctgaag tgcatgatct ttgaatatgc agagtcggtg acaagtacag caatgacttc 120 agtaagccag gcatccttgg atgtctccat gataataatt atttccttag gagcaatttg 180 tgcagtgttg ctggttatta tggtgctatt tgcaactagg tgtaaccgcg agaagaaaga 240 cactagatcc tataactgca gggtggccga atcaacttac cagcaccacc caaaaaggcc 300 atcccggcag attcacaaag gggacatcac attggtgcct accataaatg gcactctgcc 360 catcagatct catcacagat cgtctccatc ttcatctcct accttagaaa gagggcagat 420 gggcagccgg cagagtcaca acagtcacca gtcactcaac agtttggtga caatctcatc 480 aaaccacgtg ccagagaatt tctcattaga actcacccac gccactcctg ctgttgaggt 540 ctctcagctt ctttcaatgc ttcaccaggg gcaatatcag ccaagaccaa gttttcgagg 600 aaacaaatat tccaggagct acagatatgc ccttcaagac atggacaaat ttagcttgaa 660 agacagtggc cgtggtgaca gtgaggcagg agacagtgat tatgatttgg ggcgagattc 720 tccaatagat aggctgttgg gtgaaggatt cagcgacctg tttctcacag atggaagaat 780 tccagcagct atgagactct gcacggagga gtgcagggtc ctgggacact ctgaccagtg 840 ctggatgcca ccactgccct caccgtcttc tgattatagg agtaacatgt tcattccagg 900 ggaagaattc ccaacgcaac cccagcagca gcatccacat cagagtcttg aggatgacgc 960 tcagcctgca gattccggtg aaaagaagaa gagtttttcc acctttggaa aggactcccc 1020 aaacgatgag gacactgggg ataccagcac atcatctctg ctctcggaaa tgagcagtgt 1080 gttccagcgt ctcttaccgc cttccctgga cacctattct gaatgcagtg aggtggatcg 1140 gtccaactcc ctggagcgca ggaagggacc cttgccagcc aaaactgtgg gttacccaca 1200 gggggtagcg gcatgggcag ccagtacgca ttttcaaaat cccaccacca actgtgggcc 1260 gccacttgga actcactcca gtgtgcagcc ttcttcaaaa tggctgccag ccatggagga 1320 gatccctgaa aattatgagg aagatgattt tgacaatgtg ctcaaccacc tcaatgatgg 1380 gaaacacgaa ctcatggatg ccagtgaact ggtggcagag attaacaaac tgcttcaaga 1440 tgtccgccag agctaggaga ttttagcgaa gcatttttgt ttccatgtat atggaaatag 1500 ggaacaacaa caacaacaaa asaccctgaa agaactggca ttgccaaata gttgcattta 1560 tcataaatgt gtctgtgtat attgaatatt aaatactgta ttttcgtatg tacacaatgc 1620 aagtgtgatt attttaatct gtattttaaa aatacatttg taccttatat ttatgtgtaa 1680 tttaacaaac aaattttatt tttttactcc catgacagac atgtttttcc tagtcgtgta 1740 gaaactagcc actgttcaaa tctgatacac tattcaacca caaagtgtaa aggcactgct 1800 tagattagtt ttgttgggga agaattatta tgttgtatga acaaccccac tgaagcatta 1860 tacaattctt aattccatta agtgatccca ctttttttca ataacttttt agaaattaag 1920 aatcattaaa attgttaagc tattttattg ttattttctc tactttctac tagccccaat 1980 agttgaactc ttataggaaa atcgaaagat aaagtgaaag tttatttcag gactgagaaa 2040 tatcttgaag gttatttatt agatgactat ctcaaatgaa ctttttatag acsatgatga 2100 aaacagaatt aaagtcaatg tttcctgact cccaggcccc tactattcca ggccatcaca 2160 ctggcctgtt ccggagaata tttctctcac aatattatta tctacttata attatggtaa 2220 acaataaatt ttattccatc cttgtagtat gaaacatgct ccaaggaaat ggaatctgtc 2280 ctttaaatgg ataacagtat gtgttctaat ggcataaaat attactggat aaaaacagtt 2340 gtgtcagtgt ctctcctaag gtagtaaata taattgactt attctgaacc cattctattt 2400 tgaatctccc ctttcctctc acaatacttg aacattttaa tcttttggaa tattgtcttt 2460 ctttgttata actattcatt tttagctttt gtctccagtg catgatctca tatttttgct 2520 tttattttta gtataagaac atttataaaa tcatattttt gttactgcaa ttgttttatt 2580 tgttgtgtgg caaatgagaa atcctttatt~tattgtgctg tgatctctct gtgtggaatg 2640 ccttggtgag agagatgctt attatgacta ttatcatttc tgaccaagct tctattaatg 2700 ttatttctaa taatacacta tcttgattgt actctccaga aaatttttct gtcagtgaaa 2760 ataaaagaaa aattaaagta aagctaagga actgtcaaaa aaaaaaaaaa aaaaaaaaaa 2820 Ig <210> 22 <211> 460 <212> PRT
<213> Homo sapiens <400> 22 Met Ile Phe Glu Tyr Ala Glu Ser Val Thr Ser Thr Ala Met Thr Ser Val Ser Gln Ala Ser Leu Asp Val Ser Met Ile Ile Ile Ile Ser Leu Gly Ala Ile Cys Ala Val Leu Leu Val Ile Met Val Leu Phe Ala Thr Arg Cys Asn Arg Glu Lys Lys Asp Thr Arg Ser Tyr Asn Cys Arg Val Ala Glu Ser Thr Tyr Gln His His Pro Lys Arg Pro Ser Arg Gln Ile His Lys Gly Asp Ile Thr Leu Val Pro Thr Ile Asn Gly Thr Leu Pro Ile Arg Ser His His Arg Ser Ser Pro Ser Ser Ser Pro Thr Leu Glu Arg Gly Gln Met Gly Ser Arg Gln Ser His Asn Ser His Gln Ser Leu Asn Ser Leu Val Thr Ile Ser Ser Asn His Val Pro Glu Asn Phe Ser Leu Glu Leu Thr His Ala Thr Pro Ala Val Glu Val Ser Gln Leu Leu Ser Met Leu His Gln Gly Gln Tyr Gln Pro Arg Pro Ser Phe Arg Gly Asn Lys Tyr Ser Arg Ser Tyr Arg Tyr Ala Leu Gln Asp Met Asp Lys Phe Ser Leu Lys Asp Ser Gly Arg Gly Asp Ser Glu Ala Gly Asp Ser Asp Tyr Asp Leu Gly Arg Asp Ser Pro Ile Asp Arg Leu Leu Gly Glu Gly Phe Ser Asp Leu Phe Leu Thr Asp Gly Arg Ile Pro Ala Ala Met Arg Leu Cys Thr Glu Glu Cys Arg Val Leu Gly His Ser Asp Gln Cys Trp Met Pro Pro Leu Pro Ser Pro Ser Ser Asp Tyr Arg Ser Asn Met Phe Ile Pro Gly Glu Glu Phe Pro Thr Gln Pro Gln Gln Gln His Pro His Gln Ser Leu Glu Asp Asp Ala Gln Pro Ala Asp Ser Gly Glu Lys Lys Lys Ser Phe Ser Thr Phe Gly Lys Asp Ser Pro Asn Asp Glu Asp Thr Gly Asp Thr Ser Thr Ser Ser Leu Leu Ser Glu Met Ser Ser Val Phe Gln Arg Leu Leu Pro Pro Ser Leu Asp Thr Tyr Ser Glu Cys Ser Glu Val Asp Arg Ser Asn Ser Leu Glu Arg Arg Lys Gly Pro Leu Pro Ala Lys Thr Val Gly Tyr Pro Gln Gly Val Ala Ala Trp Ala Ala Ser Thr His Phe Gln Asn Pro Thr Thr Asn Cys Gly Pro Pro Leu Gly Thr His Ser Ser Val Gln Pro Ser Ser Lys Trp Leu Pro Ala Met G1u Glu Ile Pro Glu Asn Tyr Glu Glu Asp Asp Phe Asp Asn Val Leu Asn His Leu Asn Asp Gly Lys His Glu Leu Met Asp Ala Ser Glu Leu Val Ala Glu Ile Asn Lys Leu Leu Gln Asp Val Arg Gln Ser <210> 23 <211> 1219 <212> DNA
<213> Homo Sapiens <400> 23 gtggccattc ctcggtacag actagtcctg gtccttgggt gtgggcagtg ggggaggaac 60 caactggtcg aggtttcaga gccaaacctt gcctttggtt ggtgagtcct tgccccccag 120 gcctgcgctc cacgatgccc ttcacccttg gcaatctcag ggccatcctg ggtagtaacc 180 ccactcctct ctgctcccgc ccgcacctgt ggctctcact ctgggctcaa cccctgcaac 240 cctccaggag cccgacagca gccagctgcc tgcactgtcg cctccgtaag ctccaacttc 300 cagacccaga agtccctctg cttccctctg ttggaaaaag cctaaaagaa ttagcttcca 360 gattcctcta gcccctgctc cattcccacc cagtccttct gaagaggaat gagcaataca 420 tctgagctgg atttctctct agtcctttct ccagacaaat ccttcttaaa gcaaaagtcc 480 tggctgagca cctgtccttg gggaccgatc tgccgtgtga ccaggggaag aaagttcccg 540 aaagcctgtt ccaccaattc tgcttctgtg ttgtgaatcc agtctgcttt ccattagaaa 600 accgcttcgg cacttatggt cactttaata aatctagtat gtaaaaaaag aaagaaagaa 660 aagaaacaga aaaacgtgca ggcaaatgta aaatacaatg ctctctgtaa gataaatatt 720 tgcctttttt tctaaaaggt gtacgtattc tgtatgtgaa attgtctgta gaaagtttct 780 atgttcttaa atggcaatac attccaaaaa ttgtactgta gatatgtaca gcaaccgcac 840 tgggatgggg tagttttgcc tgtaatttta tttaaactcc agtttccaca cttgcatctt 900 gcaatgttgg tatggtatat atcagtgcaa aagaaaaaac aaaacaaaaa caaaaaaaaa 960 aacaaaaatc cacgcaggtc taaagcacag agtctgacgt acaaaaggaa aaatgctcag 1020 tattgaagtg tgtgaccttt gttgtaaatt acatctgtac tgtgaatgag aagtttttac 1080 aagtataata attgccttta ttacagctct ggctgagtgt tcagcctgag gatatttttt 1140 aaaaaaaaaa gaattagcat gttggaataa atttgaaaat cccaaaaaaa aaaaaaaaaa 1200 aaaaaaaaaa aaaaaaaaa 1219 <210> 24 <211> 78 <212> PRT
<213> Homo Sapiens <400> 24 Met Pro Phe Thr Leu Gly Asn Leu Arg Ala Ile Leu Gly Ser Asn Pro Thr Pro Leu Cys Ser Arg Pro His Leu Trp Leu Ser Leu Trp Ala Gln Pro Leu Gln Pro Ser Arg Ser Pro Thr Ala Ala Ser Cys Leu His Cys Arg Leu Arg Lys Leu Gln Leu Pro Asp Pro Glu Val Pro Leu Leu Pro Ser Val Gly Lys Ser Leu Lys Glu Leu Ala Ser Arg Phe Leu <210> 25 <211> 2411 <212> DNA
<213> Homo Sapiens <400> 25 ggccagaagg cggggagcca gaggcgccag gaccctagcg tggcgctcca gcaccccaga 60 ccgtggcggc gcctcgcctt agggaagagc aagggaagaa ctttatttga accgcgaaca 120 ttttttggtc actgagatcg agtctcccag tgctttggct tcccgcctct ttatcgtggg 180 tttgatccct gagctgctct cctttcccga acctcccggg gtgcagccta gagccctccc 240 gcgcggctga ctccagagta gaggaaggga ggcggcctcc ggctggtccc ccgaagccct 300 cgctgccccg cagatgcgga tggccagcca gtagcgggcg gtggccccgc gtcccgggag 360 cgcacagcaa tgcaggcgct tsacattacc ccggagcagt tctctcggct gctgcgggac 420 cacaacctga cgcgggagca gttcatcgct ctgtaccggc tgcgaccgct cgtctacacc 480 ccagagctgc cgggacgcgc caagctggcc ctcgtgctca ccggcgtgct catcttcgcc 540 ctggcgctct ttggcaatgc tctggtgttc tacgtggtga cccgcagcaa ggccatgcgc 600 accgtcacca acatctttat ctgctccttg gcgctcagtg acctgctcat caccttcttc 660 tgcattcccg tcaccatgct ccagaacatt tccgacaact ggctgggggg tgctttcatt 720 tgcaagatgg tgccatttgt ccagtctacc gctgttgtga cagaaatcct cactatgacc 780 tgcattgctg tggaaaggca ccagggactt gtgcatcctt ttaaaatgaa gtggcaatac 840 accaaccgaa gggctttcac aatgctaggt gtggtctggc tggtggcagt catcgtagga 900 tcacccatgt ggcacgtgca acaacttgag atcaaatatg acttcctata tgaaaaggaa 960 cacatctgct gcttagaaga gtggaccagc cctgtgcacc agaagatcta caccaccttc 1020 atccttgtca tcctcttcct cctgcctctt atggtgatgc ttattctgta cagtaaaatt 1080 ggttatgaac tttggataaa gaaaagagtt ggggatggtt cagtgcttcg aactattcat 1140 ggaaaagaaa tgtccaaaat agccaggaag aagaaacgag ctgtcattat gatggtgaca 1200 gtggtggctc tctttgctgt gtgctgggca ccattccatg ttgtccatat gatgattgaa 1260 tacagtaatt ttgaaaagga atatgatgat gtcacaatca agatgatttt tgctatcgtg 1320 caaattattg gattttccaa ctccatctgt aatcccattg tctatgcatt tatgaatgaa 1380 aacttcaaaa aaaatgtttt gtctgcagtt tgttattgca tagtaaataa aaccttctct 1440 ccagcacaaa ggcatggsaa ttcaggaatt acaatgatgc ggaagaaagc aaagttttcc 1500 ctcagagaga atccagtgga ggaaaccaaa ggagaagcat tcagtgatgg caacattgaa 1560 gtcaaattgt gtgaacagac agaggagaag aaaaagctca aacgacatct tgctctcttt 1620 aggtctgaac tggctgagaa ttctccttta gacagtgggc attaattata acaatatctt 1680 cataattaat gcccttcaga ttgtaaccca aagagaaaat tattttgagc aaaggtcaaa 1740 tactcttttt attcttaaga tgatgacaag aagaaaacaa atcatgtttc cattaaaaaa 1800 tgacacgaggctagtccaag tgcagtgatg attgatcacaatcatttaac1860 tttacaacca agatttctgtgttccttctc attcccactg ctagccttaaaaaagcaaca1920 cttcacttga tggaaggccaggcacggtgg ctcatgcctg actttgggaggcctagacgg1980 taatcccagc gcggatcacgaggtcaggag atcaaaacca cacggtgaaaccccatctct2040 tcctggctaa gctaaaaatacaaaaattag ccgggcgtgg ctgtagtcccagctacttgg2100 tggcgggcac gagcctcaggcgggagaatg gtgtgaaccc gcttgcagtgatccgagatc2160 gggaggcgga atgccactgcactccagcct gggcgaaaga ccgtctcaaaaaaaattttt2220 gcgagactcc ttgaaaaattcgtaaaccat acttttaaga ggatttttaaaaatcttgta2280 ttatttcagt cagaaatcagggttcttagc tagcagtttt agtcactgtaatgtgactat2340 tctcccacgc gtattgctagattgaataag aaaataaaat tccttgaaaaaaaaaaaaaa2400 aatatcttct aaaaaaaaaaa 2411 <210>

<211>

<212>
PRT

<213> sapiens Homo <400>

Met Gln Leu Asn Ile Thr Pro Glu Ser Arg Leu Arg Ala Gln Phe Leu Asp His Leu Thr Arg Glu Gln Phe Leu Tyr Leu Arg Asn Ile Ala Arg Pro Leu Tyr Thr Pro Glu Leu Pro Ala Lys Ala Leu Val Gly Arg Leu Val Leu Gly Val Leu Ile Phe Ala Leu Phe Asn Ala Thr Leu Ala Gly Leu Val Tyr Val Val Thr Arg Ser Met Arg Val Thr Phe Lys Ala Thr Asn Ile Ile Cys Ser Leu Ala Leu Leu Leu Thr Phe Phe Ser Asp Iie Phe Cys Pro Val Thr Met Leu Gln Ser Asp Trp Leu Ile Asn Zle Asn Gly Gly Phe Ile Cys Lys Met Val Val Gln Thr Ala Ala Pro Phe Ser Val Val Glu Ile Leu Thr Met Thr Ala Val Arg His Thr Cys Ile Glu Gln GIy Val His Pro Phe Lys Met Gln Tyr Asn Arg Leu Lys Trp Thr Arg Ala Thr Met Leu Gly Val Val Val Ala Ile Val Phe Trp Leu Val 165 170 . 175 Gly Ser Met Trp His Val Gln Gln Ile Lys Asp Phe Pro Leu Glu Tyr lao ls5 190 Leu Tyr Lys Glu His Ile Cys Cys Glu Trp Ser Pro Glu Leu Glu Thr Val His Lys Ile Tyr Thr Thr Phe Val Ile Phe Leu Gln Ile Leu Leu Leu Pro Leu Met Val Met Leu Ile Leu Tyr Ser Lys Ile Gly Tyr Glu Leu Trp Ile Lys Lys Arg Val Gly Asp Gly Ser Val Leu Arg Thr IIe His Gly Lys Glu Met Ser Lys Ile Ala Arg Lys Lys Lys Arg Ala Val Ile Met Met Val Thr Val Val Ala Leu Phe Ala Val Cys Trp Ala Pro Phe His Val Val His Met Met Ile Glu Tyr Ser Asn Phe Glu Lys Glu Tyr Asp Asp Val Thr Ile Lys Met Ile Phe Ala Ile Val Gln Ile Ile Gly Phe Ser Asn Ser Ile Cys Asn Pro Ile Val Tyr Ala Phe Met Asn Glu Asn Phe Lys Lys Asn Val Leu Ser Ala Val Cys Tyr Cys Ile Val Asn Lys Thr Phe Ser Pro Ala Gln Arg His Gly Asn Ser Gly Ile Thr Met Met Arg Lys Lys Ala Lys Phe Ser Leu Arg Glu Asn Pro Val Glu Glu Thr Lys Gly Glu Ala Phe Ser Asp Gly Asn Ile Glu Val Lys Leu Cys Glu Gln Thr Glu Glu Lys Lys Lys Leu Lys Arg His Leu Ala Leu Phe Arg Ser Glu Leu Ala Glu Asn Ser Pro Leu Asp Ser Gly His <210> 27 <211> 1995 <212> DNA
<213> Homo sapiens <400> 27 atcatgccac tcatttcaga acttgagcaa aacagggcag tcaggatctg atgtctttct 60 ggtctcccta agaaaactaa gctcttgagg gacagccctt ggcaatgctt tcctatctgc 120 tgagcatggt gaccttcctt aggacttcca gagttcagtt ccttctggca gagaggtttt 180 ctttctccat gccatatgga tgtgactcaa atgaggggtc ccacagcttt tcctggctac 240 cacttgctgt gaccttatac atgttggggt ttgctcttaa agaggagagc aggaagaaag 300 gttggtttca gaaaccaaga gggtcggcag tggacgcgta cattttgtca cggagtccac 360 agagctgagc ttttgagcag actctgagaa gtatcattgc ttgtgttgaa agaatacaac 420 aggatttaag tttctcttta aaaattgcac tgaagaaagg ccgggcgcgg tggctccccc 480 tgtaatccca gcgctttggg aggccgaggc ggggggatca cgaggtcaag agatcgagac 540 catcctggcc aacatggtga aaccccgtct ctaataaaaa tacaaaaatt agccgggcat 600 ggtgacgtgc acctgtagtc ccagctacta gataggctga ggcaggagaa ttgcttgaat 660 ccgggaggcg gaggttgcag tgagccgaga tcgtgccact gaactccaac ctgccaatag 720 agcgagactc cgtctcaaaa aaaaaaaaaa aaaagaaaga aatagcattg aagaaaatac 780 cgcacatcag aggaaagctt attttctgca tggtgtcttt tcaaagatag aatatttgaa 840 WO 00/11015 PC'TNS99/19351 gcatgttttc tagcgattgt gtgaatgagg gtgagctggc tgaggcatcg ctcaagctgg 900 ggggtggtgt gtaagaagca cgtggagcca caagaggcac ctcctatagt cagctaaggg 960 cttccctttc tgcgcccagc ttttgggtga agggtgattt ctactagaca catctgtgct 1020 tcagtcatag atgttaatag aggaagcagt tttcctgctg cagattcctg aatagagttg 1080 ctgaaagagt ctacttctgg actcgggaag ttgaaggcca gtctgtgtag aaaggctgag 1140 gcaacgggga aagacctgac agctagttac atacgctctg acatagtact cccatgatgg 1200 cttccagtga cacatgtgct gatagaattc taaacctctg gaatttccct gctggcgact 1260 tctatggccg ttgactgtac agggtaacct gatgccagat gctatgggcg tgatgagaac 1320 tagagcattg cagcatggag gaaactgtga ggcaccagat cctgtgcttc tgcaggccat 1380 tttctgaaaa cccctgttag gaaggttgga tttggcgtga cttgcttgag caagagtcct 1440 ggggagagat tttgaggttt aatttaacgg tatatccaga gctaacagtg actcaactcg 1500 tctagttctg caagtcagat gtatacttag agtctctctg tgaagggttt gggtctgagc 1560 tgtatagtat gtcaaactgc cagtaagcca gcccctcacc ctctgataga tattccttta 1620 atgcaccaga cttcatgttt gataaatgat taatggttga aattgtttct cttcttttgt 1680 gttttcccag ttaatagatg gtcactgttt ccacaatgtt ttatactttc agctttttgt 1740 aacttaacta taattactta attttatttt tttaaagctt gttgtggtct aatgagaagt 1800 atttttcagt gcataatgtt tttctgagct tctgtaaatg ccatcccaat gtggtttggt 1860 tttgttgaac agaaaccaaa ataaatttca aaatgttaaa aaaaaaaaaa aaaaaaaaaa 1920 aaaaaaaaaa aaaaaaaaaa aaaaa 1945 <210> 28 <211> 87 <212> PRT
<213> Homo Sapiens <400> 28 Met Leu Ser Tyr Leu Leu Ser Met Val Thr Phe Leu Arg Thr Ser Arg Val Gln Phe Leu Leu Ala Glu Arg Phe Ser Phe Ser Met Pro Tyr Gly Cys Asp Ser Asn Glu Gly Sex His Ser Phe Ser Trp Leu Pro Leu Ala Val Thr Leu Tyr Met Leu Gly Phe Ala Leu Lys Glu Glu Ser Arg Lys Lys Gly Trp Phe Gln Lys Pro Arg Gly Ser Ala Val Asp Ala Tyr Ile Leu Ser Arg Ser Pro Gln Ser <210> 29 <211> 2184 <212> DNA
<213> Homo Sapiens <400> 29 gggcgccctc tggggctccg agcccggcgg gaccatgttc accagcaccg gctccagtgg 60 gctctacaag gcgcctctgt cgaagagcct tctgctggtc cccagtgccc tctccctcct 120 gctcgccctc ctcctgcctc actgccagaa gctctttgtg tatgaccttc acgcagtcaa 180 gaacgacttc cagatttgga ggttgatatg tggaagaata atttgccttg atttgaaaga 240 tactttttgc agtagtctgc ttatttataa ttttaggata tttgaaagaa gatatggaag 300 cagaaaattt gcatcctttt tgctgggttc ctgggttttg tcagccttat ttgactttct 360 cctcattgaa gctatgcagt atttctttgg catcactgca gctagtaatt tgccttctgg 420 attcctggca cctgtgtttg ctctgtttgt accattttac tgctccatac caagagtcca 480 agtggcacaa attctgggtc cgttgtccat cacaaacaag acattgattt atatattggg 540 actgcagctt ttcacctctg gttcctacat ctggattgta gccataagtg gacttatgtc 600 cggtctgtgc tacgacagca aaatgttcca ggtgcatcag gtgctctgca tccccagctg 660 gatggcaaaa ttcttttctt ggacacttga acccatcttc tcttcttcag aacccaccag 720 cgaagccaga attgggatgg gagccacgct ggacatccag agacagcaga gaatggagct 780 gctggaccgg cagctgatgt tctctcagtt tgcacaaggg aggcgacaga gacagcagca 840 gggaggaatg atcaattgga atcgtctttt tcctccttta cgtcagcgac aaaacgtaaa 900 ctatcagggc ggtcggcagt ctgagccagc agcgccccct ctagaagttt ctgaggaaca 960 ggtcgcccgg ctcatggaga tgggattttc cagaggtgat gctttggaag ccctgagagc 1020 ttcaaacaat gacctcaatg tcgccaccaa cttcctgctg cagcactgat agtcccaggc 1080 caacactggg accggaccgg cagccgagtg acagtgcgtg gtccccacca tcagatcagc 1140 ccggggaccg agcatctctg gtgctgatgt tcttgtggga agagggaggt tccaccgcac 1200 ccctgccctc aaccgcaaga ctgttgccgt tttagtgtgg agataagttt gccattacat 1260 tagcatgtat tttctatcta tatttttatt gggcattttc cctaggttgg agagtcagca 1320 ctcgttttga atgtgtttaa aatgcattaa aatggaagat ttctgcaggc agttgaatgg 1380 cactccagat ggggaattgc tgtaaccctc ttactgtaac atgtcatctc ctgcgtcgtg 1440 atggggagag ggtaatgtta cttcacaaag gacatgtcag atccttcttc atggactttt 1500 ttagttactg ttttttctct caaacttgtt ttcgaatctc ctgggagtga gggagaaaca 1560 gggagctgaa tcctccccca agctgttcca ggccagagga ctctgcagta gcttctccta 1620 catctagtaa caaagaatgg tgataaccat gcactggttc aaggttctgg agttctccat 1680 gaaacttggg ttaattttgc tcagagtatc cagagttagc cactaggctg cgggtgaaat 1740 gggatggaga agaacaacag caggcttcct ggagccacat gggctgacta gggcactctg 1800 tggctggcat ggcatgggct cagcccagga agaggagaaa cgatcccttg cctgcccctc 1860 cctgtggcag ggctaactgc ctggccctcc tggctcgcag ccagccagcc ccctggcagc 1920 aggttctcct cagggcttgg gtcttcaacc tgtggcgaca ggaggcaggg cagactgtgg 1980 aggacaggat gcaggtcagg gagagggaag gcaggggtgg accgccatga gcatgaaaag 2040 acccgaagca agttgactct tgcaatgtgc aactgttatg ttctgcaaaa tgagcaacga 2100 tgtatcaaat tgatgcaaat ttagatgttg atacttacaa taaagttttt aatgtgtttt 2160 aaaaaaaaaa aaaaaaaaaa aaaa 2184 <210> 30 <211> 344 <212> PRT
<213> Homo Sapiens <400> 30 Met Phe Thr Ser Thr Gly Ser Ser Gly Leu Tyr Lys Ala Pro Leu Ser Lys Ser Leu Leu Leu Val Pro Ser Ala Leu Ser Leu Leu Leu Ala Leu Leu Leu Pro His Cys Gln Lys Leu Phe Val Tyr Asp Leu His Ala Val Lys Asn Asp Phe Gln Ile Trp Arg Leu Ile Cys Gly Arg Ile Ile Cys Leu Asp Leu Lys Asp Thr Phe Cys Ser Ser Leu Leu Ile Tyr Asn Phe Arg Ile Phe Glu Arg Arg Tyr Gly Ser Arg Lys Phe Ala Ser Phe Leu Leu Gly Ser Trp Val Leu Ser Ala Leu Phe Asp Phe Leu Leu Ile Glu Ala Met Gln Tyr Phe Phe Gly Ile Thr Ala Ala Ser Asn Leu Pro Ser Gly Phe Leu Ala Pro Val Phe Ala Leu Phe Val Pro Phe Tyr Cys Ser Ile Pro Arg Val Gln Val Ala Gln Ile Leu Gly Pro Leu Ser Ile Thr Asn Lys Thr Leu Ile Tyr Ile Leu Gly Leu Gln Leu Phe Thr Ser Gly Ser Tyr Ile Trp Ile Val Ala Ile Ser Gly Leu Met Ser Gly Leu Cys Tyr Asp Ser Lys Met Phe Gln Val His Gln Val Leu Cys Ile Pro Ser Trp Met Ala Lys Phe Phe Ser Trp Thr Leu Glu Pro Ile Phe Ser Ser Ser Glu Pro Thr Ser Glu Ala Arg Ile Gly Met Gly Ala Thr Leu Asp Ile Gln Arg Gln Gln Arg Met Glu Leu Leu Asp Arg Gln Leu Met Phe Ser Gln Phe Ala Gln Gly Arg Arg Gln Arg Gln Gln Gln Gly Gly Met Ile Asn Trp Asn Arg Leu Phe Pro Pro Leu Arg Gln Arg Gln Asn Val 27s 280 2as Asn Tyr Gln Gly Gly Arg Gln Ser Glu Pro Ala Ala Pro Pro Leu Glu Val Ser Glu Glu Gln Val Ala Arg Leu Met Glu Met Gly Phe Ser Arg Gly Asp Ala Leu Glu Ala Leu Arg Ala Ser Asn Asn Asp Leu Asn Val Ala Thr Asn Phe Leu Leu Gln His <210> 31 <211> 2880 <212> DNA
<213> Homo sapiens <400> 31 ccggcgtccg ggcgcgctgg agaggacgcg aggagccatg aggcgccagc ctgcgaaggt 60 ggcggcgctg ctgctcgggc tgctcttgga gtgcacagaa gccaaaaagc attgctggta 120 tttcgaagga ctctatccaa cctattatat atgccgctcc tacgaggact gctgtggctc 180 caggtgctgt gtgcgggccc tctccataca gaggctgtgg tacttctggt tccttctgat 240 gatgggcgtg cttttctgct gcggagccgg cttcttcatc cggaggcgca tgtacccccc 300 gccgctgatc gaggagccag ccttcaatgt gtcctacacc aggcagcccc caaatcccgg 360 cccaggagcc cagcagccgg ggccgcccta ttacaccgac ccaggaggac cggggatgaa 420 ccctgtcggg aattccatgg caatggcttt ccaggtccca cccaactcac cccaggggag 480 tgtggcctgc ccgccccctc cagcctactg caacacgcct ccgcccccgt acgaacaggt 540 agtgaaggcc aagtagtggg gtgcccacgt gcaagaggag agacaggaga gggcctttcc 600 ctggcctttc tgtcttcgtt gatgttcact tccaggaacg gtctcgtggg ctgctaaggg 660 cagttcctct gatatcctca cagcaagcac agctctcttt caggctttcc atggagtaca 720 atatatgaac tcacactttg tctcctctgt tgcttctgtt tctgacgcag tctgtgctct 780 cacatggtag tgtggtgaca gtccccgagg gctgacgtcc ttacggtggc gtgaccagat 840 ctacaggaga gagactgaga ggaagaaggc agtgctggag gtgcaggtgg catgtagagg 900 ggccaggccg agcatcccag gcaagcatcc ttctgcccgg gtattaatag gaagccccat 960 gccgggcggc tcagccgatg aagcagcagc cgactgagct gagcccagca ggtcatctgc 1020 tccagcctgt cctctcgtca gccttcctct tccagaagct gttggagaga cattcaggag 1080 agagcaagcc ccttgtcatg tttctgtctc tgttcatatc ctaaagatag acttctcctg 1140 caccgccagg gaagggtagc acgtgcagct ctcaccgcag gatggggcct agaatcaggc 1200 ttgccttgga ggcctgacag tgatctgaca tccactaagc aaatttattt aaattcatgg 1260 gaaatcactt cctgccccaa actgagacat tgcattttgt gagctcttgg tctgatttgg 1320 agaaaggact gttacccatt tttttggtgt gtttatggaa gtgcatgtag agcgtcctgc 1380 cctttgaaat cagactgggt gtgtgtcttc cctggacatc actgcctctc cagggcattc 1440 tcaggcccgg gggtctcctt ccctcaggca gctccagtgg tgggttctga agggtgcttt 1500 caaaacgggg cacatctggc tgggaagtca catggactct tccagggaga gagaccagct 1560 gaggcgtctc tctctgaggt tgtgttgggt ctaagcgggt gtgtgctggg ctccaaggag 1620 gaggagcttg ctgggaaaag acaggagaag tactgactca actgcactga ccatgttgtc 1680 ataattagaa taaagaagaa gtggtcggaa atgcacattc ctggatagga atcacagctc 1740 accccaggat ctcacaggta gtctcctgag tagttgacgg ctagcgggga gctagttccg 1800 ccgcatagtt atagtgttga tgtgtgaacg ctgacctgtc ctgtgtgcta agagctatgc 1860 agcttagctg aggcgcctag attactagat gtgctgtatc acggggaatg aggtgggggt 1920 gcttattttt taatgaacta atcagagcct cttgagaaat tgttactcat tgaactggag 1980 catcaagaca tctcatggaa gtggatacgg agtgatttgg tgtccatgct tttcactctg 2040 aggacattta atcggagaac ctcctgggga attttgtggg agacacttgg gaacaaaaca 2100 gacaccctgg gaatgcagtt gcaagcacag atgctgccac cagtgtctct gaccaccctg 2160 gtgtgactgc tgactgccag cgtggtacct cccatgctgc aggcctccat ctaaatgaga 2220 caacaaagca caatgttcac tgtttacaac caagacaact gcgtgggtcc aaacactcct 2280 cttcctccag gtcatttgtt ttgcattttt aatgtcttta ttttttgtaa tgaaaaagca 2340 cactaagctg cccctggaat cgggtgcagc tgaataggca cccaaaagtc cgtgactaaa 2400 tttcgtttgt ctttttgata gcaaattatg ttaagagaca gtgatggcta gggctcaaca 2460 attttgtatt cccatgtttg tgtgagacag agtttgtttt cccttgaact tggttagaat 2520 tgtgctactg tgaacgctga tcctgcatat ggaagtcccg cttcggtgac atttcctggc 2580 cattcttgtt tccattgtgt ggatggtggg ttgtgcccac ttcctggagt gagacagctc 2640 ctggtgtgta gaattcccgg agcgtccgtg gttcagagta aacttgaagc agatctgtgc 2700 atgcttttct ctgcaacaat tggctcgttt ctcttttttg ttctcttttg ataggatcct 2760 gtttcctatg tgtgcaaaat aaaaataaat ttgggcaaaa aaaaaaaaaa aaaaaaaaaa 2820 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2880 <210> 32 <211> 172 <212> PRT
<213> Homo sapiens <400> 32 Met Arg Arg Gln Pro Ala Lys Val Ala Ala Leu Leu Leu Gly Leu Leu Leu Glu Cys Thr Glu Ala Lys Lys His Cys Trp Tyr Phe Glu Gly Leu Tyr Pro Thr Tyr Tyr Ile Cys Arg Ser Tyr Glu Asp Cys Cys Gly Ser Arg Cys Cys Val Arg Ala Leu Ser Ile Gln Arg Leu Trp Tyr Phe Trp Phe Leu Leu Met Met Gly Val Leu Phe Cys Cys Gly Ala Gly Phe Phe Ile Arg Arg Arg Met Tyr Pro Pro Pro Leu Ile Glu Glu Pro Ala Phe Asn Val Ser Tyr Thr Arg Gln Pro Pro Asn Pro Gly Pro Gly Ala Gln Gln Pro Gly Pro Pro Tyr Tyr Thr Asp Pro Gly Gly Pro Gly Met Asn Pro Val Gly Asn Ser Met Ala Met Ala Phe Gln Val Pro Pro Asn Ser Pro Gln Gly Ser Val Ala Cys Pro Pro Pro Pro Ala Tyr Cys Asn Thr Pro Pro Pro Pro Tyr Glu Gln Val Val Lys Ala Lys <210> 33 <211> 3406 <212> DNA
<213> Homo sapiens <400> 33 taaagaacaa tcctttaagg gagaacctag aagccattca acaaggttaa aatcttcagg 60 cttccgagga tttggtagac agatcagagg cacgtttccc acaactgcga agaggcgctg 120 aggcaattct gcaagaagat tttggggttt tggaaaagaa gctatggaaa acggaggggc 180 aggcactctg cagataaggc aagtcctgct tttctttgtt ttgctgggaa tgtctcaggc 240 gggctctgaa actgggaact ttttggtgat ggaggaattg cagagcggga gctttgtagg 300 aaatttggca aagaccctgg gactcgaggt gagtgagctg tcttcgcggg gggctcgggt 360 ggtttctaat gataacaaag agtgtttgca gctggacaca aacactgggg atttgctcct 420 gagagaaatg ctagacaggg aggagctctg tggctccaat gagccttgtg tgctgtattt 480 ccaagtgtta atgaaaaacc ccacgcagtt tttacaaatt gagctccagg tcagggatat 540 aaatgatcac tctcccgtct tcttggaaaa agaaatgctc ttagaaatcc cagagaacag 600 tcctgttggt gctgtgttct tgcttgaaag tgcaaaggat ttagatgtag gaatcaatgc 660 tgtaaaaagc tacacaataa atccgaactc tcatttccac gttaaaataa gagtcaatcc 720 agacaatagg saataccctg agttagttct ggacaaggcg ctggattatg aagagcgccc 780 ggagctcagt ttcatcctca ctgctctgga tggcgggtcc cctcccaggt ctggaactgc 840 cttggtcagg gtggtggttg tagatattaa tgacaactcc cctgagtttg agcaggcttt 900 ttatgaggtg aagattctgg agaatagcat ccttggctcc ctggttgtga ccgtctcagc 960 ctgggattta gactctggaa caaacagtga actatcctat accttttccc atgcctcaga 1020 agatattcgc aagacatttg aaattaatca aaagtctggt gacattactt taacagcacc 1080 tttggatttt gaagcaattg agtcatactc aataatcatt caagccacag atgggggagg 1140 actttttgga aaatctacag tcagaattca ggtgatggat gtaaacgaca acgctcctga 1200 aatcactgtg tcatcaatta ccagtccaat cccagaaaac actccagaga ctgtggttat 1260 ggttttcagg atacgagaca gagactctgg ggacaacgga aagatggttt gttctatccc 1320 ggaggacatc ccattcgtgc taaaatcttc ggtaaataat tactacactt tggaaacaga 1380 gagaccgctg gacagagaga gcagagccga gtacaacatc accatcaccg tcaccgactt 1440 ggggaccccc aggctaaaaa ccgagcacaa cataaccgtg ctggtctccg acgtcaatga 1500 caacgccccc gccttcaccc aaacttccta cgccctgttc gtccgcgaga acaacagccc 1560 cgccctgcac atcggcagca tcagcgccac agacagagac tcgggcacca acgcccaggt 1620 caactactcg ctgctgccgt cccaggaccc gcacctgccc ctcgcctccc tggtctccat 1680 caacgcggac aacggccacc tgtttgccct caggtcgctg gactacgagg ccctgcaggg 1740 gttccagttc cgcgtgggcg ccacagacca cggctccccg gctttgagca gcgaggcgct 1800 ggtgcgcgtg ctggtgctgg acgccaacga caactcgccc ttcgtgctgt acccgctgca 1860 gaacggctcc gcgccctgca ccgagctggt gccctgggcg gccgagccgg gctacctggt 1920 gaccaaggtg gtggcggtgg acggtgactc gggccagaac gcctggctgt cgtaccagct 1980 gctcaaggcc acggagcccg ggctattcgg cgtgtgggcg cacaatggcg aggtgcgcac 2040 cgccaggctg ctgagcgagc gcgacgcggc caagcacagg ctggtggtgc tggtcaagga 2100 caatggcgag cctccgcgct cggccaccgc cacgctgcac gtgctcctgg tggacggctt 2160 ctcccagccc tacctgcctc tcccggaggc ggccccggcc caggcccagg ccgactcgct 2220 cactgtctac ctggtggtgg cgttggcctc agtgtcgtcg ctcttcctct tctcggtgct 2280 cctgttcgtg gcggtgcggc tgtgcaggag gagcagggcg gccccggtcg gtcgctgctc 2340 ggtgcctgag ggcccctttc caggacatct ggtggacgtg agtggcaccg ggaccctgtc 2400 ccagagctac cactatgagg tgtgtgtgac tggaggctcc aggtcaaata agttcaaatt 2460 tctgaaacca attatcccca acttcctacc ccagagcaca ggtagtgaag tcgaagaaaa 2520 tcccccattt cagaataatt tgggtttctg ataaagaatg aaaaataaaa cctgtgttta 2580 tgaatacatt tataattagg aacttatcgt gaggtgcctg taaagtagta tttttgatca 2640 cttcaaatac atactcttca agtcaagaaa taaatttctt tacatagaaa aggatacaga 2700 tttagtacca agaacacttc acaaagcagg aaatgtgcat gtgtaatggt ttatgtcaaa 2760 caattatgct taatataaag tctattaagt ggtaagtctt gtttgagata ttttaaattg 2820 ctttccattg ttttcaatat ttactgtgac ttttgttttc tgagttgatt agaatgctgt 2880 tcgagtatac ctaccctagt ttcagaagca tagattgtag tgtacctttt taaactttat 2940 ttttttaaaa aaagttgttt tatgaatcat acactatttt cacactttta atctcagaag 3000 aaacatatgt gacatggtat tttagtaatg accaaataga cggtcttaga gattcagtaa 3060 gttcactaag gtccactaac taataagtga caaaactgag catccatcct agatctgcct 3120 gactctaagt cagtgacttt gctcccattc catactgttt ttgtcattgg atatcacctg 3180 gcaagtttct gcctaactaa agagaagaaa agtttttatc gtattcatac tactgttcaa 3240 tctttattta gaaataaact ttatctatga tttcattttc ttataaacca gtaatcttgc 3300 ttttctgggt aaattttcag ctattattac taatgctctg atctgcccaa atcttaagta 3360 aaaaacaaaa ttgaaagagc aaaaaaaaaa aaaaaaaaaa aaaaaa 3406 <210> 34 <211> 795 <212> PRT
<213> Homo Sapiens <400> 34 Met Glu Asn Gly Gly Ala Gly Thr Leu Gln Ile Arg Gln Val Leu Leu Phe Phe Val Leu Leu Gly Met Ser Gln Ala Gly Ser Glu Thz Gly Asn Phe Leu Val Met Glu Glu Leu Gln Ser Gly Ser Phe Val Gly Asn Leu Ala Lys Thr Leu Gly Leu Glu Val Ser Glu Leu Ser Ser Arg Gly Ala Arg Val Val Ser Asn Asp Asn Lys Glu Cys Leu Gln Leu Asp Thr Asn Thr Gly Asp Leu Leu Leu Arg Glu Met Leu Asp Arg Glu Glu Leu Cys Gly Ser Asn Glu Pro Cys Val Leu Tyr Phe Gln Val Leu Met Lys Asn Pro Thr Gln Phe Leu Gln Ile Glu Leu Gln Val Arg Asp Ile Asn Asp His Ser Pro Val Phe Leu Glu Lys Glu Met Leu Leu Glu Ile Pro Glu Asn Ser Pro Val Gly Ala Val Phe Leu Leu Glu Ser Ala Lys Asp Leu Asp Val Gly Ile Asn Ala Val Lys Ser Tyr Thr Ile Asn Pro Asn Ser His Phe His Val Lys Ile Arg Val Asn Pro Asp Asn Arg Lys Tyr Pro Glu Leu Val Leu Asp Lys Ala Leu Asp Tyr Glu Glu Arg Pro Glu Leu Ser Phe Ile Leu Thr Ala Leu Asp Gly Gly Ser Pro Pro Arg Ser Gly Thr Ala Leu Val Arg Val Val Val Val Asp Ile Asn Asp Asn Ser Pro Glu Phe Glu Gln Ala Phe Tyr Glu Val Lys Ile Leu Glu Asn Ser Ile Leu Gly Ser Leu Val Val Thr Val Ser Ala Trp Asp Leu Asp Ser Gly Thr Asn Ser Glu Leu Ser Tyr Thr Phe Ser His Ala Ser Glu Asp Ile Arg Lys Thr Phe Glu Ile Asn Gln Lys Ser Gly Asp Ile Thr Leu Thr Ala Pro Leu Asp Phe Glu Ala Ile Glu Ser Tyr Ser Ile Ile Ile Gln Ala Thr Asp Gly Gly Gly Leu Phe Gly Lys Ser Thr Val Arg Ile Gln Val Met Asp Val Asn Asp Asn Ala Pro Glu Ile Thr Val Ser Ser Ile Thr Ser Pro Ile Pro Glu Asn Thr Pro Glu Thr Val Val Met Val Phe Arg Ile Arg Asp Arg Asp Ser Gly Asp Asn Gly Lys Met Val Cys Ser Ile Pro Glu Asp Ile Pro Phe Val Leu Lys Ser Ser Val Asn Asn Tyr Tyr Thr Leu Glu Thr Glu Arg Pro Leu Asp Arg Glu Ser Arg Ala Glu Tyr Asn Ile Thr Ile Thr Val Thr Asp Leu Gly Thr Pro Arg Leu Lys Thr Glu His Asn Ile Thr Val Leu Val Ser Asp Val Asn Asp Asn Ala Pro Ala Phe Thr Gln Thr Ser Tyr Aia Leu Phe Val Arg Glu Asn Asn Ser Pro Ala Leu His Ile Gly Ser Ile Ser Ala Thr Asp Arg Asp Ser Gly Thr Asn Ala Gln Val Asn Tyr Ser Leu Leu Pro Ser Gln Asp Pro WO 00/11015 PCI'/US99/19351 His Leu Pro Leu Ala Ser Leu Val Ser Ile Asn Ala Asp Asn Gly His Leu Phe Ala Leu Arg Ser Leu Asp Tyr Glu Ala Leu Gln Gly Phe Gln Phe Arg Val Gly Ala Thr Asp His Gly Ser Pro Ala Leu Ser Ser Glu Ala Leu Val Arg Val Leu Val Leu Asp Ala Asn Asp Asn Ser Pro Phe Val Leu Tyr Pro Leu Gln Asn Gly Ser Ala Pro Cys Thr Glu Leu Val Pro Trp Ala Ala Glu Pro Gly Tyr Leu Val Thr Lys Val Val Ala Val Asp Gly Asp Ser Gly Gln Asn Ala Trp Leu Ser Tyr Gln Leu Leu Lys Ala Thr Glu Pro Gly Leu Phe Gly Val Trp Ala His Asn Gly Glu Val Arg Thr Ala Arg Leu Leu Ser Glu Arg Asp Ala Ala Lys His Arg Leu Val Val Leu Val Lys Asp Asn Gly Glu Pro Pro Arg Ser Ala Thr Ala Thr Leu His Val Leu Leu Val Asp Gly Phe Ser Gln Pro Tyr Leu Pro Leu Pro Glu Ala Ala Pro Ala Gln Ala Gln Ala Asp Ser Leu Thr Val 675 ' 680 685 Tyr Leu Val Val Ala Leu Ala Ser Val Ser Ser Leu Phe Leu Phe Ser Val Leu Leu Phe Val Ala Val Arg Leu Cys Arg Arg Ser Arg Ala Ala Pro Val Gly Arg Cys Ser Val Pro Glu Gly Pro Phe Pro Gly His Leu Val Asp Val Ser Gly Thr Gly Thr Leu Ser Gln Ser Tyr His Tyr Glu Val Cys Val Thr Gly Gly Ser Arg Ser Asn Lys Phe Lys Phe Leu Lys Pro Ile Ile Pro Asn Phe Leu Pro Gln Ser Thr Gly Ser Glu Val Glu Glu Asn Pro Pro Phe Gln Asn Asn Leu Gly Phe <210> 35 <211> 3809 <212> DNA
<213> Homo sapiens <400> 35 ggggaccgga gtggggagcg cggcgtggag gtgccacccg gcgcgggtgg cggagagatc 60 agaagcctct~tccccaagcc gagccaacct cagcggggac ccgggctcag ggacgcggcg 120 gcggcggcgg cgactgcagt ggctggacga tggcagcgtc cgccggagcc ggggcggtga 180 ttgcagcccc agacagccgg cgctggctgt ggtcggtgct ggcggcggcg cttgggctct 240 tgacagctgg agtatcagcc ttggaagtat atacgccaaa agaaatcttc gtggcaaatg 300 gtacacaagg gaagctgacc tgcaagttca agtctactag tacgactggc gggttgacct 360 cagtctcctg gagcttccag ccagaggggg ccgacactac tgtgtcgttt ttccactact 420 cccaagggca agtgtacctt gggaattatc caccatttaa agacagaatc agctgggctg 480 gagaccttga caagaaagat gcatcaatca acatagaaaa tatgcagttt atacacaatg 540 gcacctatat ctgtgatgtc aaaaaccctc ctgacatcgt tgtccagcct ggacacatta 600 ggctctatgt cgtagaaaaa gagaatttgc ctgtgtttcc agtttgggta gtggtgggca 660 tagttactgc tgtggtccta ggtctcactc tgctcatcag catgattctg gctgtcctct 720 atagaaggaa aaactctaaa cgggattaca ctggggccca gtcatatatg cacagttaga 780 ccactccggc ggacatcaca gtgacaagat taacaagtca gagtctgtgg tgtatgcgga 840 tatccgaaag aattaagaga atacctagaa catatcctca gcaagaaaca aaaccaaact 900 ggactctcgt gcagaaaatg tagcccatta ccacatgtag ccttggagac ccaggcaagg 960 acaagtacac gtgtactcac agagggagag aaagatgtgt acaaaggata tgtataaata 1020 ttctatttag tcatcctgat atgaggagcc agtgttgcat gatgaaaaga tggtatgatt 1080 ctacatatgt acccattgtc ttgctgtttt tgtactttct tttcaggtca tttacaattg 1140 ggagatttca gaaacattcc tttcaccatc atttagaaat ggtttgcctt aatggagaca 1200 atagcagatc ctgtagtatt tccagtagac atggcctttt aatctaaggg cttaagactg 1260 attagtctta gcatttactg tagttggagg atggagatgc tatgatggaa gcatacccag 1320 ggtggccttt agcacagtat cagtaccatt tatttgtctg ccgcttttaa aaaataccca 1380 ttggctatgc cacttgaaaa caatttgaga agtttttttg aagtttttct cactaaaata 1440 tggggcaatt gttagcctta catgttgtgt agacttactt taagtttgca cccttgaaat 1500 gtgtcatatc aatttctgga ttcataatag caagattagc aaaggataaa tgccgaaggt 1560 cacttcattc tggacacagt tggatcaata ctgattaagt agaaaatcca agctttgctt 1620 gagaactttt gtaacgtgga gagtaaaaag tatcggtttt attctttgct gatgtccttt 1680 ctgcttgaaa taacagtcac catacagcta aaggagagga gtttctttcc ttctaagtag 1740 gcagaaatgg tatcattatg ttgccgctct ccaatctccc agagctcgct ctctagagaa 1800 tcaccttctt tcgctttttt ttttttttga ggtagagtct cactatgttg cccagactag 1860 ccttgaactc ttgggctcaa gtgattctcc ctcctcagcc tcccgagtag ctggaacgaa 1920 ctatagttgc accactgcag ctggcaagaa tcaccttttt tataaagcgt cagtcatgct 1980 tccagcaaga ggcagcatca gtcatggctt tataacagct tcatggtgcc tcaaagactg 2040 ttgaggttaa tgagagccta gattagacag tttggctgtc cttccctaaa acttgttttc 2100 tcctattcac tactccccac cgcacttaaa atctatgagt ttttactttt tactgggaat 2160 ggaaagtgtg gtgaagatca ttcaacactt atgttgtcat ttctcccatt ttctgaattt 2220 ttttttaaat ttcccccctt ttaaaattgt tcgaaagccc acagttatgg aaagaattac 2280 tgtctagatg gtctgcagaa cgtgtttggg gtgagtggga gtgaggggca atgttacttt 2340 ttctccttgt agtttggagt ccattatgag ctgctgcttt ttcttctcat cttgtcatct 2400 tctggggatg tttgaaggct gagttccaac agaattcaca aagggaataa aacaggattg 2460 agattttgag gtgtgcacaa ggtggtaaga taaagggcat atgagcttca aaactaatgc 2520 tgttgcatac atgaagcctt ttgttttttg aggagctatt tttgttattc ttgtaacgct 2580 ccaccttaca tgccacgtct gtgtgagtca acagggatca ggtttggtca ccacacatgt 2640 ctgaagctgg gcagcgtctg ctctgtgttc tgtgtggaat ggagaaaaaa acgcctgccc 2700 tgctgccttc catgttcata ggcccagccc aagagagtga cacacagtgc tggccctgag 2760 acatttccac aaagtggtca actctgcctt gcatcctaaa actttttggg catctatttt 2820 gaaaactata ggagcctttg gaaggcctct tatgtttgga ggggaagggt gttgagattg 2880 tcaccatcct tcaagctgag actcctggtg agcctttgcc accatgaaaa ccacatagct 2940 gaccagggct gtgcttgagg tacagaggac acacatcgta gacaggcctg tgtcatgttt 3000 ccttacagtc gttttttaca gagaaaaggg gcattgtttt ttcactgctt tctcaacagt 3060 tcctgtgaat aaatgaaaca tttcggagct ccctgagagc aagagccttc acttcttctt 3120 gcggtgccgg gaccatgtgt tggtgaagct ggtgctgtgg gggccactca ctcgaatgac 3180 acctggaggc ctgttcctcc cttaccactc ccttccccag cccgacttct tggcctcctg 3240 cccaaccaga cacctcaaac tctgtcagcg ccctggcatt ctggcagaga atcctcacca 3300 gttctcacca accttccccc caggcaaggg cagctgccag catggtgctc tgccaggaca 3360 ggtttccctg aaggaagctg gatgagcctctcagggcagg acctcttccc3420 ctcacactga aagccctgca cacccacccc ttggctccccttttccctgt gcctcagcac3480 tgcagccctt tcctttcctg gttgcagata gttgcctaaagggcagatct gccctctcca3540 acgaactaag tgtcttcgtc ctggcaaaca aaaattatgcgctaattctg tatgggagca3600 gggtcgtctt ctcaaaaggc attacttaga tcaaactatctctagttttt caatggaaat3660 gattgaaatt atatcagcta gggaaaaacc ttattattttttgatcttca gttgtatttt3720 atcaagctca tgtgaatatt ttaatacatc tctgaaaaaaaaaaaaaaaa aaaaaaaaaa3780 tttttcaatt aaaaaaaaaa aaaaaaaaaa 3809 aaaaaaaaa <210> 36 <211> 209 <212> PRT

<213> Homo sapiens <400> 36 Met Ala Ala Ser Ala Gly Ala Val Ala Ala Pro Asp Ala Gly Ile Ser Arg Arg Trp Leu Trp Ser Ala Ala Leu Gly Leu Leu Val Leu Ala Thr Ala Gly Val Ser Ala Leu Tyr Thr Lys Glu Ile Phe Glu Val Pro Val Ala Asn Gly Thr Gln Gly Thr Cys Phe Lys Ser Thr Lys Leu Lys Ser Thr Thr Giy Gly Leu Thr Ser Trp Phe Gln Pro Glu Ser Val Ser Gly Ala Asp Thr Thr Val Ser His Tyr Gln Gly Gln Val Phe Phe Ser Tyr Leu Gly Asn Tyr Pro Pro Asp Arg Ser Trp Ala Gly Phe Lys Ile Asp Leu Asp Lys Lys Asp Ala Asn Ile Asn Met Gln Phe Ser Ile G1u Ile His Asn Gly Thr Tyr Ile Val Lys Pro Pro Asp Ile Cys Asp Asn Val Val Gln Pro Gly His Ile Tyr Val Glu Lys Glu Asn Arg Leu Val Leu Pro Val Phe Pro Val Trp Val Gly Val Thr Ala Val Val Val Ile Val Leu Gly Leu Thr Leu Leu Met Ile Ala Val Leu Tyr Ile Ser Leu Arg Arg Lys Asn Ser Lys Arg Thr Gly Gln Ser Tyr Met Asp Tyr Ala His Ser <210> 37 <211> 1954 <212> DNA
<213> Homo sapiens <400> 37 gagacttggg ctggagccgc cctgggtgtc agcgggctcg gctcccgcgc acgctccggc 60 cgtcgcgcag cctcggcacc tgcaggtccg tgcgtcccgc ggctggcgcc cctgactccg 120 tcccggccag ggagggccat gatttccctc ccggggcccc tggtgaccaa cttgctgcgg 180 tttttgttcc tggggctgag tgccctcgcg cccccctcgc gggcccagct gcaactgcac 240 ttgcccgcca accggttgca ggcggtggag ggaggggaag tggtgcttcc agcgtggtac 300 accttgcacg gggaggtgtc ttcatcccag ccatgggagg tgccctttgt gatgtggttc 360 ttcaaacaga aagaaaagga ggatcaggtg ttgtcctaca tcaatggggt cacaacaagc 420 aaacctggag tatccttggt ctactccatg ccctcccgga acctgtccct gcggctggag 480 ggtctccagg agaaagactc tggcccctac agctgctccg tgaatgtgca agacaaacaa 540 ggcaaatcta ggggccacag catcaasacc ttagaactca atgtactggt tcctccagct 600 cctccatcct gccgtctcca gggtgtgccc catgtggggg caaacgtgac cctgagctgc 660 cagtctccaa ggagtaagcc cgctgtccaa taccagtggg atcggcagct tccatccttc 720 cagactttct ttgcaccagc attagatgtc atccgtgggt ctttaagcct caccaacctt 780 tcgtcttcca tggctggagt ctatgtctgc aaggcccaca atgaggtggg cactgcccaa 840 tgtaatgtga cgctggaagt gagcacaggg cctggagctg cagtggttgc tggagctgtt 900 gtgggtaccc tggttggact ggggttgctg gctgggctgg tcctcttgta ccaccgccgg 960 ggcaaggccc tggaggagcc agccaatgat atcaaggagg atgccattgc tccccggacc 1020 ctgccctggc ccaagagctc agacacaatc tccaagaatg ggaccctttc ctctgtcacc 1080 tccgcacgag ccctccggcc accccatggc cctcccaggc ctggtgcatt gacccccacg 1140 cccagtctct ccagccaggc cctgccctca ccaagactgc ccacgacaga tggggcccac 1200 cctcaaccaa tatcccccat ccctggtggg gtttcttcct ctggcttgag ccgcatgggt 1260 gctgtgcctg tgatggtgcc tgcccagagt caagctggct ctctggtatg atgaccccac 1320 cactcattgg ctaaaggatt tggggtctct ccttcctata agggtcacct ctagcacaga 1380 ggcctgagtc atgggaaaga gtcacactcc tgacccttag tactctgccc ccacctctct 1440 ttactgtggg aaaaccatct cagtaagacc taagtgtcca ggagacagaa ggagaagagg 1500 aagtggatct ggaattggga ggagcctcca cccacccctg actcctcctt atgaagccag 1560 ctgctgaaat tagctactca ccaagagtga ggggcagaga cttccagtca ctgagtctcc 1620 caggccccct tgatctgtac cccaccccta tctaacacca cccttggctc ccactccagc 1680 tccctgtatt gatataacct gtcaggctgg cttggttagg ttttactggg gcagaggata 1740 gggaatctct tattaaaact aacatgaaat atgtgttgtt ttcatttgca aatttaaata 1800 aagatacata atgtttgtat gasaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1920 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1954 <210> 38 <211> 390 <212> PRT
<213> Homo sapiens <400> 38 Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Leu Arg Phe Leu Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Gly Gly Glu Val Val Leu Pro Ala Trp Tyr Thr Leu His Gly Glu Val Ser Ser Ser Gln Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg Leu Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg Gly Ser Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val Tyr Val Cys Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu Val Ser Thr Gly Pro Gly Ala Ala Val Val Ala Gly Ala Val Val Gly Thr Leu Val Gly Leu Gly Leu Leu Ala Gly Leu Val Leu Leu Tyr His Arg Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile Lys Glu Asp Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser Asp Thr Ile Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg Pro Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro Thr Pro Ser Leu Ser Ser Gln Ala Leu Pro Ser Pro Arg Leu Pro Thr Thr Asp Gly Ala His Pro Gln Pro Ile Ser Pro Ile Pro Gly Gly Val Ser Ser Ser Gly Leu Ser Arg Met Gly Ala Val Pro Val Met Val Pro Ala Gln Ser Gln Ala Gly Ser Leu Val <210> 39 <211> 1933 <212> DNA
<213> Homo sapiens <400> 39 ggggtggggc caggaggaag atggcggcgt ccgcagctgc cgctgagctc caggcttctg 60 ggggtccgcg gcacccagtg tgtctgttgg tgttgggaat ggcgggatcc gggaaaacca 120 cttttgtaca gaggctcaca ggacacctgc atgcccaagg cactccaccg tatgtgatca 180 acctggatcc agcagtacat gaagttccct ttcctgccaa tattgatatt cgtgatactg 240 taaagtataa agaagtaatg aaacaatatg gacttggacc caatggcggc atagtgacct 300 cactcaatct ctttgctacc agatttgatc aggtgatgaa atttattgag aaggcccaga 360 acatgtccaa atatgtgttg attgacacac ctggacagat tgaggtattc acctggtcag 420 cttctgggac aattatcact gaagcccttg catcctcatt tccaacagtt gtcatctatg 480 taatggacac atcgagaagt accaacccag tgaccttcat gtccaacatg ctctatgcct 540 gcagcatctt atacaaaacc aagctgcctt tcattgtggt catgaataaa actgacatca 600 ttgaccacag ctttgcagtg gaatggatgc aggattttga ggctttccaa gatgccttga 660 atcaagagac tacatacgtc agtaacctga ctcgttcaat gagcctggtg ttagatgagt 720 tttacagctc actcagggtg gtgggtgtct ctgctgttct gggtactgga ttagatgaac 780 tctttgtgca agttaccagt gctgccgaag aatatgaaag ggagtatcgt cctgaatatg 840 aacgtctgaa aaaatcactg gccaacgcag agagccaaca gcagagagaa caactggaac 900 gccttcgaaa agatatgggt tctgtagcct tggatgcagg gactgccaaa gacagcttat 960 ctcctgtgct gcacccttct gatttgatcc tgactcgagg aaccttggat gaagaggatg 1020 aggaagcaga cagcgatact gatgacattg accacagagt tacagaggaa agccatgaag 1080 agccagcatt ccagaatttt atgcaagaat cgatggcaca atactggaag agaaacaata 1140 aataggagac tttagcacac ttcacttgtt tctagaagtc cagaattttg gacctccacg 1200 tgaaagaact gttcttacct ctgaactggg ggctcccata agggataatt ttcctcagag 1260 tagcaaagtt tctcttatta gagaaatctt gtgactcaga tgaagtcagg gatagaagac 1320 ccttggacct ggcaggttaa tgctgattat tccttggcct ttcccttgta tttatgcaag 1380 gaaggatata ctgagctgat actcttccaa gcctacaact tcaagtttta tcatttgaac 1440 tcaagtactt ttgctgctga ggaatggaat caaaagaacg tagtctcctg gtaaccacct 1500 cagatctcta ttattaggct agatgtatag cctctactcc cccagcttct tgctcttgac 1560 cctgcactgt aagttgccct tctattagca gccaaggaaa agggaaacat gagcttatcc 1620 agaacggtgg cagagtctcc ttggcaatca accaacgttg ctatgaaata tgcctcacac 1680 tgtatagctc attataggac gtcaggtttg ttgaaaaaag tgggcaagac atgattaatg 1740 aatcagaatc ctgtttcatt ggtgacttgg ataaagactt tttaatttta actttgaaaa 1800 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aasaaaaaaa aaaaaaaaaa aaaaaaaaaa 1920 aaaaaaaaaa aaa 1933 <210> 40 <211> 374 <212> PRT
<213> Homo Sapiens <400> 40 Met Ala Ala Ser Ala Ala Ala Ala Glu Leu Gln Ala Ser Gly Gly Pro Arg His Pro Val Cys Leu Leu Val Leu Gly Met Ala Gly Ser Gly Lys Thr Thr Phe Val Gln Arg Leu Thr Gly His Leu His Ala Gln Gly Thr Pro Pro Tyr Val Ile Asn Leu Asp Pro Ala Val His Glu Val Pro Phe Pro Ala Asn Ile Asp Ile Arg Asp Thr Val Lys Tyr Lys Glu Val Met Lys Gln Tyr Gly Leu Gly Pro Asn Gly Gly Ile Val Thr Ser Leu Asn Leu Phe Ala Thr Arg Phe Asp Gln Val Met Lys Phe Ile Glu Lys Ala Gln Asn Met Ser Lys Tyr Val Leu Ile Asp Thr Pro Gly Gln Ile Glu Val Phe Thr Trp Ser Ala Ser Gly Thr Ile Ile Thr Glu Ala Leu Ala Ser Ser Phe Pro Thr Val Val Ile Tyr Val Met Asp Thr Ser Arg Ser Thr Asn Pro Val Thr Phe Met Ser Asn Met Leu Tyr Ala Cys Ser Ile Leu Tyr Lys Thr Lys Leu Pro Phe Ile Val Val Met Asn Lys Thr Asp Ile Ile Asp His Ser Phe Ala Val Glu Trp Met Gln Asp Phe Glu Ala Phe Gln Asp Ala Leu Asn Gln Glu Thr Thr Tyr Val Ser Asn Leu Thr Arg Ser Met Ser Leu Val Leu Asp Glu Phe Tyr Ser Ser Leu Arg Val Val Gly Val Ser Ala Val Leu Gly Thr Gly Leu Asp Glu Leu Phe Val Gln Val Thr Ser Ala Ala Glu Glu Tyr Glu Arg Glu Tyr Arg Pro Glu Tyr Glu Arg Leu Lys Lys Ser Leu Ala Asn Ala Glu Ser Gln Gln Gln Arg Glu Gln Leu Glu Arg Leu Arg Lys Asp Met Gly Ser Val Ala Leu Asp Ala Gly Thr Ala Lys Asp Ser Leu Ser Pro Val Leu His Pro Ser Asp Leu Ile Leu Thr Arg Gly Thr Leu Asp Glu Glu Asp Glu Glu Ala Asp Ser Asp Thr Asp Asp Ile Asp His Arg Val Thr Glu Glu Ser His Glu Glu Pro Ala Phe Gln Asn Phe Met Gln Glu Ser Met Ala Gln Tyr Trp Lys Arg Asn Asn Lys <210> 41 DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PARTIE DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST LE TOME _ 1-DE a NOTE. Pour les tomes additionels, veuiliez contacter le Bureau canadien des brevets -:':, ~ i..
JUMBO APPLlCATIONS/PATENTS
THIS SECTION OF THE APPLICATIONIPATENT CONTAINS MORE
THAN ONE VOLUME -. THIS IS VOLUME ~OF -. -PfOTE:.For additional volumes please contact'the Canadian Patent Ofiffice -,., ., ,a. ~ ;" .
. . ~;...~ ._ _ . ,. , . .

Claims (89)

What is claimed is:
1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:1;
(b) the nucleotide sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934;
(c) the nucleotide sequence of the full-length protein coding sequence of clone vb11_1 deposited with the ATCC under accession number 98846;
(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;
(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
(g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d);
and (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:1.
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:

(a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with the polynucleotide of claim 2;
and (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. An isolated polynucleotide encoding the protein of claim 6.
8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846.
9. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:2;
(b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and (c) the amino acid sequence encoded by the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins.
10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:3;
(b) the nucleotide sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482;
(c) the nucleotide sequence of SEQ ID NO:3 from nucleotide 201 to nucleotide 482;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vb12_1 deposited with the ATCC under accession number 98846;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;
(f) the nucleotide sequence of a mature protein coding sequence of clone vb12_1 deposited with the ATCC under accession number 98846;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:3.
13. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:4;
(b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and (c) the amino acid sequence encoded by the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins.
14. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:5;
(b) the nucleotide sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527;
(c) the nucleotide sequence of SEQ ID NO:5 from nucleotide 1468 to nucleotide 1527;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vb14_1 deposited with the ATCC under accession number 98846;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;
(f) the nucleotide sequence of a mature protein coding sequence of clone vb14_1 deposited with the ATCC under accession number 98846;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)(g), and that has a length that is at least 25% of the length of SEQ ID NO:5.
15. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:6;
(b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and (c) the amino acid sequence encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins.
16. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:7;
(b) the nucleotide sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294;
(c) the nucleotide sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294;
(d) the nucleotide sequence of the full-length protein coding sequence of clone ve11_1 deposited with the ATCC under accession number 98846;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;
(f) the nucleotide sequence of a mature protein coding sequence of clone ve11_1 deposited with the ATCC under accession number 98846;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:7.
17. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:8;
(b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and (c) the amino acid sequence encoded by the cDNA insert of clone vell_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins.
18. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:9;
(b) the nucleotide sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468;
(c) the nucleotide sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
(f) the nucleotide sequence of a mature protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:9.
19. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:10;
(b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and (c) the amino acid sequence encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins.
20. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:11;
(b) the nucleotide sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641;
(c) the nucleotide sequence of SEQ ID NO:11 from nucleotide 262 to nucleotide 1641;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
(f) the nucleotide sequence of a mature protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:11.
21. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:12;
(b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and (c) the amino acid sequence encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins.
22. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:13;
(b) the nucleotide sequence of SEQ ID NO:13 from nucleotide 380 to nucleotide 892;
(c) the nucleotide sequence of SEQ ID NO:13 from nucleotide 416 to nucleotide 892;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;
(f) the nucleotide sequence of a mature protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:13.
23. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:14;
(b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and (c) the amino acid sequence encoded by the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins.
24. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:15;
(b) the nucleotide sequence of SEQ ID NO:15 from nucleotide 62 to nucleotide 1057;
(c) the nucleotide sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vl1_1 deposited with the ATCC under accession number 98846;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vl1-1 deposited with the ATCC under accession number 98846;
(f) the nucleotide sequence of a mature protein coding sequence of clone vl1_1 deposited with the ATCC under accession number 98846;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 98846;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:15.
25. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:16;
(b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and (c) the amino acid sequence encoded by the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 98846;
the protein being substantially free from other mammalian proteins.
26. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:17;

(b) the nucleotide sequence of SEQ ID NO:17 from nucleotide 74 to nucleotide 529;
(c) the nucleotide sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;
(f) the nucleotide sequence of a mature protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:17.
27. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:18;
(b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and (c) the amino acid sequence encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;

the protein being substantially free from other mammalian proteins.
28. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:19;
(b) the nucleotide sequence of SEQ ID NO:19 from nucleotide 174 to nucleotide 3170;
(c) the nucleotide sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vk1_2 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vb21_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:19.
29. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:20;
(b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and (c) the amino acid sequence encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
30. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:21;
(b) the nucleotide sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453;
(c) the nucleotide sequence of SEQ ID NO:21 from nucleotide 224 to nucleotide 1453;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:22;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (ar(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:21.
31. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:22;
(b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and (c) the amino acid sequence encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
32. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:23;
(b) the nucleotide sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368;
(c) the nucleotide sequence of SEQ ID NO:23 from nucleotide 243 to nucleotide 368;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:23.
33. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:24;
(b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and (c) the amino acid sequence encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
34. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:25;
(b) the nucleotide sequence of SEQ ID NO:25 from nucleotide 370 to nucleotide 1662;
(c) the nucleotide sequence of the full-length protein coding sequence of done vc38_1 deposited with the ATCC under accession number 98862;
(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:26;
(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;

(g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d);
and (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:25.
35. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:26;
(b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and (c) the amino acid sequence encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
36. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
{a) the nucleotide sequence of SEQ ID NO:27;
(b) the nucleotide sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365;
(c) the nucleotide sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:28;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:27.
37. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:28;
(b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and (c) the amino acid sequence encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
38. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:29;
(b) the nucleotide sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066;
(c) the nucleotide sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:30;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:29.
39. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:30;
(b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and (c) the amino acid sequence encoded by the cDNA insert of clone vc4a_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
40. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:31;
(b) the nucleotide sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553;
(c) the nucleotide sequence of SEQ ID NO:31 from nucleotide 104 to nucleotide 553;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of done vc46_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:32;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:31.
41. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:32;
(b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and (c) the amino acid sequence encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
42. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:33;
(b) the nucleotide sequence of SEQ ID NO:33 from nucleotide 164 to nucleotide 2548;
(c) the nucleotide sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:34;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:33.
43. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:34;
(b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and (c) the amino acid sequence encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
44. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:35;
(b) the nucleotide sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776;
(c) the nucleotide sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:35.
45. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:36;
(b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and (c) the amino acid sequence encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
46. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:37;
(b) the nucleotide sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308;
(c) the nucleotide sequence of SEQ ID NO:37 from nucleotide 211 to nucleotide 1308;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of done vc51_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of done vc51_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:38;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:37.
47. ~A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:38;
(b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and (c) the amino acid sequence encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
48. ~An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:39;
(b) the nucleotide sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142;
(c) the nucleotide sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:40;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:39.
49. ~A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:40;
(b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ TD NO:40; and (c) the amino acid sequence encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
the protein being substantially free from other mammalian proteins.
50. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:41;
(b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416;
(c) the nucleotide sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:4.
51. ~A protein comprising an amino and sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:42;
(b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and (c) the amino acid sequence encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
52. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:43;
(b) the nucleotide sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461;
(c) the nucleotide sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;~

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:44;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)(g), and that has a length that is at least 25% of the length of SEQ ID NO:43.
53. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:44;
(b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and (c) the amino acid sequence encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
54. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:45;

(b) the nucleotide sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350;
(c) the nucleotide sequence of SEQ ID NO:45 from nucleotide 2237 to nucleotide 2350;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc47_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc47_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:46;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:45.
55. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:46;
(b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and (c) the amino and sequence encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins.
56. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:47;
(b) the nucleotide sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337;
(c) the nucleotide sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of done vc54_1 deposited with the ATCC under accession number 9888b;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc54-1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:48;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:47.
57. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:48;
(b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and (c) the amino acid sequence encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98586;
the protein being substantially free from other mammalian proteins.
58. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:49;
(b) the nucleotide sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637;
(c) the nucleotide sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:50;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:49.
59. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:50;
(b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and (c) the amino acid sequence encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
60. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:51;
(b) the nucleotide sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934;
(c) the nucleotide sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934;
(d) the nucleotide sequence of the full-length protein coding sequence of clone ve13_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone ve13_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:52;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:51.
61. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:52;
(b) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and (c) the amino acid sequence encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
62. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:53;
(b) the nucleotide sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503;
(c) the nucleotide sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503;
(d) the nucleotide sequence of the full-length protein coding sequence of clone ve16_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone ve16_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:54;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:53.
63. ~A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:54;
(b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and (c) the amino acid sequence encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
64. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:55;
(b) the nucleotide sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063;
(c) the nucleotide sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;

(f) the nucleotide sequence of a mature protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:56;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino and sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:55.
65. ~A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:56;
(b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and (c) the amino acid sequence encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
66. ~An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:57;
(b) the nucleotide sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886;
(c) the nucleotide sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:58;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:57.
67. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:58;
(b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and (c) the amino acid sequence encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
68. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence or SEQ ID NO:59;
(b) the nucleotide sequence of SEQ ID NO:59 from nucleotide 30 to nucleotide 344;
(c) the nucleotide sequence of SEQ ID NO:59 from nucleotide 84 to nucleotide 344;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vp7_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone vp7_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:60;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino and sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:59.
69. ~A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:60;
(b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and (c) the amino acid sequence encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
70. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:61;
(b) the nucleotide sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757;
(c) the nucleotide sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
(f) the nucleotide sequence of a mature protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:62;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:61.
71. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:62;
(b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and (c) the amino acid sequence encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
the protein being substantially free from other mammalian proteins.
72. ~An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:63;
(b) the nucleotide sequence of SEQ ID NO:63 from nucleotide 1048 to nucleotide 3726;
(c) the nucleotide sequence of the full-length protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933;
(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;
(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:64;
(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64;
(g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)(d);
and (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)(d), and that has a length that is at least 25% of the length of SEQ ID NO:63.
73. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:64;
(b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and (c) the amino acid sequence encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;
the protein being substantially free from other mammalian proteins.
74. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:65;
(b) the nucleotide sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667;
(c) the nucleotide sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:66;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:65.
75. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:66;
(b) a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; and (c) the amino acid sequence encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
the protein being substantially free from other mammalian proteins.
76. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:67;
(b) the nucleotide sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457;
(c) the nucleotide sequence of SEQ ID NO:67 from nucleotide 158 to nucleotide 457;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
(f) the nucleotide sequence of a mature protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;
{g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:68;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:67.
77. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:68;
(b) a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68; and (c) the amino acid sequence encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
the protein being substantially free from other mammalian proteins.
78. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:69;
(b) the nucleotide sequence of SEQ ID NO:69 from nucleotide 29 to nucleotide 1387;
(c) the nucleotide sequence of SEQ ID NO:69 from nucleotide 113 to nucleotide 1387;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;
(f) the nucleotide sequence of a mature protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:70;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:69.
79. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:70;
(b) a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70; and (c) the amino acid sequence encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins.
80. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:71;
(b) the nucleotide sequence of SEQ ID NO:71 from nucleotide 44 to nucleotide 1513;
(c) the nucleotide sequence of SEQ ID NO:71 from nucleotide 92 to nucleotide 1513;
(d) the nucleotide sequence of SEQ ID NO:71 from nucleotide 1 to nucleotide 458;
(e) the nucleotide sequence of the full-length protein coding sequence of clone vp15-1 deposited with the ATCC under accession number 207012;

(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012;
(g) the nucleotide sequence of a mature protein coding sequence of clone vp15_1 deposited with the ATCC under accession number 207012;
(h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012;
(i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:72;
(j)~a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72;
(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h);
and (l) the nucleotide sequence of a polynudeotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:71.
81. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:72;
(b) the amino acid sequence of SEQ ID NO:72 from amino acid 1 to amino acid 139;
(c) a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72; and (d) the amino acid sequence encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins.
82. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:73;
(b) the nucleotide sequence of SEQ ID NO:73 from nucleotide 348 to nucleotide 743;
(c) the nucleotide sequence of SEQ ID NO:73 from nucleotide 414 to nucleotide 743;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vp17_1 deposited with the ATCC under accession number 207012;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;
(f) the nucleotide sequence of a mature protein coding sequence of clone vp17_1 deposited with the ATCC under accession number 207012;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:74;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino and sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74;
(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:73.
83. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:74;
(b) a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74; and (c) the amino acid sequence encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins.
84. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:75;
(b) the nucleotide sequence of SEQ ID NO:75 from nucleotide 144 to nucleotide 461;
(c) the nucleotide sequence of the full-length protein coding sequence of clone vp19_1 deposited with the ATCC under accession number 207012;
(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012;
(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:76;
(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;
(g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d);
and (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:75.
85. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:76;
(b) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; and (c) the amino acid sequence encoded by the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012;

the protein being substantially free from other mammalian proteins.
86. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:77;
(b) the nucleotide sequence of SEQ ID NO:77 from nucleotide 54 to nucleotide 368;
(c) the nucleotide sequence of SEQ ID NO:77 from nucleotide 141 to nucleotide 368;
(d) the nucleotide sequence of SEQ ID NO:77 from nucleotide 51 to nucleotide 332;
(e) the nucleotide sequence of the full-length protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012;
(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
(g) the nucleotide sequence of a mature protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012;
(h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
(i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:78;
(j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78;
(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h);
and (l) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:77.
87. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:78;
(b) the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 93;
(c) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; and (d) the amino acid sequence encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
the protein being substantially free from other mammalian proteins.
88. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:79;
(b) the nucleotide sequence of SEQ ID NO:79 from nucleotide 2 to nucleotide 1018;
(c) the nucleotide sequence of SEQ ID NO:79 from nucleotide 53 to nucleotide 1018;
(d) the nucleotide sequence of the full-length protein coding sequence of clone vp14_1 deposited with the ATCC under accession number 207011;
(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;
(f) the nucleotide sequence of a mature protein coding sequence of clone vp14_1 deposited with the ATCC under accession number 207011;
(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;
(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:80;
(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g);
and (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:79.
89. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:80;
(b) a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80; and (c) the amino acid sequence encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;
the protein being substantially free from other mammalian proteins.
CA002340616A 1998-08-24 1999-08-24 Secreted proteins and polynucleotides encoding them Abandoned CA2340616A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US9765998P 1998-08-24 1998-08-24
US9763898P 1998-08-24 1998-08-24
US60/097,659 1998-08-24
US60/097,638 1998-08-24
US9961898P 1998-09-09 1998-09-09
US60/099,618 1998-09-09
US10209298P 1998-09-28 1998-09-28
US60/102,092 1998-09-28
US10997898P 1998-11-25 1998-11-25
US60/109,978 1998-11-25
US11364598P 1998-12-23 1998-12-23
US11364698P 1998-12-23 1998-12-23
US60/113,645 1998-12-23
US60/113,646 1998-12-23
US37924699A 1999-08-23 1999-08-23
US09/379,246 1999-08-23
PCT/US1999/019351 WO2000011015A1 (en) 1998-08-24 1999-08-24 Secreted proteins and polynucleotides encoding them

Publications (1)

Publication Number Publication Date
CA2340616A1 true CA2340616A1 (en) 2000-03-02

Family

ID=27574713

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002340616A Abandoned CA2340616A1 (en) 1998-08-24 1999-08-24 Secreted proteins and polynucleotides encoding them

Country Status (5)

Country Link
EP (1) EP1107978A1 (en)
JP (1) JP2002537757A (en)
AU (1) AU5784799A (en)
CA (1) CA2340616A1 (en)
WO (1) WO2000011015A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030082540A1 (en) * 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7417126B2 (en) 1997-10-17 2008-08-26 Genentech, Inc. PRO246 antibodies
IL142989A0 (en) * 1998-11-06 2002-04-21 Nucleotide and protein sequences of nogo genes and methods based thereon
NZ511087A (en) * 1998-11-20 2004-01-30 Arena Pharm Inc Human orphan G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US7816492B2 (en) 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
EP1159413A4 (en) * 1999-02-26 2005-12-14 Millennium Pharm Inc Secreted proteins and uses thereof
PT1632499E (en) * 1999-03-08 2007-09-11 Genentech Inc Gene sequences amplified in tumours and their diagnostic uses
EP1189944A4 (en) * 1999-06-21 2002-09-11 Smithkline Beecham Corp Axor16, a g protein coupled receptor
EP1207201A4 (en) * 1999-08-27 2003-03-12 Takeda Chemical Industries Ltd Novel g protein-coupled receptor protein and dna thereof
WO2001025427A1 (en) * 1999-10-01 2001-04-12 Kyowa Hakko Kogyo Co., Ltd. Shear stress-response dna
AU7999300A (en) * 1999-10-07 2001-05-10 Zymogenetics Inc. Novel human phosphodiesterase zcytor13
US6750054B2 (en) 2000-05-18 2004-06-15 Lexicon Genetics Incorporated Human semaphorin homologs and polynucleotides encoding the same
EP1666494A1 (en) * 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1287021A2 (en) * 2000-05-18 2003-03-05 Bayer Aktiengesellschaft Human galanin receptor-like g protein coupled receptor
WO2002004518A2 (en) * 2000-07-06 2002-01-17 Bayer Corporation Human neuropeptide y-like g protein-coupled receptor
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
EP1293569A3 (en) * 2001-09-14 2004-03-31 Research Association for Biotechnology Full-length cDNAs
JP2003088388A (en) 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk NEW FULL-LENGTH cDNA
EP1440089A2 (en) * 2001-11-01 2004-07-28 Amersham plc Human angiomotin-like protein 1
CN1324047C (en) 2002-04-12 2007-07-04 先灵公司 G-protein coupled receptor ligands and methods
WO2004022086A1 (en) * 2002-09-02 2004-03-18 Takeda Pharmaceutical Company Limited Adrenocortical hormone secretion controller
FR2848569A1 (en) * 2002-12-17 2004-06-18 Exonhit Therapeutics Sa New nucleic acid encoding variants of human kallikrein-3, useful for diagnosis of prostatic cancer and in screening for therapeutic agents, also related polypeptides and antibodies
WO2004106935A2 (en) * 2003-05-27 2004-12-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
EP2070546A1 (en) 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
WO2005100566A1 (en) 2004-04-14 2005-10-27 Banyu Pharmaceutical Co., Ltd. Novel monkey gpr103 and monkey qrfp and method of evaluating compound by using gpr103
EP2140000A4 (en) * 2007-03-23 2010-10-27 Agency Science Tech & Res Method of enhancing migration of neural precursor cells
EP3027656B1 (en) * 2013-07-30 2019-06-26 SBI Biotech Co., Ltd. Medicament comprising anti-phospholipase d4 antibody

Also Published As

Publication number Publication date
AU5784799A (en) 2000-03-14
EP1107978A1 (en) 2001-06-20
WO2000011015A1 (en) 2000-03-02
JP2002537757A (en) 2002-11-12

Similar Documents

Publication Publication Date Title
CA2340616A1 (en) Secreted proteins and polynucleotides encoding them
US20020193567A1 (en) Secreted proteins and polynucleotides encoding them
WO1998033916A2 (en) Secreted proteins and polynucleotides encoding them
EP0998490A2 (en) Secreted proteins and polynucleotides encoding them
WO1998055614A2 (en) Secreted proteins and polynucleotides encoding them
EP0973890A2 (en) Secreted proteins and polynucleotides encoding them
CA2306457A1 (en) Secreted proteins and polynucleotides encoding them
WO1998027205A2 (en) Secreted proteins and polynucleotides encoding them
CA2310214A1 (en) Secreted proteins and polynucleotides encoding them
CA2324492A1 (en) Secreted proteins and polynucleotides encoding them
CA2327551A1 (en) Secreted proteins and polynucleotides encoding them
EP1007661A2 (en) Secreted proteins and polynucleotides encoding them
WO1998044113A1 (en) Secreted proteins and polynucleotides encoding them
CA2322732A1 (en) Secreted proteins and polynucleotides encoding them
CA2311683A1 (en) Secreted proteins and polynucleotides encoding them
WO1998041539A2 (en) Secreted proteins and polynucleotides encoding them
CA2309782A1 (en) Secreted proteins and polynucleotides encoding them
CA2305689A1 (en) Secreted proteins and polynucleotides encoding them
CA2325057A1 (en) Secreted proteins and polynucleotides encoding them
EP0948620A2 (en) Secreted proteins and polynucleotides encoding them
CA2318303A1 (en) Secreted proteins and polynucleotides encoding them
WO1998030582A2 (en) Secreted proteins and polynucleotides encoding them
CA2324504A1 (en) Secreted proteins and polynucleotides encoding them
CA2309624A1 (en) Secreted proteins and polynucleotides encoding them
CA2362538A1 (en) Secreted proteins and polynucleotides encoding them

Legal Events

Date Code Title Description
FZDE Dead